LUCKHURST CHRISTOPHER ANDREW (GB)
WO2016156816A1 | 2016-10-06 | |||
WO2020212350A1 | 2020-10-22 | |||
WO2014175370A1 | 2014-10-30 | |||
WO2021239863A1 | 2021-12-02 | |||
WO2016046530A1 | 2016-03-31 | |||
WO2016156816A1 | 2016-10-06 | |||
WO2017009650A1 | 2017-01-19 | |||
WO2017093718A1 | 2017-06-08 | |||
WO2017103614A1 | 2017-06-22 | |||
WO2017149313A1 | 2017-09-08 | |||
WO2017109488A1 | 2017-06-29 | |||
WO2017141036A1 | 2017-08-24 | |||
WO2017163078A1 | 2017-09-28 | |||
WO2017158381A1 | 2017-09-21 | |||
WO2017158388A1 | 2017-09-21 | |||
WO2018065768A1 | 2018-04-12 | |||
WO2018060742A1 | 2018-04-05 | |||
WO2018060689A1 | 2018-04-05 | |||
WO2018060691A1 | 2018-04-05 | |||
WO2018220355A1 | 2018-12-06 | |||
WO2018234755A1 | 2018-12-27 | |||
WO2020212350A1 | 2020-10-22 | |||
WO2020212351A1 | 2020-10-22 | |||
WO2021043870A1 | 2021-03-11 | |||
WO2021204856A1 | 2021-10-14 | |||
WO2021239863A1 | 2021-12-02 | |||
WO2021245186A1 | 2021-12-09 | |||
WO2021249909A1 | 2021-12-16 | |||
WO2022084479A1 | 2022-04-28 | |||
WO2019171042A1 | 2019-09-12 | |||
WO2001077073A1 | 2001-10-18 | |||
WO2015179190A1 | 2015-11-26 | |||
WO2013030218A1 | 2013-03-07 | |||
WO2015017502A1 | 2015-02-05 | |||
WO2016019237A2 | 2016-02-04 | |||
WO2009026197A1 | 2009-02-26 | |||
WO2009129365A1 | 2009-10-22 | |||
WO2009129370A1 | 2009-10-22 | |||
WO2009129371A1 | 2009-10-22 | |||
WO2019222468A1 | 2019-11-21 | |||
WO2019071073A1 | 2019-04-11 | |||
WO2020036940A1 | 2020-02-20 | |||
WO2020072964A1 | 2020-04-09 | |||
WO2015183987A1 | 2015-12-03 | |||
WO2006067165A2 | 2006-06-29 | |||
WO2007119214A2 | 2007-10-25 | |||
WO2012170290A1 | 2012-12-13 | |||
WO2018213150A1 | 2018-11-22 | |||
WO2018234775A1 | 2018-12-27 |
US201515513125A | 2015-09-22 | |||
US201815894025A | 2018-02-12 | |||
US201916448066A | 2019-06-21 | |||
US201615558632A | 2016-03-24 | |||
US201916297937A | 2019-03-11 | |||
US201916419558A | 2019-05-22 | |||
US201916419747A | 2019-05-22 | |||
US202016788446A | 2020-02-12 | |||
US201615738900A | 2016-07-14 | |||
US201615776149A | 2016-11-29 | |||
US201615781615A | 2016-12-16 | |||
US201716078518A | 2017-03-02 | |||
US201616060299A | 2016-12-21 | |||
US201716070936A | 2017-02-16 | |||
US201716087515A | 2017-03-23 | |||
US201716080229A | 2017-03-17 | |||
US201716080506A | 2017-03-17 | |||
US201716336685A | 2017-10-04 | |||
US16336202A | 2002-06-07 | |||
US201716334836A | 2017-09-27 | |||
US201716336363A | 2017-09-27 | |||
US201816615040A | 2018-05-30 | |||
US201816615709A | 2018-06-19 | |||
US201916977019A | 2019-03-05 | |||
US20080300268A1 | 2008-12-04 | |||
US6106864A | 2000-08-22 |
BINGOL ET AL., NATURE, vol. 510, 2015, pages 370 - 5
GERSCH ET AL., NAT STRUCT MOL BIOL, vol. 24, no. 11, 2017, pages 920 - 930
CUNNINGHAM ET AL., NAT CELL BIOL, vol. 17, no. 2, 2015, pages 160 - 169
JACOUPY ET AL., SCI REP, vol. 9, no. 1, 2019, pages 11829
RICCIO ET AL., J CELL BIOL, vol. 218, no. 3, 2019, pages 798 - 807
PHU ET AL., MOLECULAR CELL, vol. 77, 2020, pages 1107 - 1123
BEDFORD ET AL., NATURE REV, vol. 10, 2011, pages 29 - 46
KURITA ET AL., RESPIRATORY RESEARCH, vol. 18, 2017, pages 114
WILLIAMS ET AL., PHARMACOL RES, vol. 102, December 2015 (2015-12-01), pages 264 - 269
WILLIAMS ET AL., BIOMOLECULES, vol. 5, 2015, pages 2619 - 2642
WILLIAMS ET AL., AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 309, 2015, pages G324 - G340
LUCIANI ET AL., NAT. COMMUN, vol. 11, 2020, pages 970
KLUGE ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 28, 2018, pages 2655 - 2659
FALGUEYRET ET AL., J. MED. CHEM, vol. 44, 2001, pages 94 - 104
RUSILOWICZ-JONES ET AL., BIORXIV 2020.04.16.044206, 20 April 2020 (2020-04-20)
TSEFOU ET AL., BIORXIV 2021.02.02.429344, 2 February 2021 (2021-02-02)
YUE ET AL., CELL RESEARCH, vol. 24, pages 482 - 496
LARSON-CASEY ET AL., IMMUNITY, vol. 44, 2016, pages 582 - 596
TANG ET AL., KIDNEY DISEASES, vol. 1, 2015, pages 71 - 79
MEHTA ET AL., LANCET, vol. 385, no. 9987, 2015, pages 2616 - 2643
KELLUM ET AL., NEPHROL DIAL TRANSPLANT, vol. 35, 2020, pages 1652 - 1662
CHAWLA ET AL., NAT REV NEPHROL, vol. 13, no. 4, 2017, pages 241 - 257
MCWILLIAMS ET AL., CELL METAB, vol. 27, no. 2, 2018, pages 439 - 449
EMMA ET AL., NAT REV NEPHROL, vol. 12, no. 5, 2016, pages 267 - 280
EIRIN ET AL., HANDB EXP PHARMACOL, vol. 240, 2017, pages 229 - 250
KAWAKAMI ET AL., J AM SOC NEPHROL, vol. 26, no. 5, 2015, pages 1040 - 1052
CONNOR ET AL., PLOS GENET, vol. 13, no. 3, 2017, pages e 1006620
TANG ET AL., AUTOPHAGY, vol. 14, no. 5, 2018, pages 880 - 897
WANG ET AL., CELL DEATH DIS, vol. 9, no. 11, 2018, pages 1113
KOBAYASHI ET AL., J IMMUNOL, vol. 197, no. 2, pages 504 - 516
ARAYA ET AL., AUTOPHAGY, vol. 15, no. 3, 2019, pages 510 - 526
REID ET AL.: "The Interplay of Mitophagy and Inflammation in Duchenne Muscular Dystrophy", LIFE, vol. 11, 2021, pages 648
VILA ET AL., CELL DEATH AND DIFFERENTIATION, vol. 24, 2017, pages 330 - 342
LUAN ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 13, 2021, pages 1 - 12
E. L. ELIELS. H. WILEN: "Stereochemistry of Organic Compounds", 1994, WILEY
STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
HALEBLIAN, J. PHARM SCI, vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288
H BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER
WYNN ET AL., NAT REV IMMUNOL, vol. 4, no. 8, August 2004 (2004-08-01), pages 583 - 594
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
LIANGCHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 11, no. 6, 2001, pages 981 - 986
VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, vol. 25, no. 2, 2001, pages 1 - 14
NISHIDA ET AL., LAB INVEST, vol. 93, no. 2, February 2013 (2013-02-01), pages 230 - 41
KARUPPAGOUNER ET AL., SCI REP, vol. 4, 2 May 2014 (2014-05-02), pages 4874
KRUSE ET AL., CELL METAB., vol. 7, no. 4, April 2008 (2008-04-01), pages 312 - 20
LEARN MEM, vol. 21, no. 2, 17 January 2014 (2014-01-17), pages 119 - 26
NEUROSCIENCE, no. 409, 15 June 2019 (2019-06-15), pages 169 - 179
CHEVALIER ET AL., KIDNEY INT, vol. 75, no. 11, 2009, pages 1145 - 1152
Claims 1. A compound of formula (I): a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein either: (a) X1 is N; and X2, X3 and X4 are CR6; or (b) X1 is N; one of X2, X3 and X4 are N; and two of X2, X3 and X4 are CR6; or (c) X1 and X4 are CR6; and X2 and X3 are N; ring A is selected from: (i) a 5-membered monocyclic heteroaryl ring comprising 1 to 3 heteroatoms, each independently selected from N and O; (ii) a 6-membered monocyclic heteroaryl ring comprising 1 to 3 heteroatoms, each independently selected from N, O and S; (iii) a 4 to 6-membered saturated or partially saturated monocyclic heterocyclyl ring comprising 1 to 3 heteroatoms, each independently selected from N, O and S; and (iv) phenyl or naphthyl; ring A is either unsubstituted or substituted by 1 or 2 R7 substituents; ring B is selected from: (i) phenyl or naphthyl; (ii) a 5 to 6-membered monocyclic heteroaryl ring comprising 1 to 3 heteroatoms, each independently selected from N, O and S; and (iii) a 9 to 10-membered bicyclic heteroaryl ring comprising 1 to 4 heteroatoms, each independently selected from N, O and S; ring B is either unsubstituted or substituted by 1 to 5 substituents, each independently selected from halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C6)cycloalkyl, O(C3-C6)cycloalkyl, (C1-C6)alkoxy(C1-C6)alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl, piperidinyl, NH(C1-C6)alkyl, N((C1-C6)alkyl)2, C(O)NH(C1-C6)alkyl, C(O)N((C1-C6)alkyl)2, NHC(O)(C1-C6)alkyl, N(C1-C6)alkyl)C(O)(C1-C6)alkyl), C(O)(C1-C6)alkyl, C(O)O(C1-C6)alkyl, CO2H, CONH2, SO2NH(C1-C6)alkyl and SO2N((C1-C6)alkyl)2; R1 is selected from hydrogen, (C1-C6)alkyl and (C3-C6)cycloalkyl; R2 and R3 are each independently selected from hydrogen, halo, (C1-C4)alkyl and (C1-C4)alkoxy; R4 and R5 are each independently selected from hydrogen and (C1-C4)alkyl; R6 is hydrogen or (C1-C4)alkyl; and each R7 is independently selected from halo, (C1-C6)alkyl and (C1-C6)alkoxy; with the proviso that when ring A is unsubstituted oxazolyl or oxadiazolyl, and ring B is phenyl, and R1, R2, R3, R4 and R5 are each hydrogen, and two of X1, X2, X3 and X4 are N, then ring B is not substituted by CF3 in the position meta to ring A. 2. The compound according to claim 1 having the formula (IA): a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein: Z is N or CR11; R8, R11 and R12 are each independently selected from hydrogen, halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C6)cycloalkyl, O(C3-C6)cycloalkyl, (C1-C6)alkoxy(C1-C6)alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl and piperidinyl; R9 and R10 are each independently selected from hydrogen, halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C6)cycloalkyl, O(C3-C6)cycloalkyl, (C1-C6)alkoxy(C1-C6)alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl and piperidinyl; or R9 and R10 together form a 5 to 6-membered saturated, partially saturated, or aromatic ring comprising 1 to 2 heteroatoms, each independently selected from N, O and S, wherein the ring is either unsubstituted or substituted with 1 to 2 substituents, each independently selected from halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl and halo(C1-C6)alkoxy; with the proviso that when ring A is unsubstituted oxazolyl or oxadiazolyl, and R1, R2, R3, R4 and R5 are each hydrogen, and two of X1, X2, X3 and X4 are N, and Z is CR11, and R11 is hydrogen or halo, then R9 is not CF3. 3. The compound according to claim 2, wherein Z is CR11. 4. The compound according to claim 2, wherein Z is N. 5. The compound according to any one of claims 1 to 4, wherein ring A is a 5-membered monocyclic heteroaryl ring comprising 1 to 3 heteroatoms, each independently selected from N and O. 6. The compound according to claim 5, wherein ring A is selected from oxazolyl and oxadiazolyl. 7. The compound according to any one of claims 1 to 4, wherein ring A is a 6-membered monocyclic heteroaryl ring comprising 1 to 3 heteroatoms, each independently selected from N, O and S. 8. The compound according to claim 7, wherein ring A is pyridinyl. 9. The compound according to any one of claims 1 to 4, wherein ring A is pyrrolidinyl. 10. The compound according to any one of claims 1 to 4, wherein ring A is phenyl. 11. The compound according to any one of claims 1 to 10, wherein R1 is selected from hydrogen, methyl and cyclopropyl. 12. The compound according to any one of claims 1 to 11, wherein R2, R3, R4 and R5 are each hydrogen. 13. The compound according to any one of claims 1 to 12, wherein R6 is hydrogen or methyl. 14. The compound according to any one of claims 1 to 13, wherein ring A is unsubstituted. 15. The compound according to any one of claims 1 to 13, wherein each R7 is independently selected from fluoro, chloro, methyl and methoxy. 16. The compound according to any one of claims 1 to 15, wherein R8 and R11 are each independently selected from hydrogen, CN and halo. 17. The compound according to claim 16, wherein R8 and R11 are each hydrogen. 18. The compound according to any one of claims 1 to 17, wherein R9 is selected from hydrogen, halo, CN, (C1-C3)alkyl, (C1-C3)alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy. 19. The compound according to claim 18, wherein R9 is selected from hydrogen, chloro, CN, ethyl, cyclopropyl, CF3 and OCF3. 20. The compound according to any one of claims 1 to 19, wherein R10 is selected from hydrogen, fluoro and CN. 21. The compound according to claim 20, wherein R10 is hydrogen. 22. The compound according to any one of claims 1 to 17, wherein R9 and R10 together form a 5-membered partially saturated or aromatic ring comprising 1 to 2 heteroatoms, each independently selected from N, O and S, wherein the ring is either unsubstituted or substituted with 1 to 2 substituents, each independently selected from fluoro, chloro, methyl and methoxy. 23. The compound according to any one of claims 1 to 22, wherein R12 is selected from hydrogen, halo, CN, (C1-C3)alkyl, (C1-C3)alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy. 24. The compound according to claim 23, wherein R12 is selected from hydrogen, methoxy, cyclopropyl, cyclopropoxy, OCF3 and oxetan-3-yloxy. 25. The compound according to claim 1, which is selected from: N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazole- 2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2- cyclopropylphenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2- cyclopropylphenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3- cyclopropylphenyl)oxazole2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropoxy-5- (trifluoromethoxy) phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3- yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3- (trifluoromethyl)phenyl)picolinamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3- (trifluoromethoxy)phenyl)picolinamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)(3(trifluoromethyl)phenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5- yl)benzamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H- indazol-5-yl)benzamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; (S)-N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; (R)-N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(4-fluoro-3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-(azetidin-1-yl)-5- cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(pyrrolidin-1- yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-chloro-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)- 1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-propyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxamide; and N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-6-(1H-indazol-4-yl)nicotinamide; a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer. 26. A compound according to any one of claims 1 to 25, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, for use as a medicament. 27. A compound according to any one of claims 1 to 25, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, for use in the treatment or prevention of a condition involving mitochondrial dysfunction, cancer, or fibrosis. 28. Use of a compound according to any one of claims 1 to 25, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, in the manufacture of a medicament for use in the treatment or prevention of a condition involving mitochondrial dysfunction, cancer, or fibrosis. 29. A method for the treatment or prevention of a condition involving mitochondrial dysfunction, cancer, or fibrosis, comprising the step of administering an effective amount of a compound according to any one of claims 1 to 25, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, to a patient in need thereof. 30. The compound, use, or method, according to claims 27 to 29, wherein the condition involving mitochondrial dysfunction is selected from: a CNS disorder; neurodegenerative disease; Parkinson’s disease; Alzheimer’s disease; amyotrophic lateral sclerosis; Huntington’s disease; ischemia; stroke; dementia with Lewy bodies; frontotemporal dementia; multiple sclerosis; mitochondrial encephalopathy, lactic acidosis and stroke-like episodes syndrome; materially-inherited diabetes and deafness; Leber's hereditary optic neuropathy; cancer; neuropathy, ataxia, retinitis pigmentosa- maternally inherited Leigh syndrome; Danon disease; diabetes; diabetic nephropathy; metabolic disorders; heart failure; ischemic heart disease leading to myocardial infarction; psychiatric diseases, schizophrenia; multiple sulfatase deficiency; mucolipidosis II; mucolipidosis III; mucolipidosis IV; GMl-gangliosidosis; neuronal ceroid-lipofuscinoses; Alpers disease; Barth syndrome; beta-oxidation defects; carnitine-acyl-carnitine deficiency; carnitine deficiency; creatine deficiency syndromes; co-enzyme Q10 deficiency; complex I deficiency; complex II deficiency; complex III deficiency; complex IV deficiency; complex V deficiency; COX deficiency; chronic progressive external ophthalmoplegia syndrome; CPT I deficiency; CPT II deficiency; glutaric aciduria type II; Kearns- Sayre syndrome; lactic acidosis; long-chain acyl-CoA dehydrogenase deficiency; Leigh disease or syndrome; Leigh Syndrome French Canadian variant; lethal infantile cardiomyopathy; Luft disease; medium-chain acyl-CoA dehydrogenase deficiency; myoclonic epilepsy and ragged-red fiber syndrome; mitochondrial cytopathy; mitochondrial recessive ataxia syndrome; mitochondrial DNA depletion syndrome; myoneurogastrointestinal disorder and encephalopathy; Pearson syndrome; pyruvate dehydrogenase deficiency; pyruvate carboxylase deficiency; POLG mutations; medium/short- chain 3-hydroxyacyl-CoA dehydrogenase deficiency; and very long-chain acyl-CoA dehydrogenase deficiency; peroxisomal disorders; methylmalonic acidemia; mevalonate kinase deficiency; age- dependent decline in cognitive function and muscle strength; muscle structure disorders; and cognitive impairment associated with neurodegenerative and neuropsychiatric disorders. 31. The compound, use, or method, according to claim 30, wherein the neurodegenerative disease is selected from Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, ischemia, stroke, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia; and Parkinson’s disease related to mutations in α-synuclein, parkin, PINK1, GBA, and LRRK2, and autosomal recessive juvenile Parkinson’s disease where parkin is mutated. 32. The compound, use, or method, according to claim 30, wherein the neurodegenerative disease is selected from Leigh syndrome or disease, X-linked Leigh's disease, Leigh Syndrome French Canadian Variant, and/or the symptoms associated with Leigh’s disease. 33. The compound, use, or method, according to claims 27 to 29, wherein the cancer is selected from breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone, liver, soft tissue, cancers of tissue organs, cancers of the blood cells, CML, AML, mantle cell lymphoma, neuroblastoma, melanoma, soft tissue sarcoma, liposarcoma, fibroblastic sarcoma, leiomyosarcoma, hepatocellular carcinoma, osteosarcoma, oesophageal cancer, leukaemia, lymphoma, multiple myeloma, metastatic carcinoma, osteosarcoma, chondosarcoma, Ewing’s sarcoma, nasopharyngeal carcinoma, colorectal cancer, colorectal cancer, non-small cell lung carcinoma, cancer where apoptotic pathways are dysregulated, and cancer where proteins of the BCL-2 family are mutated, or over or under expressed. 34. The compound, use, or method, according to claims 27 to 29, wherein the fibrosis is selected from fibrosis or a fibrotic disorder associated with the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia. 35. The compound, use, or method, according to claim 34, wherein the fibrosis is selected from fibrosis, a fibrotic disorder associated with major organ diseases, fibroproliferative disorders, and scarring associated with trauma. 36. The compound, use, or method, according to claim 35, wherein the fibrosis is selected from fibrosis or a fibrotic disorder associated with interstitial lung disease, liver cirrhosis, non-alcoholic fatty liver disease, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, kidney disease, acute kidney injury, chronic kidney disease, delayed kidney graft function, heart or vascular disease, diseases of the eye, systemic and local scleroderma, keloids, hypertrophic scars, atherosclerosis, restenosis, Dupuytren’s contracture, surgical complications, chemotherapeutics drug-induced fibrosis, radiation- induced fibrosis, accidental injury and burns, retroperitoneal fibrosis, and peritoneal fibrosis/peritoneal scarring. 37. The compound, use, or method, according to claim 36, wherein the fibrosis associated with interstitial lung disease is selected from sarcoidosis silicosis drug reactions infections collagen vascular diseases, rheumatoid arthritis, systemic sclerosis, scleroderma, pulmonary fibrosis, idiopathic pulmonary fibrosis, usual interstitial pneumonitis, interstitial lung disease, cryptogenic fibrosing alveolitis, bronchiolitis obliterans, and bronchiectasis. 38. The compound, use, or method, according to claim 36, wherein the kidney disease is acute kidney injury or chronic kidney disease. 39. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 25, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, together with one or more pharmaceutically acceptable excipients. 40. A compound selected from formulae (II) and (III): wherein PG is a protecting group and ring A, ring B, X1, X2, X3, X4, R1, R2, R3, R4 and R5 are as defined for the compound of formula (I) in any one of claims 1 to 25, a tautomer thereof, or a salt of said compound or tautomer; and wherein the protecting group is preferably selected from tert-butyloxycarbonyl, benzyloxycarbonyl, p-methoxybenzyl carbonyl, 9-fluorenylmethyloxycarbonyl, acetyl, benzoyl, benzyl, carbamate, p-methoxybenzyl, 3,4-dimethoxybenzyl, p-methoxyphenyl, tosyl, trichloroethoxycarbonyl, 4-nitrobenzenesulfonyl and 2-nitrophenylsulfenyl. |
The compounds of formula (I) of the present invention, and all aspects and preferred embodiments thereof, preferably exist as a single stereoisomer having the absolute configuration: . Where the groups R 2 , R 3 , R 4 and R 5 are all hydrogen, the compounds of formula (I) of the present invention, and all aspects and preferred embodiments thereof, preferably exist as a single stereoisomer having the absolute configuration (3R,5S): . Where the compound of formula (I) is a single stereoisomer, it preferably exists with a stereoisomeric excess of at least 60%, more preferably at least 80%, yet more preferably at least 90%, and most preferably at least 95%, for example 96%, 97%, 98%, 99%, or 100%. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high performance liquid chromatography (HPLC). Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person. Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of propan-2-ol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture. The present invention includes all crystal forms of the compounds of formula (I) including racemates and racemic mixtures (conglomerates) thereof. Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art - see, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel and S. H. Wilen (Wiley, New York, 1994). Where the present invention is directed to a compound of formula (I), preferably the compound has the absolute stereochemical configuration of formula (I)(i): Where the present invention is directed to a compound of formula (I)(A), preferably the compound has the absolute stereochemical configuration of formula (I)(A)(i): Where the present invention is directed to a compound of formula (I)(B), preferably the compound has the absolute stereochemical configuration of formula (I)(B)(i): Where the present invention is directed to a compound of formula (I)(C), preferably the compound has the absolute stereochemical configuration of formula (I)(C)(i): Where the present invention is directed to a compound of formula (I)(D), preferably the compound has the absolute stereochemical configuration of formula (I)(D)(i): Where the present invention is directed to a compound of formula (I)(E), preferably the compound has the absolute stereochemical configuration of formula (I)(E)(i): Where the present invention is directed to a compound of formula (I)(F), preferably the compound has the absolute stereochemical configuration of formula (I)(F)(i):
Where the present invention is directed to a compound of formula (I)(G), preferably the compound has the absolute stereochemical configuration of formula (I)(G)(i): In one particularly preferred aspect of each the compounds of formula (I) and formula (I)(i) of the present invention: ring B is selected from phenyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indazolyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl and dihydroquinazolinyl, and is preferably selected from phenyl, pyridinyl and indazolyl; ring B is either unsubstituted or substituted by 1 to 2 substituents, each independently selected from halo, CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, cyclopropyl, cyclopropoxy, CF 3 , OCF 3 and oxetanyloxy; ring A is selected from furanyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolidinyl and phenyl, and is preferably selected from oxazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrrolidinyl and phenyl; ring A is either unsubstituted or substituted by 1 R 7 group, which is selected from fluoro, chloro, methyl and methoxy; R 1 is selected from hydrogen, methyl and cyclopropyl; R 2 , R 3 , R 4 and R 5 are each hydrogen; and R 6 is hydrogen or methyl. In a more particularly preferred aspect of each the compounds of formula (I) and formula (I)(i) of the present invention: ring B is selected from phenyl, pyridinyl and indazolyl; ring B is either unsubstituted or substituted by 1 to 2 substituents, each independently selected from halo, CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, cyclopropyl, cyclopropoxy, CF 3 , OCF 3 and oxetanyloxy; ring A is selected from oxazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrrolidinyl and phenyl; ring A is either unsubstituted or substituted by methyl; R 1 is selected from hydrogen and cyclopropyl; R 2 , R 3 , R 4 and R 5 are each hydrogen; and R 6 is hydrogen or methyl. In one particularly preferred aspect of each of the compounds of formulae (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F), (I)(G), (I)(A)(i), (I)(B)(i), (I)(C)(i), (I)(D)(i), (I)(E)(i), (I)(F)(i) and (I)(G)(i) of the present invention: R 1 is selected from hydrogen, methyl and cyclopropyl; R 2 , R 3 , R 4 and R 5 are each hydrogen; R 6 is hydrogen or methyl; ring A is either unsubstituted or substituted by 1 or 2 R 7 groups, which are independently selected from fluoro, chloro, methyl and methoxy; R 8 and R 11 are each hydrogen; R 9 is selected from hydrogen, halo, CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, cyclopropyl, cyclopropoxy, CF 3 , OCF 3 and oxetan-3-yloxy; R 10 is selected from hydrogen, fluoro and CN, and is preferably hydrogen; and R 12 is selected from hydrogen, halo, CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, cyclopropyl, cyclopropoxy, CF 3 , OCF 3 and oxetan-3-yloxy. In a more particularly preferred aspect of each of the compounds of formulae (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F), (I)(G), (I)(A)(i), (I)(B)(i), (I)(C)(i), (I)(D)(i), (I)(E)(i), (I)(F)(i) and (I)(G)(i) of the present invention: R 1 is selected from hydrogen and cyclopropyl; R 2 , R 3 , R 4 , R 5 , R 8 , R 10 and R 11 are each hydrogen; R 6 is hydrogen or methyl; ring A is either unsubstituted or substituted by methyl; R 9 is selected from hydrogen, halo, CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, cyclopropyl, cyclopropoxy, CF 3 , OCF 3 and oxetan-3-yloxy; and R 12 is selected from hydrogen, halo, CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, cyclopropyl, cyclopropoxy, CF 3 , OCF 3 and oxetan-3-yloxy. In another particularly preferred aspect of each of the compounds of formulae (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F), (I)(G), (I)(A)(i), (I)(B)(i), (I)(C)(i), (I)(D)(i), (I)(E)(i), (I)(F)(i) and (I)(G)(i) of the present invention: R 1 is selected from hydrogen, methyl and cyclopropyl; R 2 , R 3 , R 4 , R 5 , R 8 and R 11 are each hydrogen; R 6 is hydrogen or methyl; ring A is either unsubstituted or substituted by 1 or 2 R 7 groups, which are independently selected from fluoro, chloro, methyl and methoxy; R 9 and R 10 together form a 5 to 6-membered partially saturated or aromatic ring comprising 1 to 2 nitrogen atoms, which is either unsubstituted or substituted with 1 to 2 substituents, each independently selected from fluoro, chloro, methyl and methoxy; and R 12 is selected from hydrogen, halo, CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, cyclopropyl, cyclopropoxy, CF 3 , OCF 3 and oxetan-3-yloxy, and is preferably hydrogen. In a more particularly preferred aspect of each of the compounds of formulae (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F), (I)(G), (I)(A)(i), (I)(B)(i), (I)(C)(i), (I)(D)(i), (I)(E)(i), (I)(F)(i) and (I)(G)(i) of the present invention: R 1 is selected from hydrogen and cyclopropyl; R 2 , R 3 , R 4 , R 5 , R 8 , R 11 and R 12 are each hydrogen; R 6 is hydrogen or methyl; ring A is either unsubstituted or substituted by methyl; and R 9 and R 10 , together with the phenyl ring to which they are attached, form an indazole ring, which is either unsubstituted or substituted with 1 to 2 substituents, each independently selected from fluoro and methyl, and is preferably substituted by methyl. Preferred compounds of formula (I) for use in the present invention are selected from: N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-chlorophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-methoxyphenyl)oxazole- 2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2- cyclopropylphenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-ethylphenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3- cyclopropylphenyl)oxazole2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropoxy-5- (trifluoromethoxy) phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2-(oxetan-3- yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-4-(3- (trifluoromethyl)phenyl)picolinamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-4-(3- (trifluoromethoxy)phenyl)picolinamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(3-cyanophenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)(3(trifluoromethyl)phenyl)oxazole-2- carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-2-fluoro-4-(1-methyl-1H-indazol-5- yl)benzamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-2-fluoro-4-(1-methyl-1H- indazol-5-yl)benzamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; (S)-N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin -3-yl)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; (R)-N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin -3-yl)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(4-fluoro-3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-(azetidin-1-yl)-5- cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2-(pyrrolidin-1- yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-chloro-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(5-cyano-2-cyclopropylphenyl)- 1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-propyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-3-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxamide; and N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-6-(1H-indazol-4-yl)nicotinamide; a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer. Pharmaceutical acceptable salts of the compounds of formula (I) include the acid addition and base salts (including di-salts) thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate, camsylate, citrate, edisylate, esylate, fumarate, gluceptate, gluconate, glucuronate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, hydrogen phosphate, isethionate, D- and L-lactate, malate, maleate, malonate, mesylate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, palmate, phosphate, saccharate, stearate, succinate sulfate, D-and L-tartrate, and tosylate salts. Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, ammonium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. For a review on suitable salts, see Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH, Weinheim, Germany (2002). A pharmaceutical acceptable salt of a compound of formula (I) may be readily prepared by mixing together solutions of the compound of formula (I) and the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. Pharmaceutical acceptable solvates in accordance with the invention include hydrates and solvates wherein the solvent of crystallization may be isotopically substituted, e.g., D2O, acetone-d6, DMSO-d6. Also, within the scope of the invention are clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in non-stoichiometric amounts. For a review of such complexes, see J. Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975). Hereinafter all references to compounds of formula (I) include references to salts thereof and to solvates and clathrates of compounds of formula (I) and salts thereof. The invention includes all polymorphs of the compounds of formula (I) as hereinbefore defined. Also, within the scope of the invention are so-called "prodrugs" of the compounds of formula (I). Thus, certain derivatives of compounds of formula (I) which have little or no pharmacological activity themselves can, when metabolised upon administration into or onto the body, give rise to compounds of formula (I), having the desired activity. Such derivatives are referred to as "prodrugs". Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as "pro-moieties" as described, for example, in "Design of Prodrugs" by H Bundgaard (Elsevier, 1985). Finally, certain compounds of formula (I) may themselves act as prodrugs of other compounds of formula (I). Also, within the scope of the invention are metabolites of the compounds of formula (I), that is, compounds formed in vivo upon administration of the compound of formula (I). Such metabolites may themselves be a compound of formula (I), which are particularly included with the scope of the present invention. Included within the scope of the present invention are all tautomeric forms of the compounds of formula (I). Certain derivatives of compounds of formula (I) which contain a nitrogen atom may also form the corresponding N-oxide, and such compounds are also within the scope of the present invention. The present invention also includes all pharmaceutically acceptable isotopic variations of a compound of formula (I). An isotopic variation is defined as one in which at least one atom is replaced by an atom having the same atomic number, but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 13 C and 14 C, nitrogen, such as 15 N, oxygen, such as 17 O and 18 O, phosphorus, such as 32 P, sulfur, such as 35 S, fluorine, such as 18 F, and chlorine, such as 36 Cl. Substitution of the compounds of the invention with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half- life or reduced dosage requirements, and hence may be preferred in some circumstances. Certain isotopic variations of the compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, and 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Isotopic variations of the compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples and preparations using appropriate isotopic variations of suitable reagents. The compounds of formula (I) are inhibitors of the deubiquitylating enzyme USP30. According to a further aspect, the present invention provides a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer for use in inhibiting USP30, either in vitro or in vivo. According to a further aspect, the present invention provides a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer for use as a medicament. According to a further aspect, the present invention provides a method of treatment or prevention of a disorder or condition where inhibition of USP30 is known, or can be shown, to produce a beneficial effect, in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer. In one preferred embodiment of all aspects of the invention, the disorder or condition is a CNS indication. In a further preferred embodiment of all aspects of the invention, the disorder or condition is a peripheral indication. According to a further aspect, the present invention provides the use of a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, in the manufacture of a medicament for the treatment or prevention of a disorder or condition where inhibition of USP30 is known, or can be shown, to produce a beneficial effect. The manufacture of a medicament may include, inter alia, the chemical synthesis of the compound of formula (I) or a salt thereof, or the preparation of a composition or formulation comprising the compound or salt, or the packaging of any medicament comprising the compound. In one preferred embodiment of all aspects of the invention, the disorder or condition is a CNS indication. In a further preferred embodiment of all aspects of the invention, the disorder or condition is a peripheral indication. According to a further aspect, the present invention provides a method of inhibition of USP30 in a patient comprising administering to the patient a therapeutically effective amount of a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer. The disorder or condition benefiting from USP30 activity may be selected from a condition involving mitochondrial dysfunction, cancer and fibrosis. In one preferred embodiment of all aspects of the invention, the disorder or condition benefiting from USP30 activity is a condition involving mitochondrial dysfunction. The condition involving mitochondrial dysfunction may be a CNS indication or a peripheral indication. Mitochondrial dysfunctions result from defects of the mitochondria, which are specialized compartments present in every cell of the body except red blood cells. When mitochondria fail, less and less energy is generated within the cell and cell injury or even cell death will follow. If this process is repeated throughout the body the life of the subject in whom this is happening is severely compromised. Diseases of the mitochondria appear most often in organs that are very energy demanding such as the brain, heart, liver, skeletal muscles, kidney and the endocrine and respiratory system. The condition involving mitochondrial dysfunction may be selected from a condition involving a mitophagy defect, a condition involving a mutation in mitochondrial DNA, a condition involving mitochondrial oxidative stress, a condition involving a defect in mitochondrial membrane potential, mitochondrial biogenesis, a condition involving a defect in mitochondrial shape or morphology, and a condition involving a lysosomal storage defect. In particular, the condition involving mitochondrial dysfunction may be selected from: a neurodegenerative disease; multiple sclerosis (MS); mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome; materially-inherited diabetes and deafness (MIDD); Leber's hereditary optic neuropathy (LHON); cancer (including, for example, breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone or other cancers of tissue organs and cancers of the blood cells, such as lymphoma and leukaemia, multiple myeloma, metastatic carcinoma, osteosarcoma, chondosarcoma, Ewing’s sarcoma, nasopharyngeal carcinoma, colorectal cancer, and non-small cell lung carcinoma); neuropathy, ataxia, retinitis pigmentosa, maternally inherited Leigh syndrome (NARP-MILS); Danon disease; diabetes; diabetic nephropathy; metabolic disorders; heart failure; ischemic heart disease leading to myocardial infarction; psychiatric diseases, for example schizophrenia; multiple sulfatase deficiency (MSD); mucolipidosis II (ML II); mucolipidosis III (ML III); mucolipidosis IV (ML IV); GMl-gangliosidosis (GM1); neuronal ceroid- lipofuscinoses (NCL1); Alpers disease; Barth syndrome; beta-oxidation defects; carnitine-acyl- carnitine deficiency; carnitine deficiency; creatine deficiency syndromes; co-enzyme Q10 deficiency; complex I deficiency; complex II deficiency; complex III deficiency; complex IV deficiency; complex V deficiency; COX deficiency; chronic progressive external ophthalmoplegia syndrome (CPEO); CPT I deficiency; CPT II deficiency; glutaric aciduria type II; Kearns-Sayre syndrome; lactic acidosis; long-chain acyl-CoA dehydrogenase deficiency (LCHAD); Leigh disease or syndrome; Leigh syndrome French Canadian (LSFC) variant; lethal infantile cardiomyopathy (LIC); Luft disease; medium-chain acyl-CoA dehydrogenase deficiency (MCAD); myoclonic epilepsy and ragged-red fiber (MERRF) syndrome; mitochondrial cytopathy; mitochondrial recessive ataxia syndrome; mitochondrial DNA depletion syndrome; myoneurogastointestinal disorder and encephalopathy; Pearson syndrome; pyruvate dehydrogenase deficiency; pyruvate carboxylase deficiency; POLG mutations; medium/short-chain 3-hydroxyacyl-CoA dehydrogenase (M/SCHAD) deficiency; very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency; peroxisomal disorders; methylmalonic acidemia; mevalonate kinase deficiency; age-dependent decline in cognitive function and muscle strength; muscle structure disorders; and cognitive impairment associated with neurodegenerative and neuropsychiatric disorders. The condition involving mitochondrial dysfunction may be a CNS disorder, for example a neurodegenerative disease. Neurodegenerative diseases include, but are not limited to, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, ischemia, stroke, dementia with Lewy bodies, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia. In particular, the compounds of the invention may be useful in the treatment or prevention of Parkinson’s disease, including, but not limited to, PD related to mutations in α-synuclein, parkin, PINK1, GBA, and LRRK2, and autosomal recessive juvenile Parkinson’s disease (AR-JP), or early onset Parkinson’s disease (EOPD), where parkin or PINK1 is mutated, truncated, or deleted. In particular, the compounds of the invention may be useful in treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric disorders, including, for example, cognitive impairment associated with Alzheimer’s disease and Parkinson’s disease, preclinical or prodromal forms of AD and PD, Huntington’s disease, dementia with lewy body disease, cognitive impairment associated with schizophrenia, mood disorders, bipolar and major depressive disorders. In a preferred embodiment, the present invention is directed to the treatment or prevention of Leigh syndrome or disease, including for example, X-linked Leigh's disease, Leigh syndrome French Canadian variant, and/or the symptoms associated with Leigh’s disease. In particular, the compounds of the invention may be useful in the treatment of a muscle structure disorder selected from muscular dystrophy, Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, Bethlem myopathy, central core disease, congenital fiber type disproportion, hyaline body myopathy, muscle sodium channel disorders, myotonic chondrodystrophy, myotubular myopathy, nemaline body disease, and stress urinary incontinence. The compounds of the invention or pharmaceutical compositions thereof as described herein may be combined with one or more additional agents when used for the treatment or prevention of conditions involving mitochondrial dysfunction. The compounds may be combined with one or more additional agents selected from levodopa, a dopamine agonist, a monoamino oxygenase (MAO) B inhibitor, a catechol O-methyltransferase (COMT) inhibitor, an anticholinergic, riluzole, amantadine, a cholinesterase inhibitor, memantine, tetrabenazine, an antipsychotic, diazepam, clonazepam, an antidepressant, and an anti-convulsant. The compounds may be combined with agents which reduce/remove pathogenic protein aggregates in neurodegenerative diseases such as agents which reduce/remove alpha-synuclein in Parkinson’s disease, multiple system atrophy or dementia with Lewy bodies; agents which reduce/remove Tau in Alzheimer’s disease or progressive supranuclear palsy; agents which reduce/remove TDP-43 in ALS or frontotemporal dementia. The compounds may be combined with novel agents which may be used as treatments for mitochondrial disease, including, but not limited to, nicotinamide riboside. The compounds may be combined with agents which are used as treatments for muscular dystrophies such as DMD, including corticosteroids (e.g., prednisone and deflazacort), ataluren, eteplirsen, golodirsen, casimersen, viltepso, and other exon-skipping/nonsense readthrough/gene therapies, givinostat, pamrevlumab and vamorolone, and also heart medications, such as angiotensin-converting enzyme inhibitors and beta blockers. In another preferred embodiment of all aspects of the invention, the disorder or condition benefiting from USP30 activity is cancer. The cancer may be linked to mitochondrial dysfunction. Preferred cancers include, for example, breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone or other cancers of tissue organs and cancers of the blood cells, such as lymphoma and leukaemia, multiple myeloma, metastatic carcinoma, osteosarcoma, chondosarcoma, Ewing’s sarcoma, nasopharyngeal carcinoma, colorectal cancer, colorectal cancer, and non-small cell lung carcinoma. In particular, the compounds of the invention may be useful in the treatment or prevention of cancer where apoptotic pathways are dysregulated and more particularly where proteins of the BCL-2 family are mutated, or over or under expressed. Fibrosis refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia. Fibrotic disorders that may be treated by the compounds and compositions of the present invention include, inter alia, fibrosis/fibrotic disorders associated with major organ diseases, for example, interstitial lung disease (ILD), liver cirrhosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) (hepatic fibrosis), kidney disease (renal fibrosis), acute kidney injury (AKI), acute kidney disease (AKD), chronic kidney disease (CKD), delayed kidney graft function, heart or vascular disease (cardiac fibrosis, hypertrophic cardiomyopathy (HCM)), and diseases of the eye; fibroproliferative disorders, for example, systemic and local scleroderma, keloids and hypertrophic scars, atherosclerosis, restenosis, and Dupuytren’s contracture; scarring associated with trauma, for example, surgical complications, chemotherapeutics drug-induced fibrosis (e.g., bleomycin-induced fibrosis), radiation-induced fibrosis, accidental injury and burns); retroperitoneal fibrosis (Ormond's disease); and peritoneal fibrosis/peritoneal scarring in patients receiving peritoneal dialysis, usually following renal transplantation. See, for example, Wynn et al, 2004, Nat Rev Immunol. August; 4(8): 583–594. The present invention therefore relates to methods of treatment or prevention, and compounds and compositions used in said methods, of fibrosis/fibrotic disorders of and/or associated with the major organs, including for example, the lung, liver, kidney, heart, skin, eye, gastrointestinal tract, peritoneum and bone marrow, and other diseases/disorders herein described. The compounds may be combined with agents which are used as treatments for kidney disease, including anti-diabetic agents, cardiovascular disease agents, and novel agents targeting disease relevant pathways such as oxidative stress (including, but not limited to, the nrf2/keap-1 pathway) and anti-apoptotic pathways (including, but not limited to, anti p53 agents). Interstitial lung disease (ILD) includes disorders in which pulmonary inflammation and fibrosis are the final common pathways of pathology, for example, sarcoidosis, silicosis, drug reactions, infections, and collagen vascular diseases, such as rheumatoid arthritis and systemic sclerosis (scleroderma). The fibrotic disorder of the lung includes, for example, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonitis (UIP), interstitial lung disease, cryptogenic fibrosing alveolitis (CFA), bronchiolitis obliterans, and bronchiectasis. Idiopathic pulmonary fibrosis (IPF) is the most common type of ILD and has no known cause. The compounds may be combined with agents which are treatments for IPF and potentially for ILD, including nintedanib and pirfenidone. Liver cirrhosis has similar causes to ILD and includes, for example, cirrhosis associated with viral hepatitis, schistosomiasis and chronic alcoholism. Kidney disease may be associated with diabetes, which can damage and scar the kidneys leading to a progressive loss of function, and also hypertensive diseases. Kidney fibrosis may occur at any stage of kidney disease, from acute kidney disease (AKD) post injury and chronic kidney disease (CKD), such as incident CKD and progressive CKD, through to end-stage renal disease (ESRD). Kidney fibrosis can develop as a result of cardiovascular disease such as hypertension or diabetes, both of which place immense strain on kidney function which promotes a fibrotic response. However, kidney fibrosis can also be idiopathic (without a known cause), and certain genetic mitochondrial diseases also present kidney fibrosis manifestations and associated symptoms. Heart disease may result in scar tissue that can impair the ability of the heart to pump. Diseases of the eye include, for example, macular degeneration and retinal and vitreal retinopathy, which can impair vision. In a preferred embodiment, the present invention is directed to the treatment or prevention of idiopathic pulmonary fibrosis (IPF). In another preferred embodiment, the present invention is directed to the treatment or prevention of kidney fibrosis. In another preferred embodiment, the present invention is directed to the treatment or prevention of acute kidney injury (AKI), especially in high risk patients. Examples include post-surgical AKI, for example organ transplantation, such as due to ischemia reperfusion injury, delayed graft function; oncology, such as AKI due to chemotherapy; contrast medium-induced nephropathy, such as direct- tubular cytotoxicity, hemodynamic ischemia and osmotic effects; acute interstitial nephritis, such as due to drugs or infection; AKI due to obstruction, such as kidney stones; and COVID-19-induced AKI. A particular high risk patient sub-group are those undergoing cardiac surgery, for example, coronary artery bypass graft and/or valve surgery. There are established static risk factors for AKI such as age 65 years or over, insulin dependent diabetes, CKD (adults with an estimated glomerular filtration rate [eGFR] less than 60 ml/min/1.73 m2 are at particular risk), heart failure, liver disease, history of AKI. In another preferred embodiment, the present invention is directed to the treatment or prevention of acute kidney disease (AKD) or chronic kidney disease (CKD) stemming from such AKI, including for example, tubulointerstitial fibrosis and diabetic nephropathy. In another preferred embodiment, the present invention is directed to the treatment or prevention of liver diseases, including, for example, NAFLD, NASH, liver cirrhosis, portal hypertension, acute liver failure, and hepatocellular carcinoma. Liver disease such as NAFLD and NASH may be associated with various metabolic conditions such as metabolic syndrome and Type II diabetes, which also would increase risk for various diabetes associated pathologies, including diabetic retinopathy and peripiheral neuropathies. The compounds of the invention or pharmaceutical compositions thereof as described herein may be combined with one or more additional agents when used for the treatment or prevention of conditions involving liver disease and metabolic dysfunction, including metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists, PPAR agonists, SGLT2 inhibitors, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). References to ‘treatment’ includes means to ameliorate, alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis. The compounds of the invention are useful in the treatment of the diseases disclosed herein in humans and other mammals. In another embodiment, the invention encompasses prophylactic therapy of the diseases disclosed herein and includes means to prevent or slow the appearance of symptoms of the named disorder or condition. The compounds of the invention are useful in the prevention of the diseases disclosed herein in humans and other mammals. A patient in need of treatment or prevention may, for example, be a human or other mammal suffering from the condition or at risk of suffering from the condition. According to a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt of said compound or tautomer, together with a pharmaceutically acceptable diluent or carrier. Pharmaceutical compositions of the invention comprise any of the compounds of the invention combined with any pharmaceutically acceptable carrier, adjuvant or vehicle. Examples of pharmaceutically acceptable carriers are known to those skilled in the art and include, but are not limited to, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms. The compositions may be in the form of, for example, tablets, capsules, powders, granules, elixirs, lozenges, suppositories, syrups, and liquid preparations including suspensions and solutions. The term “pharmaceutical composition” in the context of this invention means a composition comprising an active agent and comprising additionally one or more pharmaceutically acceptable carriers. The composition may further contain ingredients selected from, for example, diluents, adjuvants, excipients, vehicles, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms. The compounds of the invention or pharmaceutical compositions thereof, as described herein, may be used alone or combined with one or more additional pharmaceutical agents. The compounds may be combined with an additional anti-tumour therapeutic agent, for example, chemotherapeutic drugs or inhibitors of other regulatory proteins. In one embodiment, the additional anti-tumour therapeutic agent is a BH-3 mimetic. In a further embodiment, BH-3 mimetics may be selected from but not limited to one or more of ABT-737, ABT-199, ABT-263, and Obatoclax. In a further embodiment, the additional anti-tumour agent is a chemotherapeutic agent. Chemotherapeutic agents may be selected from but not limited to, olaparib, mitomycin C, cisplatin, carboplatin, oxaliplatin, ionizing radiation (IR), camptothecin, irinotecan, topotecan, temozolomide, taxanes, 5-fluoropyrimidines, gemcitabine, and doxorubicin. For the treatment or prevention of fibrotic disorders, for example, the compounds of the invention or pharmaceutical compositions thereof, as described herein, may be used alone or combined with one or more additional pharmaceutical agents selected from the group consisting of anticholinergic agents, beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists, LTD4 antagonists, EGFR inhibitors and endothelin antagonists. In particular, the compounds of the invention or pharmaceutical compositions thereof, as described herein, may be used alone or combined with one or more additional pharmaceutical agents selected from the group consisting of general immunosuppressive drugs, such as a corticosteroid, immunosuppressive or cytotoxic agents, or antifibrotics, such as pirfenidone or a non-specific kinase inhibitor (e.g., nintedanib). The pharmaceutical compositions of the invention may be administered in any suitably effective manner, such as oral, parenteral, topical, inhaled, intranasal, rectal, intravaginal, ocular and aural. Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in "Remington's Pharmaceutical Sciences", 19th Edition (Mack Publishing Company, 1995). Oral Administration The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth. Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi-and nano- particulates, gels, films (including muco- adhesive), ovules, sprays and liquid formulations. Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet. The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001). A typical tablet may be prepared using standard processes known to a formulation chemist, for example, by direct compression, granulation (dry, wet, or melt), melt congealing, or extrusion. The tablet formulation may comprise one or more layers and may be coated or uncoated. Examples of excipients suitable for oral administration include carriers, for example, cellulose, calcium carbonate, dibasic calcium phosphate, mannitol and sodium citrate, granulation binders, for example, polyvinylpyrrolidine, hydroxypropylcellulose, hydroxypropylmethylcellulose and gelatin, disintegrants, for example, sodium starch glycolate and silicates, lubricating agents, for example, magnesium stearate and stearic acid, wetting agents, for example, sodium lauryl sulfate, preservatives, anti-oxidants, flavours and colourants. Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled dual-, targeted and programmed release. Details of suitable modified release technologies such as high energy dispersions, osmotic and coated particles are to be found in Verma et al, Pharmaceutical Technology On-line, 25 (2), 1-14 (2001). Other modified release formulations are described in US Patent No.6,106,864. Parenteral Administration The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors, and infusion techniques. Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates, and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water. The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art. The solubility of compounds of formula (I) used in the preparation of parenteral solutions may be increased by suitable processing, for example, the use of high energy spray-dried dispersions and/or using appropriate formulation techniques, such as the use of solubility-enhancing agents. Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed, sustained, pulsed, controlled dual, targeted, and programmed release. Pharmaceutical compositions of the present invention also include compositions and methods known in the art for bypassing the blood brain barrier or can be injected directly into the brain. Suitable areas for injection include the cerebral cortex, cerebellum, midbrain, brainstem, hypothalamus, spinal cord and ventricular tissue, and areas of the peripheral nervous system including the carotid body and the adrenal medulla. Dosage The magnitude of an effective dose of a compound will, of course, vary with the nature of the severity of the condition to be treated and the route of administration. The selection of appropriate dosages is within the remit of the physician. The daily dose range is about 10 μg to about 100 mg per kg body weight of a human and non-human animal and in general may be around 10 μg to 30 mg per kg body weight per dose. The above dose may be given from one to three times per day. For example, oral administration may require a total daily dose of from 5 mg to 1000 mg, such as from 5 to 500 mg, while an intravenous dose may only require from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight. The total daily dose may be administered in single or divided doses. The skilled person will also appreciate that, in the treatment or prevention of certain conditions, compounds of the invention may be taken as a single dose on an "as required" basis (i.e. as needed or desired). Synthetic methodologies Compounds of formula (I) may be prepared using methods as described below in the general reaction schemes and the representative examples. Where appropriate, the individual transformations within a scheme may be completed in a different order. The invention is illustrated by the following non-limiting examples in which the following abbreviations and definitions are used. Compounds were characterised by liquid chromatography-mass spectrometry (LCMS) or 1 H NMR or both. According to a further aspect, the present invention provides a process for the preparation of a compound of formula (I) comprising reacting a compound of formula (IV), where Y is OH with an amine of formula (V), where PG is a protecting group, such as BOC or Cbz, to give an amide of formula (III) (Scheme 1). The amide-coupling reaction can be performed using standard methodology, for example by reaction using a coupling reagent such as DCC, HATU, HBTU, EDC or via a mixed anhydride. Alternatively, the acid (IV), where Y is OH, or the carboxylate salt thereof, such as the lithium salt, can be converted into the acid chloride (IV), where Y is Cl, using SOCl2, POCl3, PCl3 or PCl5, which can then be reacted with the amine (V), preferably in a suitable solvent in the presence of a suitable base. Alternatively, the compound (IV), where Y forms the ester, can be reacted directly with the amine (V), preferably in a suitable solvent. Compounds of formula (IV) may be prepared according to the processes disclosed in WO 2016/156816, WO 2017/103614, WO 2018/234775, WO 2020/212350, WO 2020/212351, WO 2021/043870, WO 2021/204856, WO 2021/239863, WO 2021/245186, WO 2021/249909 and WO 2022/084479. The compound of formula (III) may be deprotected using standard methods to give amine (II) which may then be reacted with cyanogen bromide to give the corresponding compound of formula (I).
In a further aspect, the present invention provides a compound selected from formulae (II) and (III): wherein PG is a protecting group and ring A, ring B, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein for the compound of formula (I) and all preferred aspects and embodiments thereof, a tautomer thereof, or a salt of said compound or tautomer. For the intermediates of the synthesis of each of the compounds of formulae (I), (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F) and (I)(G) of the present invention, the corresponding compounds of formulae (II) and (III) [(II)(i) to (II)(G)(i) and (III)(i) to (III)(G)(i)] preferably exist as single stereoisomers having the absolute configuration of formulae (II)(i) and (III)(i): Where the compounds of formulae (II) and (III) exist as single stereoisomers, they preferably exist with a stereoisomeric excess of at least 60%, more preferably at least 80%, yet more preferably at least 90%, and most preferably at least 95%, for example 96%, 97%, 98%, 99%, or 100%. Protecting groups are preferably selected from tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Cbz), p-methoxybenzyl carbonyl (MeOZ), 9-fluorenylmethyloxycarbonyl (Fmoc), acetyl (Ac), benzoyl (Bz), benzyl (Bn), carbamate, p-methoxybenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), tosyl (Ts), trichloroethoxycarbonyl (Troc), 4-nitrobenzenesulfonyl (Nosyl) and 2-nitrophenylsulfenyl (Nps). Most preferred are BOC and Cbz. Abbreviations br s broad singlet (NMR signal) MeOH methanol d doublet (NMR signal) min minute(s) DCM dichloromethane NMP N-methyl-2-pyrrolidone DEA diethylamine NMR nuclear magnetic resonance DMF N,N-dimethylformamide nOe nuclear Overhauser effect DMSO dimethylsulfoxide PDA Photodiode-Array ES electrospray rac racemic EtOAc ethyl acetate rt room temperature h hour(s) s singlet (NMR signal) HPLC High performance liquid SFC Supercritical fluid chromatography chromatography IPA isopropyl alcohol TBD 1,5,7-triazabicyclo[4.4.0]dec-5-ene LCMS Liquid chromatography – mass TEA triethylamine spectrometry m multiplet (NMR signal) TFA trifluoroacetic acid Ms mesyl/methanesulfonyl THF tetrahydrofuran MeCN acetonitrile vol volumes
LCMS Methods Method C Method C1 Method F Method H Method H1 Method J Method J1 Method N Method X1 Method used for reverse phase preparative HPLC Method X3 Method used for reverse phase preparative HPLC Method X4 Method used for reverse phase preparative HPLC Method X8 Method used for reverse phase preparative HPLC Method X9 Method used for reverse phase preparative HPLC Method X10 Method used for reverse phase preparative HPLC Method X11 Method used for reverse phase preparative HPLC Method X14 Method used for reverse phase preparative HPLC Method X15 Method used for reverse phase preparative HPLC Method X16 Method used for reverse phase preparative HPLC Method X17 Method used for reverse phase preparative HPLC Method Y4 Method used for analytical chiral SFC Method Y8 Method used for analytical chiral SFC Method Y9 Method used for analytical chiral HPLC Method Y10 Method used for analytical chiral HPLC Method Y12A Method used for analytical chiral SFC Method Y14 Method used for analytical chiral SFC Method Y20 Method used for analytical chiral SFC
Method Y21 Method used for analytical chiral HPLC Method Y28 Method used for analytical chiral HPLC Method Y30 Method used for analytical chiral HPLC Method Y31 Method used for analytical chiral HPLC Method Y32 Method used for analytical chiral HPLC Method Z1 Method used for preparative chiral HPLC Method Z2 Method used for preparative chiral HPLC Synthesis of Intermediates Intermediate A tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-azidopyrrolidine -1-carboxylate To a stirred solution of 1H-1,2,3-triazole (CAS 288-36-8, from Spectrochem, 0.76 g, 11.24 mmol) in DMF (30 mL) was added K2CO3 (3.88 g, 28.11 mmol) at 0°C. tert-Butyl (2S,4R)-4-azido-2- (((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (3.0 g, 9.37 mmol) was added at 0 °C. The mixture was allowed to warm to rt and stirred for 48 h, then poured into ice-cold water (700 mL) and extracted with EtOAc (5 x 100 mL). The combined organic phases were washed with ice-cold water (2 x 100 mL), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 15-20% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-azidopyrrolidine -1-carboxylate (upper spot, 1.0 g, 3.41 mmol, 36% yield) and subsequently (40 to 50% EtOAc in n-hexanes) tert-butyl (2S,4R)-2-((1H- 1,2,3-triazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate (lower spot, 1.0 g, 3.41 mmol, 36% yield). For tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-azidopyrrolidine -1-carboxylate (upper spot, less polar): LCMS: Method C, 1.67 min, MS: ES+ 294.0; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 7.83 (s, 2H), 4.63 - 4.65 (m, 2H), 4.02 - 4.19 (m, 2H), 3.41 - 3.44 (m, 1H), 3.04 - 3.14 (m, 1H), 2.00 - 2.17 (m, 2H), 1.43 (s, 9H). For tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-azidopyrrolidine -1-carboxylate (lower spot, more polar): LCMS: Method C, 1.52 min, MS: ES+ 294.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 7.96 - 8.02 (m, 1H), 7.77 (s, 1H), 4.56 - 4.63 (m, 2H), 4.01 - 4.21 (m, 2H), 3.41 - 3.49 (m, 1H), 3.07 - 3.15 (m, 1H), 1.95 - 2.08 (m, 2H), 1.39 (s, 9H). Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-azidopyrrolidine -1- carboxylate (lower spot, 1.0 g, 3.41 mmol) in MeOH (20 mL) was added 10% Pd/C (50% moisture) (0.50 g, 0.5 w/w). The mixture was purged with H2 gas for 1 h, then filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol- 1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.85 g, 3.18 mmol, 93% yield). LCMS: Method C, 1.26 min, MS: ES+ 268.5. Intermediate B tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamin o)pyrrolidine-1-carboxylate Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamin o)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1- carboxylate (1.0 g, 3.74 mmol) and (1-ethoxycyclopropoxy)trimethylsilane (0.78 g, 4.49 mmol) in MeOH (5 mL) was added AcOH (0.5 mL) dropwise at 0 °C. After 5 min, NaBH3CN (0.47 g, 7.48 mmol) was added in portions at 0 °C and mixture was heated at 60 °C for 6 h. The mixture was mixed with one more identical batch and was concentrated under reduced pressure. The crude product was then poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 4-5% MeOH in DCM) to yield tert-butyl (2S,4R)- 2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamino)pyrrol idine-1-carboxylate (0.38 g, 1.23 mmol, 16% yield). LCMS: Method H1, 2.34 min, MS: ES+ 308.2. Intermediate C tert-Butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-aminopyrrolidine -1-carboxylate Step (i) tert-Butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-aminopyrrolidine -1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-azidopyrrolidine -1- carboxylate (upper spot, 1.0 g, 3.41 mmol) in MeOH (20 mL) was added 10% Pd/C (50% moisture) (0.50 g, 0.5 w/w). The mixture was purged with H2 gas for 1 h, then filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-((2H-1,2,3-triazol- 2-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.98 g, 3.67 mmol, quantitative yield). LCMS: Method C, 1.31 min, MS: ES+ 268.5. Intermediate D tert-Butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-azidopyrrolidine -1-carboxylate To a stirred solution of 4H-1,2,4-triazole (CAS 288-88-0, from Spectrochem, 0.17 g, 2.40 mmol) in DMF (14 mL) was added K 2 CO 3 (0.90 g, 6.56 mmol) at 0 °C. tert-Butyl (2S,4R)-4-azido-2- (((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (0.70 g, 2.18 mmol) was added at 0 °C. The mixture was allowed to warm to rt and stirred for 48 h, then poured into ice-cold water (100 mL) and extracted with EtOAc (4 x 100 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30-35% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4- azidopyrrolidine-1-carboxylate (0.22 g, 0.75 mmol, 34% yield). LCMS: Method C, 1.53 min, MS: ES+ 294.6; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 8.43 (m, 1H), 8.01 (s, 1H), 4.34 - 4.45 (m, 2H), 4.08 - 4.17 (m, 2H), 3.40 - 3.49 (m, 1H), 3.15 - 3.18 (m, 1H), 1.95 - 2.01 (m, 2H), 1.39 (s, 9H). Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-azidopyrrolidine -1- carboxylate (0.22 g, 0.75 mmol) in MeOH (2.2 mL) was added 10% Pd/C (50% moisture) (0.11 g, 0.5 w/w). The mixture was purged with H 2 gas for 2 h, then filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1- yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.16 g, 0.59 mmol, 80% yield). LCMS: Method C, 1.23 min, MS: ES+ 268.2. Intermediate E tert-Butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-aminopyrrolidine -1-carboxylate Step (i) N'-Formylformohydrazide To hydrazine hydrate (99%) (5.00 g, 99.88 mmol) was added formic acid (8.29 mL, 219.73 mmol) dropwise at 0 °C and stirred at 0 °C for 15 min. The mixture was allowed to warm to rt and heated at 120 °C for 6 h. The mixture was cooled to rt and concentrated under reduced pressure. The residue was purified by trituration using diethyl ether (3 x 50 mL) and dried under reduced pressure to yield N'-formylformohydrazide (3.0 g, 34.06 mmol, 34% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.84 (br s, 2H), 8.01 (s, 2H). Step (ii) (E)-N'-((E)-(Dimethylamino)methylene)-N,N-dimethylformohydra zonamide To a stirred solution of N'-formylformohydrazide (3.0 g, 34.06 mmol) in DMF (30 mL) was added SOCl2 (5.46 mL, 74.93 mmol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred at rt for 48 h. The solid was filtered through a Buchner funnel, washed with diethyl ether (3 x 50 mL) and filtrate was concentrated under reduced pressure. The residue was purified by trituration using diethyl ether (2 x 50 mL), n-hexanes (2 x 50 mL) and dried under reduced pressure to yield (E)-N'-((E)- (dimethylamino)methylene)-N,N-dimethylformohydrazonamide (4.0 g, 28.12 mmol, 82% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.30 (s, 2H), 2.99 (s, 12H). Step (iii) tert-Butyl (2S,4R)-2-(aminomethyl)-4-azidopyrrolidine-1-carboxylate An autoclave, charged with a solution of tert-butyl (2S,4R)-4-azido-2- (((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (4.0 g, 12.48 mmol) in MeOH (40 mL) was purged with NH 3 gas at -78 °C and then mixture was heated at 70 °C for 15 h. The resulting mixture was concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-(aminomethyl)-4- azidopyrrolidine-1-carboxylate (1.80 g, 7.45 mmol, 59% yield). LCMS: Method C, 1.29 min, MS: ES+ 186.0 (M-56). Step (iv) tert-Butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-azidopyrrolidine -1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-(aminomethyl)-4-azidopyrrolidine-1-carboxylate (1.0 g, 4.14 mmol) and (E)-N'-((E)-(dimethylamino)methylene)-N,N-dimethylformohydra zonamide (1.17 g, 4.14 mmol) in toluene (10 mL) were added p-TSA (0.08 g, 0.41 mmol) and 4 Å molecular sieves (0.5 g, 0.5 w/w) at rt, and the mixture was heated at 110 °C for 15 h. The mixture was poured into ice-cold water (200 mL) and extracted with EtOAc (3 x 200 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5% MeOH in DCM) to yield tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4- yl)methyl)-4-azidopyrrolidine-1-carboxylate (0.49 g, 1.67 mmol, 40% yield). 1 H NMR (400 MHz, DMSO-d6) δ ppm: 8.42 (s, 2H), 4.11 - 4.31 (m, 4H), 3.12 - 3.18 (m, 1H), 1.85 - 2.12 (m, 3H), 1.42 (s, 9H). Step (v) tert-Butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-aminopyrrolidine -1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-azidopyrrolidine -1- carboxylate (0.49 g, 1.67 mmol) in MeOH (5 mL) was added 10% Pd/C (50% moisture) (0.24 g, 0.5 w/w). The mixture was purged with H2 gas for 2 h, then filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4- yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.25 g, 0.93 mmol, 56% yield). 1 H NMR (400 MHz, DMSO-d6) δ ppm: 8.39 (s, 2H), 4.06 - 4.21 (m, 3H), 3.12 - 3.28 (m, 2H), 2.89 - 3.02 (m, 1H), 1.61 - 1.81 (m, 4H), 1.43 (s, 9H). Intermediate F tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-car boxylate Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-azidopyrrolidine-1-car boxylate To a stirred solution of 1H-pyrazole (CAS 288-13-1, from Combi-Blocks, 1.05 g, 15.46 mmol) in DMF (45 mL) was added K2CO3 (5.82 g, 42.18 mmol) at 0 °C. tert-Butyl (2S,4R)-4-azido-2- (((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (4.50 g, 14.06 mmol) was added at 0 °C. The mixture was allowed to warm to rt and stirred for 48 h, then poured into ice-cold water (100 mL) and extracted with EtOAc (2 x 150 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure The residue was purified by column chromatography (silica gel, 15% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4- azidopyrrolidine-1-carboxylate (2.42 g, 8.25 mmol, 58% yield). LCMS: Method J1, 3.92 min, MS: ES+ 293.0. Step (ii) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-car boxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-azidopyrrolidine-1- carboxylate (0.42 g, 1.43 mmol) in MeOH (4.5 mL) was added 10% Pd/C (50% moisture) (0.21 g, 0.5 w/w). The mixture was purged with H 2 gas for 2 h, then filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-((1H-pyrazol-1- yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.35 g, 1.31 mmol, 91% yield). LCMS: Method J1, 2.64 min, MS: ES+ 267.0. Intermediate G tert-Butyl (2S,4R)-4-amino-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1-carboxylate & tert-Butyl (2S,4R)-4-amino-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1-carboxylate Step (i) tert-Butyl (2S,4R)-4-azido-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1-carboxylate & tert-Butyl (2S,4R)-4-azido-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1-carboxylate To a stirred solution of 3-methyl-1H-pyrazole (CAS 1453-58-3, from Combi-Blocks, 0.77 g, 9.4 mmol) in DMF (30 mL) was added NaH (60% in oil) (0.47 g, 9.8 mmol) in portions at 0 °C. tert-Butyl (2S,4R)- 4-azido-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxy late (1.37g, 4.27 mmol) was added at 0 °C. The mixture was allowed to warm to rt and stirred for 18 h, then poured into ice-cold water (200 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were washed with ice-cold water (2 x 100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 15-20% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-4-azido-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1-carboxylate & tert-butyl (2S,4R)-4-azido-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1-carboxylate as a mixture (0.97 g, 3.18 mmol, 74% yield). LCMS: Method H1, 3.17 min, MS: ES+ 307.0. Step (ii) tert-Butyl (2S,4R)-4-amino-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1-carboxylate & tert-Butyl (2S,4R)-4-amino-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-4-azido-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1- carboxylate & tert-butyl (2S,4R)-4-azido-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1- carboxylate as a mixture (0.97 g, 3.18 mmol) in MeOH (20 mL) was added 10% Pd/C (50% moisture) (0.47 g, 0.5 w/w). The mixture was purged with H 2 gas for 2 h, then filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure to yield tert-butyl (2S,4R)-4-amino-2-((3- methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate & tert-butyl (2S,4R)-4-amino-2-((5-methyl- 1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate as a mixture (0.73 g, quantitative yield). LCMS: Method H, 2.21 min, MS: ES+ 281.0. Intermediate H Lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate Step (i) 3-Acetyl-4-aminobenzonitrile A stirred solution of 1-(2-amino-5-bromophenyl)ethan-1-one (CAS 29124-56-9, from Combi-Blocks, 24.0 g, 112.68 mmol) in DMF (250ml) was purged with N2 gas for 15 min, followed by addition of CuCN (11.09 g, 123.94 mmol) and heated at 170 °C for 16 h. The mixture was poured into water (500 mL) and extracted with EtOAc (2 x 500 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 12% EtOAc in n-hexanes) to yield 3-acetyl-4-aminobenzonitrile (10.5 g, 65.62 mmol, 58% yield). LCMS: Method H1, 2.39 min, MS: ES+ 161.0. Step (ii) 3-Acetyl-4-iodobenzonitrile To a stirred solution of 3-acetyl-4-aminobenzonitrile (9.5 g, 59.37 mmol) in conc. HCl (100 mL) was added NaNO2 (8.19 g, 118.75 mmol) in portions at 0 °C and stirred for 10 min. A solution of KI (24.63 g, 148.42 mmol) in water (100 mL) was added dropwise at 0 °C and stirred for 0.5 h. The mixture was poured into water (200 mL) and extracted with EtOAc (2 x 100 mL). The combined organic phases were washed with 10% sodium thiosulphate solution (2 x 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc in n-hexanes) to yield 3-acetyl-4-iodobenzonitrile (12.5 g, 46.13 mmol, 77% yield). 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 8.18 - 8.21 (m, 2H), 7.67 (dd, J = 8.0, 2.0 Hz, 1H), 2.61 (s, 3H). Step (iii) 3-Acetyl-4-cyclopropylbenzonitrile To a stirred solution of 3-acetyl-4-iodobenzonitrile (12.5 g, 46.13 mmol) and cyclopropylboronic acid (CAS 411235-57-9, from Combi-Blocks, 7.92 g, 92.26 mmol) in toluene : water (130 mL, 8:2) was added K 3 PO 4 (19.55 g, 92.26 mmol). The mixture was purged with N 2 gas for 10 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (3.37 g, 4.61 mmol) and heated at 100 °C for 5 h. The mixture was poured into water (400 mL) and extracted with EtOAc (2 x 400 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc in n-hexanes) to yield 3-acetyl-4-cyclopropylbenzonitrile (4.8 g, 25.94 mmol, 56% yield). LCMS: Method H1, 3.01 min, MS: ES+ 186.0. Step (iv) 3-(2-Bromoacetyl)-4-cyclopropylbenzonitrile To a stirred solution of 3-acetyl-4-cyclopropylbenzonitrile (4.8 g, 25.94 mmol) in THF (50 mL) was added phenyl trimethylammonium tribromide (10.72 g, 28.53 mmol) in portions at rt and stirred for 16 h. The mixture was poured into water (200 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5% EtOAc in n-hexanes) to yield 3-(2-bromoacetyl)-4-cyclopropylbenzonitrile (4.5 g, 17.11 mmol, 65% yield). LCMS: Method H1, 3.25 min, MS: ES- 262.0, 264.0. Step (v) 4-Cyclopropyl-3-glycylbenzonitrile HCl salt To a stirred solution of 3-(2-bromoacetyl)-4-cyclopropylbenzonitrile (4.5 g, 17.11 mmol) in MeCN (50 mL) was added sodium diformylamide (1.97 g, 20.53 mmol) and heated at 80 °C for 1 h. The mixture was cooled to rt and concentrated under reduced pressure. The residue was diluted with MeOH (50 mL) and conc. HCl (4.5 mL). The mixture was further heated at 80 °C for 3 h, then allowed to cool to rt. The mixture was concentrated under reduced pressure, and the residue was stirred with diethyl ether (40 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield 4-cyclopropyl-3-glycylbenzonitrile HCl salt (5.5 g, quantitative yield). LCMS: Method H1, 2.31 min, MS: ES+ 201.0. Step (vi) Ethyl 2-((2-(5-cyano-2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoa cetate To a stirred solution of 4-cyclopropyl-3-glycylbenzonitrile HCl salt (5.5 g, 23.25 mmol) in DCM (60 mL) at 0 °C was added K 2 CO 3 (12.83 g, 93.0 mmol). Ethyl oxalyl chloride (6.32 g, 5.17 mL, 46.5 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to rt, stirred for 1 h, then poured into water (200 mL) and extracted with EtOAc (2 x 200 mL) The combined organic phases were dried over Na 2 SO 4 and concentrated under reduced pressure to yield ethyl 2-((2-(5-cyano-2- cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate (3.3 g, 11.0 mmol, 64% yield over two steps). LCMS: Method H1, 2.84 min, MS: ES+ 301.0. Step (vii) Ethyl 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(5-cyano-2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoa cetate (3.3 g, 11.0 mmol) in POCl 3 (33 mL, 10 vol) was heated at 100 °C for 5 h. The mixture was cooled to rt, slowly poured into crushed ice and extracted with EtOAc (2 x 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 15% EtOAc in n-hexanes) to yield ethyl 5-(5-cyano-2- cyclopropylphenyl)oxazole-2-carboxylate (1.2 g, 4.25 mmol, 39% yield). LCMS: Method H1, 3.38 min, MS: ES+ 283.0. Step (viii) Lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate (0.5 g, 1.77 mmol) in THF (6 mL) was added a solution of LiOH.H2O (0.15 g, 3.54 mmol) in water (1 mL) dropwise at 0 °C and stirred at rt for 3 h. The reaction mixture was concentrated under reduced pressure to yield lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate (0.50 g, quantitative yield). LCMS: Method H1, 2.14 min, MS: ES+ 255.0. Intermediate I Lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxyla te Step (i) Methyl 5-cyano-2-cyclopropylbenzoate To a stirred solution of methyl 2-bromo-5-cyanobenzoate (CAS 1031927-03-3, from Reddy N Reddy, 1.5 g, 6.27 mmol) and cyclopropylboronic acid (CAS 411235-57-9, from Combi-Blocks, 0.59 g, 6.90 mmol) in toluene : water (15 mL, 9:1) was added K3PO4 (2.65 g, 12.54 mmol). The mixture was purged with N2 gas for 15 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.45 g, 0.627 mmol) and heated at 100 °C for 3 h. The mixture was poured into water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 5% EtOAc in n-hexanes) to yield methyl 5-cyano-2- cyclopropylbenzoate (1.0 g, 4.97 mmol, 79% yield). LCMS: Method H1, 3.19 min, MS: ES+ 219.0 (M+18). Step (ii) 5-Cyano-2-cyclopropylbenzohydrazide To a stirred solution of methyl 5-cyano-2-cyclopropylbenzoate (1.0 g, 4.97 mmol) in EtOH (10 mL) was added hydrazine hydrate (99%) (5 mL, 5 vol) at 0 °C. The mixture was allowed to warm to rt and stirred for 3 h. The mixture was concentrated under reduced pressure to yield 5-cyano-2- cyclopropylbenzohydrazide (0.7 g, 3.48 mmol, 70% yield). LCMS: Method H1, 1.96min, MS: ES+ 202.0. Step (iii) Ethyl 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxyla te To a stirred solution of 5-cyano-2-cyclopropylbenzohydrazide (0.7 g, 3.48 mmol) in DCM (7 mL) were added TEA (2.11 g, 2.90 mL, 20.89 mmol) and ethyl oxalyl chloride (0.1 g, 0.85 mL, 7.66 mmol) dropwise at 0 ˚C. The mixture was allowed to warm to rt and stirred for 1 h. TsCl (0.79 g, 4.17 mmol) was added in portions at 0 °C. The mixture was allowed to warm to rt and stirred at rt for 2 h, then poured into water (30 mL) and extracted with DCM (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 40% EtOAc in n-hexanes) to yield ethyl 5-(5- cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (0.3 g, 1.05 mmol, 30% yield). LCMS: Method H1, 3.20 min, MS: ES+ 284.0. Step (vi) Lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxyla te To a stirred solution of ethyl 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxyla te (0.24 g, 0.85 mmol) in THF (4 mL) at 0 °C was added a solution of lithium hydroxide monohydrate (0.03 g, 0.85 mmol) in water (1 mL) dropwise and stirred at rt for 2 h. The mixture was concentrated under reduced pressure to yield lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxyla te (0.25 g, quantitative yield). LCMS: Method H1, 1.94 min, MS: ES+ 256.0. Intermediate J 5-(3-Chlorophenyl)oxazole-2-carboxylic acid Step (i) 2-Bromo-1-(3-chlorophenyl)ethan-1-one To a stirred solution of 1-(3-chlorophenyl)ethan-1-one (CAS 99-02-5, from Sigma-Aldrich, 2.0 g, 12.98 mmol) in DCM (40 mL) was added phenyl trimethylammonium tribromide (4.88 g, 12.98 mmol) at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h, then poured into water (50 mL) and extracted with DCM (2 x 50 mL). The combined organic phases were dried over Na 2 SO 4 and concentrated under reduced pressure to yield 2-bromo-1-(3-chlorophenyl)ethan-1-one (1.1 g, 4.74 mmol, 36% yield). This crude material was used directly in the next step. Step (ii) 2-Amino-1-(3-chlorophenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(3-chlorophenyl)ethan-1-one (1.0 g, 4.31 mmol) in MeCN (25 mL) was added sodium diformylamide (0.62 g, 6.46 mmol) and heated at 80 °C for 12 h. The reaction mixture was cooled to rt and concentrated under reduced pressure. The residue was diluted with MeOH (5 mL) and conc. HCl (2 mL). The mixture was further heated at 60 °C for 2 h, then allowed to cool to rt. The mixture was concentrated under reduced pressure, and the residue was stirred with n-hexanes (25 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield 2-amino-1-(3-chlorophenyl)ethan-1-one HCl salt (0.8 g, 3.89 mmol, 90% yield). LCMS: Method C1, 0.89 min, MS: ES+: 170.2. Step (iii) Ethyl 2-((2-(3-chlorophenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 2-amino-1-(3-chlorophenyl)ethan-1-one HCl salt (0.8 g, 3.89 mmol) in DCM (20 mL) was added K2CO3 (1.61 g, 11.67 mmol) at 0 °C. Ethyl oxalyl chloride (0.79 g, 0.65 mL, 5.83 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to rt, stirred for 2 h, then poured into ice-cold water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 20% EtOAc in n-hexanes) to yield ethyl 2-((2-(3- chlorophenyl)-2-oxoethyl)amino)-2-oxoacetate (0.7 g, 2.60 mmol, 66% yield). LCMS: Method C1, 1.22 min, MS: ES+ 270.3. Step (iv) Ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(3-chlorophenyl)-2-oxoethyl)amino)-2-oxoacetate (0.7 g, 2.60 mmol) in POCl 3 (15 mL, 20 vol) was heated at 100 °C for 16 h. The mixture was cooled to rt, poured into ice- cold water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was suspended in MeOH (10 mL) and stirred at -78 °C for 15 min. The solid was collected by filtration under reduced pressure to afford ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate (0.4 g, 1.59 mmol, 61% yield). LCMS: Method C1 135 min MS: ES+: 2522 Step (v) 5-(3-Chlorophenyl)oxazole-2-carboxylic acid To a stirred solution of ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate (0.2 g, 0.79 mmol) in THF : water (3 : 1, 4 mL) was added lithium hydroxide monohydrate (0.17 g, 3.98 mmol) in portions at 0 °C. The mixture was stirred at rt for 2 h, then poured into water (20 mL), acidified with 1N HCl to pH ~2 to for a precipitate. The solid was collected by filtration under reduced pressure to yield 5-(3-chlorophenyl)oxazole-2-carboxylic acid (0.15 g, 0.67 mmol, 84% yield). LCMS: Method H1, 1.93 min, MS: ES+ 224.0. Intermediate K 5-(2-Methoxyphenyl)oxazole-2-carboxylic acid Step (i) 2-Bromo-1-(2-methoxyphenyl) ethan-1-one To a stirred solution of 1-(2-methoxyphenyl) ethan-1-one (CAS 579-74-8, from Spectrochem, 2.0 g, 13.31 mmol) in THF (40 mL) was added phenyl trimethylammonium tribromide (5.0 g, 13.31 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 16 h, then poured into water (50 mL) and extracted with DCM (2 x 50 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure to yield 2-bromo-1-(2-methoxyphenyl) ethan-1-one (2 g, 8.73 mmol, 65% yield). LCMS: Method F, 6.41 min, MS: ES+: 229.0, 231.0. Step (ii) 2-Amino-1-(2-methoxyphenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(2-methoxyphenyl)ethan-1-one (2.0 g, 8.73 mmol) in MeCN (50 mL) was added sodium diformylamide (1.25 g, 13.09 mmol) and heated at 80 °C for 12 h. The reaction mixture was cooled to rt and concentrated under reduced pressure. The residue was diluted with MeOH (20 mL) and conc. HCl (10 mL). The mixture was further heated at 80 °C for 3 h, then allowed to cool to rt. The mixture was concentrated under reduced pressure, and the residue was stirred with n-hexanes (50 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield 2-amino-1-(2-methoxyphenyl)ethan-1-one HCl salt (1.2 g, 7.26 mmol, 83 % yield). LCMS: Method H1,1.80 min, MS: ES+: 166.0. Step (iii) Ethyl 2-((2-(2-methoxyphenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 2-amino-1-(2-methoxyphenyl)ethan-1-one HCl salt (1.2 g, 7.26 mmol) in DCM (30 mL) was added K 2 CO 3 (3.0 g, 21.78 mmol) at 0 °C. Ethyl oxalyl chloride (1.48 g, 1.20 mL, 10.89 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to rt, stirred for 3 h, then poured into ice-cold water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over Na 2 SO 4 and concentrated under reduced pressure to yield ethyl 2-((2-(2- methoxyphenyl)-2-oxoethyl)amino)-2-oxoacetate (1.0 g, 3.76 mmol, 51% yield). LCMS: Method H1, 2.64 min, MS: ES+ 266.0. Step (iv) Ethyl 5-(2-methoxyphenyl)oxazole-2-carboxylate To a stirred solution of ethyl 2-((2-(2-methoxyphenyl)-2-oxoethyl)amino)-2-oxoacetate (1.0 g, 3.76 mmol) in POCl3 (20 mL, 20 vol) was heated at 100 °C for 3 h. The mixture was cooled to rt, poured into ice-cold water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to yield ethyl 5-(2- methoxyphenyl)oxazole-2-carboxylate (0.8 g, 3.23 mmol, 85% yield). LCMS: Method H1, 3.19 min, MS: ES+: 248.0. Step (v) 5-(2-Methoxyphenyl)oxazole-2-carboxylic acid To a stirred solution of ethyl 5-(2-methoxyphenyl)oxazole-2-carboxylate (0.8 g, 3.23 mmol) in THF : water (6 mL, 2:1) was added LiOH.H2O (0.81 g, 19.42 mmol) in portions at 0 °C. The mixture was stirred at rt for 12 h, then poured into water (20 mL), acidified with 1N HCl to pH ~2 to form a precipitate. The solid was collected by filtration under reduced pressure to yield 5-(2-methoxyphenyl)oxazole-2-carboxylic acid (0.6 g, 2.73 mmol, 84% yield). LCMS: Method C1, 1.00 min, MS: ES+ 220.1. Intermediate L Ethyl 5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate Step (i) Ethyl 2-cyclopropylbenzoate To a stirred solution of ethyl 2-bromobenzoate (CAS 6091-64-1, from Combi-Blocks, 8.0 g, 35.09 mmol) and cyclopropylboronic acid (CAS 411235-57-9, from Combi-Blocks, 3.01 g, 35.09 mmol) in toluene : water (80 mL, 9:1) was added K3PO4 (14.89 g, 70.18 mmol). The mixture was purged with N 2 gas for 20 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]- dichloropalladium(II) (2.56 g, 3.50 mmol) and heated at 120 °C for 3 h. The mixture was poured into water (50 mL) and extracted with EtOAc (2 x 40 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 6% EtOAc in n-hexanes) to yield ethyl 2-cyclopropylbenzoate (5.7 g, 29.98 mmol, 85% yield). LCMS: Method C1, 1.14 min, MS: ES+ 191.0. Step (ii) 2-Cyclopropylbenzohydrazide To a stirred solution of ethyl 2-cyclopropylbenzoate (5.56 g, 29.24 mmol) in EtOH (28 mL) was added hydrazine hydrate (99%) (16.68 mL, 3 vol) at 0 °C and the mixture was heated at 80 °C for 48 h. The mixture was concentrated under reduced pressure to yield 2-cyclopropylbenzohydrazide (4.5 g, 25.55 mmol, 87% yield). LCMS: Method C1, 0.97 min, MS: ES+ 177.2. Step (iii) Ethyl 2-(2-(2-cyclopropylbenzoyl)hydrazineyl)-2-oxoacetate To a stirred solution of 2-cyclopropylbenzohydrazide (4.4 g, 24.98 mmol) in DCM (44 mL) were added TEA (7.57 g, 10.42 mL, 74.94 mmol) and ethyl oxalyl chloride (6.82 g, 5.59 mL, 49.96 mmol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 3 h, then poured into water (120 mL) and extracted with DCM (3 x 50 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure to yield ethyl 2-(2-(2-cyclopropylbenzoyl)hydrazineyl)-2- oxoacetate (13.0 g, quantitative yield). LCMS: Method C1, 1.09 min, MS: ES+ 277.2. Step (iv) Ethyl 5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of ethyl 2-(2-(2-cyclopropylbenzoyl)hydrazineyl)-2-oxoacetate (13 g, 47.08 mmol) in DCM (130 mL) was added TEA (14.26 g, 19.64 mL, 141.24 mmol) and TsCl (10.72 g, 56.49 mmol) in portions at 0 °C. The mixture was allowed to warm at rt and stirred for 3 h, then poured into water (100 mL) and extracted with DCM (3 x 100 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 20% EtOAc in n-hexanes) to yield ethyl 5-(2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (2.97 g, 11.49 mmol, 46% yield over two steps). LCMS: Method C1, 1.36 min, MS: ES+ 259.16. Intermediate M Lithium 5-(2-cyclopropylphenyl)oxazole-2-carboxylate Step (i) 1-(2-Cyclopropylphenyl)ethan-1-one To a stirred solution of 1-(2-bromophenyl)ethan-1-one (CAS 2142-69-0, from Combi-Blocks, 10.0 g, 50.51 mmol) and cyclopropylboronic acid (CAS 411235-57-9, from Combi-Blocks, 8.67 g, 101.02 mmol) in toluene : water (100 mL, 8:2) was added K 3 PO 4 (21.41 g, 101.02 mmol). The mixture was purged with N 2 gas for 10 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]- dichloropalladium(II) (3.69 g, 5.05 mmol) and heated at 100 °C for 5 h. The mixture was poured into water (300 mL) and extracted with EtOAc (2 x 300 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 1 to 2% EtOAc in n-hexanes) to yield 1-(2-cyclopropylphenyl)ethan-1-one (6.0 g, 37.5 mmol, 74% yield). LCMS: Method H1, 3.15 min, MS: ES+ 161.0. Step (ii) 2-Bromo-1-(2-cyclopropylphenyl)ethan-1-one To a stirred solution of 1-(2-cyclopropylphenyl)ethan-1-one (6.0 g, 37.5 mmol) in THF (70 mL) was added phenyl trimethylammonium tribromide (15.50 g, 41.25 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 16 h, then poured into water (200 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 1% EtOAc in n-hexanes) to yield 2-bromo-1-(2-cyclopropylphenyl)ethan-1-one (6.2 g, 26.05 mmol, 69% yield). LCMS: Method H1, 3.38 min, MS: ES+ 239.0, 240.9. Step (iii) 2-Amino-1-(2-cyclopropylphenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(2-cyclopropylphenyl)ethan-1-one (6.2 g, 26.05 mmol) in MeCN (60 mL) was added sodium diformylamide (3.0 g, 31.26 mmol) and heated at 80 °C for 3 h. The reaction mixture was cooled to rt and concentrated under reduced pressure. The residue was diluted with MeOH (60 mL) and conc. HCl (6.5 mL). The mixture was further heated at 80 °C for 16 h, then allowed to cool to rt. The mixture was concentrated under reduced pressure, and the residue was stirred with diethyl ether (50 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield 2-amino-1-(2-cyclopropylphenyl)ethan-1-one HCl salt (8.2 g, quantitative yield). LCMS: Method H1, 2.36 min, MS: ES+ 176.0. Step (iv) Ethyl 2-((2-(2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 2-amino-1-(2-cyclopropylphenyl)ethan-1-one HCl salt (8.2 g, 38.77 mmol) in DCM (85 mL) was added K 2 CO 3 (21.40 g, 155.08 mmol) at 0 °C. Ethyl oxalyl chloride (10.54 g, 8.63 mL, 77.54 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to rt, stirred for 1 h, then poured into water (200 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to yield ethyl 2-((2-(2- cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate (4.1 g, 14.90 mmol, 57% yield over two steps). LCMS: Method H1, 3.09 min, MS: ES+ 276.0. Step (v) Ethyl 5-(2-cyclopropylphenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate (4.1 g, 14.90 mmol) in POCl3 (41 mL, 10 vol) was heated at 100 °C for 5 h. The mixture was cooled to rt, slowly poured into crushed ice and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 20% EtOAc in n-hexanes) to yield ethyl 5-(2- cyclopropylphenyl)oxazole-2-carboxylate (1.5 g, 5.83 mmol, 39% yield). LCMS: Method H1, 3.58 min, MS: ES+: 258.0. Step (vi) Lithium 5-(2-cyclopropylphenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(2-cyclopropylphenyl)oxazole-2-carboxylate (0.5 g, 1.94 mmol) in THF (4 mL) was added a solution of lithium hydroxide monohydrate (0.16 g, 3.88 mmol) in water (1 mL) dropwise at 0 °C and stirred at rt for 2 h. The reaction mixture was concentrated under reduced pressure to yield lithium 5-(2-cyclopropylphenyl)oxazole-2-carboxylate (0.51 g, quantitative yield). LCMS: Method H1, 2.07 min, MS: ES+ 230.0. Intermediate O Lithium 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate Step (i) 2-Bromo-1-(2-(trifluoromethoxy)phenyl)ethan-1-one To a stirred solution of 1-(2-(trifluoromethoxy)phenyl)ethan-1-one (CAS 220227-93-0, from Sigma- Aldrich, 1.0 g, 4.89 mmol) in THF (40 mL) was added phenyl trimethylammonium tribromide (1.84 g, 4.89 mmol) at 0 °C. The mixture was allowed to warm to rt and stirred for 16 h, then poured into water (50 mL) and extracted with DCM (3 x 50 mL). The combined organic phases were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to yield 2-bromo-1-(2- (trifluoromethoxy)phenyl)ethan-1-one (1.2 g, 4.25 mmol, 86% yield). This crude material was used directly in the next step. Step (ii) 2-Amino-1-(2-(trifluoromethoxy)phenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(2-(trifluoromethoxy)phenyl)ethan-1-one (1.2 g, 4.23 mmol) in MeCN (30 mL) was added sodium diformylamide (0.61 g, 6.35 mmol) and heated at 80 °C for 16 h. The reaction mixture was cooled to rt and concentrated under reduced pressure. The residue was diluted with MeOH (5 mL) and conc. HCl (6 mL). The mixture was further heated at 80 °C for 3 h, then allowed to cool to rt. The mixture was concentrated under reduced pressure, and the residue was stirred with n-hexanes (25 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield 2-amino-1-(2-(trifluoromethoxy)phenyl)ethan-1-one HCl salt (1.2 g, quantitative yield). LCMS: Method C1, 0.92 min, MS: ES+: 220.1. Step (iii) Ethyl 2-oxo-2-((2-oxo-2-(2-(trifluoromethoxy)phenyl)ethyl)amino)ac etate To a stirred solution of 2-amino-1-(2-(trifluoromethoxy)phenyl)ethan-1-one HCl salt (1.2 g, 5.47 mmol) in DCM (30 mL) was added K2CO3 (2.26 g, 16.37 mmol) at 0 °C. Ethyl oxalyl chloride (1.11 g, 0.90 mL, 8.21 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 3 h at rt, then poured into ice-cold water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel 30% EtOAc in n-hexanes) to yield ethyl 2-oxo-2-((2-oxo-2-(2-(trifluoromethoxy)phenyl)ethyl)amino)ac etate (0.65 g, 2.30 mmol, 48% yield over two steps). LCMS: Method C1, 1.30 min, MS: ES+ 320.2. Step (iv) Ethyl 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-oxo-2-((2-oxo-2-(2-(trifluoromethoxy)phenyl)ethyl)amino)ac etate (0.6 g, 2.03 mmol) in POCl 3 (10 mL, 15 vol) was heated at 110 °C for 3 h. The mixture was cooled to rt, poured into ice-cold water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30% EtOAc in n-hexanes) to yield ethyl 5-(2- (trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.32 g, 1.06 mmol, 52% yield). LCMS: Method C1, 1.47 min, MS: ES+: 302.2. Step (v) Lithium 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, 0.99 mmol) in THF : MeOH: water (1: 1 : 1, 9 mL) was added LiOH.H2O (0.12 g, 2.98 mmol) in portions at 0 °C. The mixture was stirred at rt for 3 h, and the mixture was concentrated under reduced pressure. The residue was stirred with pentane (10 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield lithium 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, quantitative yield). LCMS: Method C1, 1.13 min, MS: ES+ 274.0. Intermediate P Lithium 5-(3-bromophenyl)oxazole-2-carboxylate Step (i) 2-Amino-1-(3-bromophenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(3-bromophenyl)ethan-1-one (CAS 18523-22-3, from Combi- Blocks, 6.0 g, 21.74 mmol) in MeCN (150 mL) was added sodium diformylamide (3.1 g, 32.62 mmol) and heated at 70 °C for 24 h. The mixture was cooled to rt and concentrated under reduced pressure. The residue was diluted with MeOH (60 mL) and conc. HCl (30 mL). The mixture was further heated at 70 °C for 4 h, then allowed to cool to rt. The mixture was concentrated under reduced pressure, and the residue was stirred with IPA (25 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to afford 2-amino-1-(3-bromophenyl)ethan-1-one HCl salt (7.2 g, quantitative yield). LCMS: Method C1, 0.99 min, MS: ES+: 214.1, 216.1. Step (ii) Ethyl 2-((2-(3-bromophenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 2-amino-1-(3-bromophenyl)ethan-1-one HCl salt (7.0 g, 28.11 mmol) in DCM (100 mL) was added K 2 CO 3 (11.65 g, 84.34 mmol) at 0 °C. Ethyl oxalyl chloride (5.75 g, 4.71 mL, 42.17 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to rt, stirred for 3 h, then poured into water (100 mL) and extracted with DCM (2 x 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to afford ethyl 2-((2-(3-bromophenyl)-2- oxoethyl)amino)-2-oxoacetate (3.0 g, 9.58 mmol, 44% yield over two steps). LCMS: Method C1, 1.19 min, MS: ES+ 314.0, 316.1. Step (iii) Ethyl 5-(3-bromophenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(3-bromophenyl)-2-oxoethyl)amino)-2-oxoacetate (3.0 g, 9.58 mmol) in POCl3 (9.0 mL, 3 vol) was heated at 100 °C for 3 h. The mixture was cooled to rt, poured into ice- cold water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over Na2SO4, filtered and and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30% EtOAc in n-hexanes) to yield ethyl 5-(3- bromophenyl)oxazole-2-carboxylate (1.2 g, 4.06 mmol, 42% yield). LCMS: Method C1, 1.36 min, MS: ES+: 295.9, 297.9. Step (iv) Lithium 5-(3-bromophenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(3-bromophenyl)oxazole-2-carboxylate (1.1 g, 3.72 mmol) in THF : MeOH : water (10 mL, 1:1:1) was added LiOH.H2O (0.45 g, 11.18 mmol) in portions at 0 °C. The mixture was stirred at 0 °C for 3 h, then concentrated under reduced pressure to yield lithium 5-(3- bromophenyl)oxazole-2-carboxylate (1.1 g, quantitative yield). LCMS: Method C1, 1.04 min, MS: ES+ 268.1, 269.9. Intermediate Q Ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol e-2-carboxylate Step (i) Methyl 2-cyclopropyl-5-(trifluoromethoxy)benzoate To a stirred solution of methyl 2-bromo-5-(trifluoromethoxy)benzoate (CAS 1150114-81-0, from Combi-Blocks, 1.30 g, 4.36 mmol) and cyclopropylboronic acid (CAS 411235-57-9, from Angene, 0.37 g, 4.36 mmol) in toluene: water (13 mL, 7:3) was added K 3 PO 4 (1.84 g, 8.69 mmol). The mixture was purged with N 2 gas for 10 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]- dichloropalladium(II) (0.31 g, 0.43 mmol) and heated at 100 °C for 3 h. The mixture was poured into water (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 2% EtOAc in n-hexanes) to yield methyl 2-cyclopropyl-5- (trifluoromethoxy)benzoate (0.85 g, 3.26 mmol, 75% yield). 1 H NMR (400 MHz, CDCl3) δ 7.68 (s, 1H), 7.26 (d, J = 11.6 Hz, 1H), 7.05 (d, J = 8.8 Hz, 1H), 3.95 (s, 3H), 2.65 - 2.69 (m, 1H), 1.02 - 1.05 (m, 2H), 0.68 - 0.70 (m, 2H). Step (ii) 2-Cyclopropyl-5-(trifluoromethoxy)benzohydrazide To a stirred solution of methyl 2-cyclopropyl-5-(trifluoromethoxy)benzoate (1.1 g, 4.22 mmol) in MeOH (28 mL) was added hydrazine hydrate (99%) (3.3 mL, 3 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h. The mixture was concentrated under reduced pressure to yield 2-cyclopropyl-5-(trifluoromethoxy)benzohydrazide (1.07 g, 4.13 mmol, 97% yield). LCMS: Method C1, 1.11 min, MS: ES+ 261.5. Step (iii) Ethyl 2-(2-(2-cyclopropyl-5-(trifluoromethoxy)benzoyl)hydrazineyl) -2-oxoacetate To a stirred solution of 2-cyclopropyl-5-(trifluoromethoxy)benzohydrazide (1.0 g, 3.84 mmol) in DCM (10 mL) were added TEA (1.16 g, 1.6 mL, 11.52 mmol) and ethyl oxalyl chloride (1.04 g, 0.85 mL, 7.68 mmol) dropwise at 0 ˚C. The mixture was allowed to warm to rt and stirred for 2 h, then poured into water (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure to yield ethyl 2-(2-(2-cyclopropyl-5- (trifluoromethoxy)benzoyl)hydrazineyl)-2-oxoacetate (1.64 g, quantitative yield). LCMS: Method C1, 1.20 min, MS: ES+ 361.1. Step (iv) Ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol e-2-carboxylate To a stirred solution of ethyl 2-(2-(2-cyclopropyl-5-(trifluoromethoxy)benzoyl)hydrazineyl) -2- oxoacetate (1.6 g, 4.44 mmol) in DCM (16 mL) were added TEA (1.34 g, 1.85 mL, 13.32 mmol) and TsCl (1.01 g, 5.32 mmol) in portions at 0 °C. The mixture was allowed to warm at rt and stirred for 2 h, then poured into water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 filtered and concentrated under reduced pressure The residue was purified using flash column chromatography (silica gel, 20% EtOAc in n-hexanes) to yield ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol e-2-carboxylate (0.6 g, 1.75 mmol, 39% yield over two steps). LCMS: Method C1, 1.43 min, MS: ES+ 343.1. Intermediate R Ethyl 5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-c arboxylate Step (i) tert-Butyl 2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazine-1-carboxyl ate To a stirred solution of 2-fluoro-5-(trifluoromethoxy)benzoic acid (CAS 886497-85-4, from Combi- Blocks, 7.0 g, 31.23 mmol) in THF (70 mL) were added DIPEA (12.08 g, 16 mL, 105.25 mmol) and HATU (23.7 g, 62.46 mmol) in portions at 0 °C. After 30 min, tert-butyl hydrazinecarboxylate (4.95 g, 37.48 mmol) was added at 0 °C. The mixture was slowly warmed to rt and stirred at rt for 16 h, then poured into ice-cold water (50 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 25% EtOAc in n-hexanes) to yield tert-butyl 2-(2- fluoro-5-(trifluoromethoxy)benzoyl)hydrazine-1-carboxylate (9.0 g, 26.62 mmol, 85% yield). LCMS: Method J1, 3.43 min, MS: ES+ 283.1 (M-56). Step (ii) 2-Fluoro-5-(trifluoromethoxy)benzohydrazide TFA salt To a stirred solution of tert-butyl 2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazine-1-carboxyl ate (5.0 g, 14.78 mmol) in DCM (50 mL) was added TFA (25 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield 2-fluoro- 5-(trifluoromethoxy)benzohydrazide TFA salt (5.0 g, quantitative yield). LCMS: Method C1, 1.02 min, MS: ES+ 239.2. Step (iii) Ethyl 2-(2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazineyl)-2-ox oacetate To a stirred solution of 2-fluoro-5-(trifluoromethoxy)benzohydrazide TFA salt (10.0 g, 20.99 mmol) in DCM (100 mL) was added K2CO3 (17.38 g, 125.97 mmol) at 0 °C. Ethyl oxalyl chloride (8.59 g, 6.97 mL, 62.98 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 4 h. The mixture was poured into water (100 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to afford ethyl 2-(2-(2-fluoro-5-(trifluoromethoxy)benzoyl)- hydrazineyl)-2-oxoacetate (10.0 g, 29.56 mmol, 88% yield over two steps). LCMS: Method C1, 1.13 min, MS: ES+ 339.2. Step (iv) Ethyl 5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-c arboxylate A stirred solution of ethyl 2-(2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazineyl)-2-ox oacetate (10 g, 29.56 mmol) in DCM (100 mL) were added TEA (12.2 mL, 8.85 g, 88.68 mmol) and TsCl (6.76 g, 35.48 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 4 h. The mixture was poured into water (100 mL) and extracted with DCM (2 x 250 mL). The combined organic phases were dried over Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 10% EtOAc in n-hexanes) to afford ethyl 5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-c arboxylate (2.6 g, 8.12 mmol, 27% yield). LCMS: Method J1, 4.02 min, MS: ES+: 320.8. Intermediate S Lithium 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate Step (i) tert-Butyl (2-(5-cyano-2-fluorophenyl)-2-oxoethyl)carbamate To a stirred solution of 3-bromo-4-fluorobenzonitrile (CAS 79630-23-2, from Combi-Blocks) (20.0 g, 100.53 mmol) in dry THF (150 mL) was added isopropylmagnesium chloride (2 M in THF) (50.26 mL, 100.53 mmol) dropwise at rt under N2 atmosphere. The resulting dark solution was stirred at rt for 1.5 h (during which time a precipitate formed). Meanwhile, to a stirred suspension of tert-butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate (21.92 g, 100.53 mmol) in THF (50 mL) was added isopropylmagnesium chloride (2 M in THF) (50.26 mL, 100.53 mmol) dropwise at 0 °C. The resulting solution was stirred for 15 minutes before being added dropwise at 0 °C to the aryl Grignard initially generated. The mixture was stirred at rt for 16 h. The resulting reaction mixture was poured into water (100 mL) and extracted with EtOAc (2 x 200 mL). The organic phase was combined, dried over Na2SO4, filtered and concentrated under reduced pressure. This crude material was purified by column chromatography (25% EtOAc in n-hexanes) to yield tert-butyl (2-(5-cyano-2-fluorophenyl)-2- oxoethyl)carbamate (3.0 g, 10.78 mmol, 10% yield). LCMS: Method H1, 3.01 min, MS: ES+ 179.0 (M-100). Step (ii) 4-Fluoro-3-glycylbenzonitrile TFA salt To a stirred solution of tert-butyl (2-(5-cyano-2-fluorophenyl)-2-oxoethyl)carbamate (2.2 g, 7.9 mmol) in DCM (22 mL) was added TFA (6.6 mL, 3 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 3 h, then concentrated under reduced pressure to yield 4-fluoro-3-glycylbenzonitrile TFA salt (4.0 g, quantitative yield). LCMS: Method C1, 0.37 min, MS: ES+ 178.9. Step (iii) Ethyl 2-((2-(5-cyano-2-fluorophenyl)-2-oxoethyl)amino)-2-oxoacetat e To a stirred solution of 4-fluoro-3-glycylbenzonitrile TFA salt (4.0 g, 13.6 mmol) in DCM (20 mL) was added TEA (4.1 g, 5.7 mL, 41.0 mmol) at 0 °C. Ethyl oxalyl chloride (3.73 g, 3.0 mL, 27.3 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h, then poured into ice-cold water (150 mL) and extracted with EtOAc (2 x 100 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure yield ethyl 2-((2-(5-cyano-2- fluorophenyl)-2-oxoethyl)amino)-2-oxoacetate (2.8 g, 10.07 mmol, 44% yield over two steps). LCMS: Method C1, 1.08 min, MS: ES+ 279.1. Step (iv) Ethyl 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(5-cyano-2-fluorophenyl)-2-oxoethyl)amino)-2-oxoacetat e (2.8 g, 10.07 mmol) in POCl3 (14 mL, 5 vol) was heated at 100 °C for 3 h. The mixture was cooled to rt, poured into ice-cold water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30% EtOAc in n-hexanes) to yield ethyl 5-(5- cyano-2-fluorophenyl)oxazole-2-carboxylate (0.8 g, 3.07 mmol, 38% yield over two steps). LCMS: Method C1, 1.19 min, MS: ES+ 261.1. Step (v) Lithium 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate (0.8 g, 3.07 mmol) in THF (8 mL) was added a solution of LiOH.H2O (0.15 g, 3.69 mmol) in water (2 mL) dropwise at 0 °C and stirred at rt for 1 h. The reaction mixture was concentrated under reduced pressure to yield lithium 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate (0.9 g, quantitative yield). LCMS: Method C1, 0.92 min, MS: ES+ 232.9. Intermediate Y 2-Fluoro-4-(1-methyl-1H-indazol-5-yl)benzoic acid To a stirred solution of 4-bromo-2-fluorobenzoic acid (CAS 112704-79-7, from Ark-Pharma, 2.5 g, 11.47 mmol) and (1-methyl-1H-indazol-5-yl)boronic acid (CAS 590418-08-9, from BLD-Pharma, 2.22 g, 12.61 mmol) in 1,4-dioxane : water (25 mL, 9:1) was added K3PO4 (4.86 g, 22.94 mmol). The mixture was purged with N2 gas for 15 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.83 g, 1.14 mmol) and heated at 100 °C for 3 h. The mixture was poured into water (100 mL) and extracted with EtOAc (2 x 150 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield 2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzoic acid (1.7 g, 6.29 mmol, 54% yield). LCMS: Method J1, 3.08 min, MS: ES+ 271.1. Intermediate Z 3-(3-(Trifluoromethoxy)phenyl)pyrrolidine TFA salt Step (i) tert-Butyl 4-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-pyrrole-1- carboxylate To a stirred solution of NaHMDS (1M in THF) (5.39 mL, 5.39 mmol) in THF (4 mL) was added tert-butyl 3-oxopyrrolidine-1-carboxylate (CAS 101385-93-7, from Combi-Blocks, 0.50 g, 2.69 mmol) in portions at -78 °C and stirred at -78 °C for 15 min. A solution of 1,1,1-trifluoro-N-phenyl-N- ((trifluoromethyl)sulfonyl)methanesulfonamide (CAS 37595-74-7, from TCI, 0.90 g, 2.69 mmol) in THF (4 mL) was added dropwise and stirred at -78 °C for 2 h. Three more identical batches were carried out in similar manner and all four reaction mixtures were mixed and poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to yield tert-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-pyrrole-1- carboxylate (3.3 g, 10.4 mmol, 96% yield). The crude was carried to the next step. Step (ii) tert-Butyl 4-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrole-1-carb oxylate To a stirred solution of tert-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-pyrrole-1- carboxylate (2.50 g, 7.88 mmol) and (3-(trifluoromethoxy)phenyl)boronic acid (CAS 179113-90-7, from Combi-Blocks, 1.61 g, 7.88 mmol) in 1,4-dioxane : water (10 mL, 8:2) was added K 3 PO 4 (5.0 g, 2.36 mmol). The mixture was purged with N 2 gas for 20 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.50 g, 0.78 mmol) and heated at 80 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 4% EtOAc in n-hexanes) to yield tert-butyl 4-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrole-1-carb oxylate (1.1 g, 3.34 mmol, 42% yield). MS: ES+ 273.97 (M-56). Step (iii) tert-Butyl 3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl 4-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrole-1- carboxylate (1.0 g, 3.03 mmol) in MeOH (5 mL) was added 10% Pd/C (50% moisture) (0.5 g, 0.5 w/w). The mixture was purged with H2 gas for 2 h, then filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure to yield tert-butyl 3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1- carboxylate (0.5 g, 1.51 mmol, 49% yield). LCMS: Method C1, 1.47 min, MS: ES+ 275.9 (M-56). Step (iv) 3-(3-(Trifluoromethoxy)phenyl)pyrrolidine TFA salt To a stirred solution of tert-butyl 3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxylate (0.45 g, 1.45 mmol) in DCM (4 mL) was added TFA (2.4 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield 3-(3- (trifluoromethoxy)phenyl) pyrrolidine TFA salt (0.65 g, quantitative yield). LCMS: Method C1, 1.14 min, MS: ES+ 232.0. Intermediate Z1 Ethyl 5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate Step (i) 4-Fluoro-N-methoxy-N-methyl-3-(trifluoromethoxy)benzamide To a stirred solution of 4-fluoro-3-(trifluoromethoxy)benzoic acid (CAS 886496-49-7, from Combi- Blocks, 5.0 g, 22.32 mmol) in THF (50 mL) were added DIPEA (8.63 g, 11.44 mL, 66.96 mmol) and HATU (12.72 g, 33.48 mmol) in portions at 0 °C. After 30 min, N,O-dimethylhydroxylamine HCl (2.39 g, 24.55 mmol) was added at 0 °C. The mixture was allowed to warm to rt and stirred at rt for 16 h, then poured into ice-cold water (100 mL) and extracted with EtOAc (2 x 150 mL). The combined organic phases were dried over Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 16% EtOAc in n-hexanes) to yield 4-fluoro- N-methoxy-N-methyl-3-(trifluoromethoxy)benzamide (4.80 g, 17.97 mmol, 81% yield). LCMS: Method J1, 3.78 min, MS: ES+ 267.8. Step (ii) 1-(4-Fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one To a stirred solution of 4-fluoro-N-methoxy-N-methyl-3-(trifluoromethoxy)benzamide (4.80 g, 17.97 mmol) in THF (48 mL) was added methylmagnesium bromide (3 M in diethyl ether) (17.97 mL, 53.91 mmol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred at rt for 16 h, then poured into water (150 mL), 1N HCl (10 mL) was added and extracted with EtOAc (2 x 150 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 12% EtOAc in n-hexanes) to yield 1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one (3.0 g, 13.51 mmol, 75% yield). 1 H NMR (400 MHz, DMSO-d6) δ ppm: 8.06 - 8.12 (m, 2H), 7.70 (t, J = 8.8 Hz, 1H), 2.62 (s, 3H). Step (iii) 2-Bromo-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one To a stirred solution of 1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one (3.0 g, 13.51 mmol) in THF (30 mL) was added pyridinium tribromide (4.75 g, 14.86 mmol) in portions at rt and stirred at rt for 16 h. The mixture was poured into water (150 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% n-hexanes) to yield 2-bromo- 1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one (2.0 g, 6.66 mmol, 49% yield). The material was forwarded to the next step. Step (iv) 2-Amino-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one (2.0 g, 6.66 mmol) in MeCN (20 mL) was added sodium diformylamide (0.76 g, 7.99 mmol) and heated at 80 °C for 16 h. The mixture was cooled to rt and concentrated under reduced pressure. The residue was diluted with MeOH (20 mL) and conc HCl (2 mL) The mixture was further heated at 80 °C for 16 h, then allowed to cool to rt. The mixture was concentrated under reduced pressure, and the residue was stirred with diethyl ether (20 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield 2-amino-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one HCl salt (2.9 g, quantitative yield). LCMS: Method J1, 2.47 min, MS: ES+ 238.0. Step (v) Ethyl 2-((2-(4-fluoro-3-(trifluoromethoxy)phenyl)-2-oxoethyl)amino )-2-oxoacetate To a stirred solution of 2-amino-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one HCl salt (2.90 g, 10.60 mmol) in DCM (30 mL) at 0 °C was added K2CO3 (4.39 g, 31.8 mmol). Ethyl oxalyl chloride (2.17 g, 1.77 mL, 15.9 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to rt, stirred for 4 h, then poured into water (50 mL) and extracted with DCM (2 x 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to yield ethyl 2-((2- (4-fluoro-3-(trifluoromethoxy)phenyl)-2-oxoethyl)amino)-2-ox oacetate (1.70 g, 5.04 mmol, 75% yield over two steps). LCMS: Method J1, 3.80 min, MS: ES+ 337.8. Step (vi) Ethyl 5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(4-fluoro-3-(trifluoromethoxy)phenyl)-2-oxoethyl)amino )-2- oxoacetate (1.70 g, 5.04 mmol) in POCl3 (9 mL, 5.3 vol) was heated at 120 °C for 16 h. The mixture was cooled to rt, slowly poured into crushed ice and extracted with EtOAc (2 x 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 20% EtOAc in n-hexanes) to yield ethyl 5-(4- fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.96 g, 3.01 mmol, 60% yield). LCMS: Method J1, 3.86 min, MS: ES+ 320.1. Intermediate Z2 Ethyl 5-(2-(azetidin-1-yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2 -carboxylate Step (i) Methyl 2-(azetidin-1-yl)-5-bromonicotinate To a stirred solution of azetidine hydrochloride (CAS 36520-39-5, from Combi-Blocks, 1.79 g, 19.27 mmol) in DMSO (40 mL) was added K2CO3 (6.64 g, 48.18 mmol) at rt and stirred for 5 min. Methyl 5-bromo-2-chloronicotinate (CAS 78686-79-0, from Combi-Blocks, 4.0 g, 16.06 mmol) at rt and the mixture was heated at 80 ℃ for 2 h. The mixture was poured into ice-cold water (100 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield methyl 2-(azetidin-1-yl)-5-bromonicotinate (3.8 g, 14.07 mmol, 87% yield). LCMS: Method C1, 1.35 min, MS: ES+ 271.1, 273.1. Step (ii) Methyl 2-(azetidin-1-yl)-5-cyanonicotinate To a stirred solution of methyl 2-(azetidin-1-yl)-5-bromonicotinate (1.90 g, 7.03 mmol) in DMF (19 mL) was added zinc cyanide (2.46 g, 21.09 mmol) and zinc dust (0.23 g, 3.51 mmol) at rt. The mixture was degassed with N 2 gas for 10 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.26 g, 0.35 mmol) and 1,1′-bis(diphenylphosphino)ferrocene (0.39 g, 0.70 mmol). The mixture was heated at 130 °C for 2 h. One more identical batch was carried out in similar manner and both reaction mixtures were mixed. The resulting mixture was poured into ice-cold water (50 mL), extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 14% EtOAc in n-hexanes) to yield methyl 2-(azetidin-1-yl)-5-cyanonicotinate (1.3 g, 5.99 mmol, 42% yield). LCMS: Method C1, 1.14 min, MS: ES+: 218.1. Step (iii) 2-(Azetidin-1-yl)-5-cyanonicotinohydrazide Methyl 2-(azetidin-1-yl)-5-cyanonicotinate (1.2 g, 5.52 mmol) was added to hydrazine hydrate (99%) (31.2 mL, 26 vol) at 0 ℃. The mixture was stirred at rt for 8 h, then poured into water (20 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield 2-(azetidin-1-yl)-5- cyanonicotinohydrazide (0.90 g, 4.14 mmol, 75% yield). LCMS: Method C1, 0.79 min, MS: ES+ 218.2. Step (iv) Ethyl 5-(2-(azetidin-1-yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2 -carboxylate To a stirred solution of 2-(azetidin-1-yl)-5-cyanonicotinohydrazide (0.9 g, 4.14 mmol) in DCM (10 mL) were added TEA (1.25 g, 1.72 mL, 12.42 mmol) and ethyl oxalyl chloride (0.85 g, 0.69 mL, 6.21 mmol) dropwise at 0 ˚C. The mixture was allowed to warm to rt and stirred for 1 h. TEA (1.25 g, 1.72 mL, 12.42 mmol) and TsCl (0.94 g, 4.96 mmol) was added in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h. The resulting mixture was poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 27% EtOAc in n-hexanes) to yield ethyl 5-(2-(azetidin-1-yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2 - carboxylate (0.55 g, 1.83 mmol, 44% yield). LCMS: Method C1, 1.20 min, MS: ES+ 300.2. Intermediate Z3 Ethyl 5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole -2-carboxylate Step (i) Methyl 5-bromo-2-(pyrrolidin-1-yl)nicotinate To a stirred solution of pyrrolidine (3.56 g, 50.2 mmol) in DMSO (50 mL) was added K 2 CO 3 (8.31 g, 60.24 mmol) at rt and stirred for 5 min. Methyl 5-bromo-2-chloronicotinate (CAS 78686-79-0, from Combi-Blocks, 5.0 g, 20.08 mmol) was added at rt into the reaction mixture and heated at 80 ℃ for 2 h. The mixture was poured into ice-cold water (100 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield methyl 5-bromo-2-(pyrrolidin-1-yl)nicotinate (4.8 g, 16.90 mmol, 84% yield). LCMS: Method C1, 1.37 min, MS: ES+ 285.1, 287.0. Step (ii) Methyl 5-cyano-2-(pyrrolidin-1-yl)nicotinate To a stirred solution of methyl 5-bromo-2-(pyrrolidin-1-yl)nicotinate (0.50 g, 1.76 mmol) in DMF (5 mL) was added zinc cyanide (0.62 g, 5.28 mmol) and zinc dust (0.06 g, 0.88 mmol) at rt. The reaction mixture was degassed with N2 gas for 10 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.06 g, 0.09 mmol) and 1,1′-bis(diphenylphosphino)ferrocene (0.14 g, 0.26 mmol). The reation mixture was heated at 130 °C for 2 h. Eight more identical batches were carried out in similar manner and all nine reaction mixtures were combined for workup. The resulting mixture was poured into ice-cold water (100 mL), extracted with EtOAc (2 x 100 mL). The combined organic phases were washed with ice-cold water (4 x 100 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 34% EtOAc in n-hexanes) to yield methyl 5-cyano-2- (pyrrolidin-1-yl)nicotinate (2.0 g, 8.65 mmol, 54% yield). LCMS: Method C1, 1.20 min, MS: ES+: 232.1. Step (iii) 5-Cyano-2-(pyrrolidin-1-yl)nicotinohydrazide To a stirred solution of methyl 5-cyano-2-(pyrrolidin-1-yl)nicotinate (2.0 g, 8.65 mmol) in ethanol (20 mL) was added hydrazine hydrate (99%) (20 mL, 10 vol) at rt. The reaction mixture was heated at 80 ℃ for 16 h. The mixture was cooled to rt and concentrated under reduced pressure. The residue was suspended in water (20 mL) to form a precipitate. The solid was collected by filtration under reduced pressure to yield 5-cyano-2-(pyrrolidin-1-yl)nicotinohydrazide (0.72 g, 3.11 mmol, 36% yield). LCMS: Method C1, 0.90 min, MS: ES+ 232.1. Step (iv) Ethyl 5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole -2-carboxylate To a stirred solution of 5-cyano-2-(pyrrolidin-1-yl)nicotinohydrazide (0.72 g, 3.11 mmol) in DCM (7 mL) were added TEA (0.94 g, 1.29 mL, 9.33 mmol) and ethyl oxalyl chloride (0.46 g, 0.38 mL, 3.42 mmol) dropwise at 0 ˚C. The mixture was allowed to warm to rt and stirred for 1 h. TEA (0.94 g, 1.29 mL, 9.33 mmol) and TsCl (0.71 g, 3.73 mmol) was added in portions at 0 °C. The mixture was allowed to warm to rt and stirred at rt for 1 h, then poured into water (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 30% EtOAc in n-hexanes) to yield ethyl 5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4- oxadiazole-2-carboxylate (0.23 g, 0.73 mmol, 23% yield). LCMS: Method C1, 1.25 min, MS: ES+ 314.1. Intermediate Z4 Ethyl 5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-c arboxylate Step (i) Methyl 2-chloro-5-(trifluoromethoxy)benzoate To an autoclave, charged with a solution of 2-bromo-1-chloro-4-(trifluoromethoxy)benzene (CAS 468075-00-5, from Combi-Blocks, 5.0 g, 18.25 mmol) in MeOH (100 mL) were added TEA (5.54 g, 7.63 mL, 54.76 mmol) and [1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (1.33 g, 1.82 mmol). The mixture was heated at 80 °C for 16 h under pressure of CO gas (50 psi). The mixture was filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure. The residue was poured into water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 5% EtOAc in n-hexanes) to yield methyl 2-chloro-5-(trifluoromethoxy)benzoate (3.0 g, 11.81 mmol, 65% yield). 1 H NMR (400 MHz, DMSO-d6) δ ppm: 7.79 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.6 Hz, 1H), 3.88 (s, 3H). Step (ii) 2-Chloro-5-(trifluoromethoxy)benzohydrazide To a stirred solution of methyl 2-chloro-5-(trifluoromethoxy)benzoate (3.0 g, 3.81 mmol) in MeOH (30 mL) was added hydrazine hydrate (99%) (15 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield 2-chloro-5- (trifluoromethoxy)benzohydrazide (2.50 g, 9.84 mmol, 83% yield). LCMS: Method H1, 2.37min, MS: ES+ 254.9. Step (iii) Ethyl 5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-c arboxylate To a stirred solution of 2-chloro-5-(trifluoromethoxy)benzohydrazide (2.50 g, 9.84 mmol) in DCM (25 mL) were added TEA (2.98 g, 4.11 mL, 29.52 mmol) and ethyl oxalyl chloride (1.47 g, 1.56 mL, 10.82 mmol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h. TsCl (2.24 g, 11.81 mmol) was added in portions at 0 °C. The mixture was allowed to warm to rt and stirred at rt for 2 h, then poured into water (50 mL) and extracted with DCM (3 x 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 5% EtOAc in n-hexanes) to yield ethyl 5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-c arboxylate (1.5 g, 4.46 mmol, 45% yield). LCMS: Method C1, 1.34 min, MS: ES+ 337.0. Intermediate Z5 Ethyl 5-(2-bromo-5-(trifluoromethoxy) phenyl)-1,3,4-oxadiazole-2-carboxylate Step (i) 2-Bromo-5-(trifluoromethoxy)benzohydrazide To a stirred solution of methyl 2-bromo-5-(trifluoromethoxy)benzoate (CAS 1150114-81-0, from Enamine, 7.0 g, 23.49 mmol) in MeOH (70 mL) was added hydrazine hydrate (99%) (21 mL, 3 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h, then concentrated under reduced pressure to yield 2-bromo-5-(trifluoromethoxy)benzohydrazide (5.10 g, 17.11 mmol, 73% yield). LCMS: Method C, 1.39 min, MS: ES+ 299.0, 301.0. Step (ii) Ethyl 2-(2-(2-bromo-5-(trifluoromethoxy)benzoyl)hydrazineyl)-2-oxo acetate To a stirred solution of 2-bromo-5-(trifluoromethoxy)benzohydrazide (5.10 g, 17.11 mmol) in DCM (51 mL) were added TEA (5.19 g, 7.2 mL, 51.34 mmol) and ethyl oxalyl chloride (2.80 g, 2.29 mL, 20.53 mmol) dropwise at 0 °C. The mixture was allowed to warm to rt, stirred for 2 h, then poured into water (50 mL) and extracted with DCM (3 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4, filtered and concentrated under reduced pressure to yield ethyl 2-(2-(2-bromo-5- (trifluoromethoxy)benzoyl)hydrazineyl)-2-oxoacetate (8.0 g, quantitative yield). LCMS: Method C1, 1.12 min, MS: ES+ 399.0, 401.0. Step (iii) Ethyl 5-(2-bromo-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-ca rboxylate To a stirred solution of ethyl 2-(2-(2-bromo-5-(trifluoromethoxy)benzoyl)hydrazineyl)-2-oxo acetate (8.0 g, 20.10 mmol) in DCM (80 mL) were added TEA (6.10 g, 8.40 mL, 60.30 mmol) and TsCl (3.81 g, 20.10 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h, then poured into water (50 mL) and extracted with DCM (3 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 12% EtOAc in n-hexanes) to yield ethyl 5-(2-bromo-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate (3.63 g, 9.55 mmol, 56% yield over two steps). LCMS: Method C1, 1.35 min, MS: ES+ 380.9, 382.9. Intermediate Z6 Ethyl 3-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol e-5-carboxylate Step (i) 2-Amino-5-(trifluoromethoxy)benzonitrile To a stirred solution of 2-bromo-4-(trifluoromethoxy)aniline (CAS 175278-17-8, from BLDpharm, 20.0 g, 78.44 mmol) in NMP (150 mL) was added CuCN (14.0 g, 156.80 mmol) and heated at 165 °C for 18 h. The mixture was poured into aqueous ammonia solution (300 mL) and extracted with EtOAc (3 x 300 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 8% EtOAc in n-hexanes) to yield 2-amino-5-(trifluoromethoxy)benzonitrile (11.2 g, 55.43 mmol, 70% yield). LCMS: Method H1, 3.04 min, MS: ES- 201.0. Step (ii) 2-Iodo-5-(trifluoromethoxy)benzonitrile To a stirred solution of 2-amino-5-(trifluoromethoxy)benzonitrile (6.0 g, 29.69 mmol) in concentrated HCl (60 mL) was added NaNO2 (4.0 g, 57.97 mmol) in portions at 0 °C and stirred for 10 min at 0 °C. A solution of KI (24.63 g, 74.09 mmol) in water (60 mL) was added dropwise at 0 °C and stirred for 0.5 h. The mixture was poured into water (300 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were washed with 10% sodium thiosulphate solution (2 x 150 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 6% EtOAc in n-hexanes) to yield 2-iodo-5-(trifluoromethoxy)benzonitrile (7.79 g, 24.89 mmol, 84% yield). 1 H NMR (400 MHz, DMSO-d6) δ ppm: 8.13 - 8.16 (m, 1H), 8.01 (s, 1H), 7.48 (d, J = 8.4 Hz, 1H). Step (iii) 2-Cyclopropyl-5-(trifluoromethoxy)benzonitrile To a stirred solution of 2-iodo-5-(trifluoromethoxy)benzonitrile (2.6 g, 8.30 mmol) and cyclopropylboronic acid (CAS 411235-57-9, from Combi-Blocks, 1.42 g, 16.53 mmol) in toluene : water (10 mL, 4:1) was added K 3 PO 4 (3.52 g, 16.60 mmol). The mixture was purged with N 2 gas for 10 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.67 g, 0.91 mmol) and heated at 100 °C for 1 h. Two more identical batches were carried out in similar manner and all three reaction mixtures were mixed and poured into water (500 mL) and extracted with EtOAc (3 x 200 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0.5% EtOAc in n-hexanes) to yield 2-cyclopropyl-5-(trifluoromethoxy)benzonitrile (8.2 g, quantitative yield). 1 H NMR (400 MHz, DMSO-d6) δ ppm: 7.90 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 8.8 Hz, 1H), 2.16 - 2.19 (m, 1H), 1.12 - 1.14 (m, 2H), 0.84 - 0.85 (m, 2H). Step (iv) (Z)-2-Cyclopropyl-N'-hydroxy-5-(trifluoromethoxy)benzimidami de To a stirred solution of 2-cyclopropyl-5-(trifluoromethoxy)benzonitrile (4.0 g, 17.62 mmol) and sodium hydroxide (2.11 g, 52.75 mmol) in EtOH: water (23 mL, 2:1) was added hydroxylamine HCl (3.67 g, 52.81 mmol) and heated at 40 °C for 48 h. The mixture was concentrated under reduced pressure and poured into water (100 mL), and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure to yield (Z)-2-cyclopropyl- N'-hydroxy-5-(trifluoromethoxy)benzimidamide (4.40 g, 16.92 mmol, 96% yield). LCMS: Method H1, 2.79 min, MS: ES+ 261.0. Step (v) Ethyl 3-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol e-5-carboxylate To a stirred solution of (Z)-2-cyclopropyl-N'-hydroxy-5-(trifluoromethoxy)benzimidami de (1.50 g, 5.76 mmol) in pyridine (5 mL) was added ethyl oxalyl chloride (1.18 g, 0.98 mL, 8.64 mmol) dropwise at 0 °C. The mixture was heated at 80 °C for 3 h, then cooled to rt and concentrated under reduced pressure. The obtained crude was diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure to yield ethyl 3-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol e-5-carboxylate (1.44 g, 4.20 mmol, 73% yield). LCMS: Method C, 2.05 min, MS: ES+ 343.1. Intermediate Z7 Ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol e-3-carboxylate Step (i) 2-Cyclopropyl-5-(trifluoromethoxy)benzoic acid To a stirred solution of methyl 2-cyclopropyl-5-(trifluoromethoxy)benzoate (1.10 g, 4.23 mmol) in THF: water (10 mL, 1:1) was added LiOH.H 2 O (0.35 g, 8.46 mmol) in portions at rt and stirred at rt for 4 h. The mixture was then poured into water (30 mL), acidified with citric acid to pH ~4 and extracted with EtOAc (2 x 70 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to yield 2-cyclopropyl-5-(trifluoromethoxy)benzoic acid (1.08 g, quantitative yield). LCMS: Method J1, 3.91 min, MS: ES+ 244.8. Step (ii) Ethyl (Z)-2-(2-cyclopropyl-5-(trifluoromethoxy)benzamido)-2-(hydro xyimino)acetate To a stirred solution of 2-cyclopropyl-5-(trifluoromethoxy)benzoic acid (1.20 g, 4.87 mmol) in THF (12 mL) were added DIPEA (1.88 g, 2.5 mL, 14.63 mmol) and HATU (2.78 g, 7.31 mmol) in portions at 0 °C. After 30 min, ethyl (Z)-2-amino-2-(hydroxyimino)acetate (CAS 10489-74-4, from Combi- Blocks, 0.77 g, 5.85 mmol) was added at 0 °C. The mixture was slowly warmed to rt and stirred at rt for 4 h, then poured into ice-cold water (30 mL) and extracted with EtOAc (2 x 70 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure to yield ethyl (Z)-2-(2-cyclopropyl-5-(trifluoromethoxy)benzamido)-2-(hydro xyimino)acetate (0.90 g, 2.50 mmol, 59% yield over two steps). LCMS: Method J1, 3.71 min, MS: ES+ 361.2. Step (iii) Ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol e-3-carboxylate A solution of ethyl (Z)-2-(2-cyclopropyl-5-(trifluoromethoxy)benzamido)-2-(hydro xyimino)acetate (0.90 g, 2.50 mmol) in pyridine (5 mL) was heated at 110 °C for 16 h. The mixture was warmed to rt and then poured into water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 12% EtOAc in n-hexanes) to yield ethyl 5-(2- cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-c arboxylate (0.17 g, 0.49 mmol, 20% yield over two steps). LCMS: Method J1, 4.50 min, MS: ES+ 342.9. Synthesis of Examples Example 1 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cy clopropylphenyl)-N- cyclopropyloxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate (0.3 g, 1.15 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamin o)pyrrolidine- 1-carboxylate (0.35 g, 1.13 mmol) in pyridine (5 mL) at 0 °C was added POCl 3 (0.53 g, 0.3 mL, 3.45 mmol) dropwise. The mixture was stirred at rt for 2 h, then poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4- (5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carb oxamido)pyrrolidine-1-carboxylate (0.22 g, 0.41 mmol, 36% yield). LCMS: Method H1, 3.24 min, MS: ES+ 544.2. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2-cyclopropylphenyl)-N- cyclopropyloxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamido)pyrrol idine-1-carboxylate (0.22 g, 0.40 mmol) in DCM (5 mL) was added TFA (1.1 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H- 1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cycl opropylphenyl)-N-cyclopropyloxazole-2- carboxamide TFA salt (0.25 g, quantitative yield). LCMS: Method H1, 2.62 min, MS: ES+ 444.2. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide TFA salt (0.25 g, 0.45 mmol) in THF (5 mL) was added K 2 CO 3 (0.18 g, 1.34 mmol) at rt and stirred for 5 min. The mixture was cooled to 0 °C, then cyanogen bromide (0.05 g, 0.45 mmol) was added. The mixture was allowed to warm to rt, stirred for 1 h, then poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80-90% EtOAc in n-hexanes) to yield N-((3R,5S)- 5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5- (5-cyano-2-cyclopropylphenyl)-N- cyclopropyloxazole-2-carboxamide (0.02 g, 0.05 mmol, 13% yield over two steps). LCMS: Method H1, 2.88 min, MS: ES+ 469.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 8.23 (s, 1H), 8.13 (s, 1H), 7.92 (s, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.79 (s, 1H), 7.41 (d, J = 8.4 Hz, 1H), 4.61 - 4.62 (m, 2H), 4.30 - 4.45 (m, 2H), 3.76 - 3.79 (m, 1H), 3.62 - 3.66 (m, 1H), 2.90 - 2.31 (m, 1H), 2.19 - 2.20 (m, 3H), 1.14 - 1.16 (m, 2H), 0.83 - 0.85 (m, 2H), 0.57 - 0.70 (m, 4H); Chiral SFC: Method Y21, 9.34 min. Example 2 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cy clopropylphenyl)-N- cyclopropyl-1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-car boxylate To a stirred solution of lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxyla te (0.3 g, 1.14 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamin o) pyrrolidine-1-carboxylate (0.35 g, 1.14 mmol) in pyridine (3 mL) at 0 °C was added POCl 3 (0.52 g, 0.32 mL, 3.42 mmol) dropwise. The mixture was stirred at rt for 20 min, then poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 65% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol- 1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropy l-1,3,4-oxadiazole-2- carboxamido)pyrrolidine-1-carboxylate (0.30 g, 0.55 mmol, 48% yield). LCMS: Method H1, 3.96 min, MS: ES+ 545.2. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2-cyclopropylphenyl)-N- cyclopropyl-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxam ido)pyrrolidine-1-carboxylate (0.30 g, 0.55 mmol) in DCM (3 mL) was added TFA (1.5 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2-cyclopropylphenyl)-N- cyclopropyl-1,3,4-oxadiazole-2-carboxamide TFA salt (0.40 g, quantitative yield). LCMS: Method J1, 2.75 min, MS: ES+ 445.3. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxam ide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2- cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxam ide TFA salt (0.40 g, 0.71 mmol) in THF (4 mL) was added K2CO3 (0.29 g, 2.15 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.07 g, 0.71 mmol) was added at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylp henyl)-N-cyclopropyl-1,3,4- oxadiazole-2-carboxamide (0.09 g, 0.18 mmol, 35% yield over two steps). LCMS: Method H1, 2.77 min, MS: ES+ 470.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 8.34 (s, 1H), 8.24 (s, 1H), 8.0 (d, J = 8.0 Hz, 1H), 7.80 (s, 1H), 7.36 (d, J = 8.0 Hz, 1H), 4.62 - 4.63 (m, 2H), 4.35 - 4.42 (m, 2H), 3.78 - 3.82 (m, 1H), 3.65 - 3.69 (m, 1H), 3.05 - 3.17 (m, 1H), 2.80 - 2.91 (m, 1H), 2.59 - 2.64 (m, 1H), 2.17 - 2.25 (m, 1H), 1.14 - 1.23 (m, 2H), 0.9 - 1.0 (m, 2H), 0.60 - 0.83 (m, 4H); Chiral SFC: Method Y28, 14.39 min. Example 3 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-cyanopheny l)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-cyanophenyl)oxazole-2-carboxylate (0.54 g, 2.24 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.30 g, 1.12 mmol) in THF (6 mL) was added TBD (0.31 g, 2.24 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 24 h and heated at 70 °C for 24 h. The mixture was poured into water (100 mL) and extracted with EtOAc (4 x 100 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 3.5% MeOH in DCM) to yield tert-butyl (2S,4R)-2-((1H-1,2,3- triazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxami do)pyrrolidine-1-carboxylate (0.14 g, 0.30 mmol, 27% yield). LCMS: Method C, 1.52 min, MS: ES+ 464.5. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3-cyanophenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3- cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.14 g, 0.30 mmol) in DCM (2.8 mL) was added TFA (0.7 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carbox amide TFA salt (0.15 g, quantitative yield). LCMS: Method C, 1.33 min, MS: ES+ 364.5. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3- cyanophenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.31 mmol) in THF (3 mL) was added K 2 CO 3 (0.13 g, 0.94 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.03 g, 0.31 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into ice-cold water (100 mL) and the solid filtered through a Buchner funnel, washed with n-hexanes (2 x 100 mL). The solid residue was purified by trituration using diethylether (2 x 5 mL) to yield N-((3R,5S)-5-((1H-1,2,3- triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanopheny l)oxazole-2-carboxamide (0.07 g, 0.18 mmol, 59% yield over two steps). LCMS: Method H, 2.27 min, MS: ES+ 389.1; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.39 (d, J = 6.8 Hz, 1H), 8.34 (s, 1H), 8.20 (s, 1H), 8.14 (d, J = 8.0 Hz, 1H), 8.10 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.78 (s, 1H), 7.75 (t, J = 8.0 Hz, 1H), 4.61 - 4.63 (m, 2H), 4.33 - 4.38 (m, 2H), 3.65 - 3.69 (m, 1H), 3.39 - 3.43 (m, 1H), 2.16 - 2.25 (m, 1H), 1.95 - 2.03 (m, 1H); Chiral SFC: Method Y12A, 4.55 min. Example 4 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-(trifluoro methoxy)phenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.20 g, 0.66 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.18 g, 0.66 mmol) in THF (10 mL) was added DBU (1 mL, 5 vol) at rt and stirred for 16 h. The mixture was poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 50% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-(trifluoro methoxy)phenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate (0.08 g, 0.15 mmol, 23% yield). LCMS: Method C1, 1.28 min, MS: ES+ 523.4. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3-(trifluoromethoxy)phenyl)oxazole- 2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1 -carboxylate (0.08 g, 0.15 mmol) in DCM (3 mL) was added TFA (0.4 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)o xazole-2-carboxamide TFA salt (0.14 g, quantitative yield). LCMS: Method C1, 1.07 min, MS: ES+ 423.3. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.14 g, 0.25 mmol) in THF (3 mL) was added K2CO3 (0.07 g, 0.51 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.04 g, 0.38 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 68% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy) phenyl)oxazole-2-carboxamide (0.03 g, 0.08 mmol, 51% yield over two steps). LCMS: Method H1, 2.80 min, MS: ES+ 448.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.38 (d, J = 6.4 Hz, 1H), 8.20 (s, 1H), 8.10 (s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.83 (s, 1H), 7.79 (s, 1H), 7.69 (t, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 4.62 - 4.65 (m, 2H), 4.33 - 4.41 (m, 2H), 3.66 - 3.70 (m, 1H), 3.40 - 3.44 (m, 1H), 2.18 - 2.25 (m, 1H), 1.97 - 2.03 (m, 1H); Chiral SFC: Method Y12A, 3.77 min. Example 5 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-chlorophenyl)oxazole-2- carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-chlorophen yl)oxazole-2-carboxamido) pyrrolidine-1-carboxylate To a stirred solution of 5-(3-chlorophenyl)oxazole-2-carboxylic acid (0.1 g, 0.44 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.10 g, 0.37 mmol) in THF (5 mL) were added DIPEA (0.14 g, 0.19 mL, 1.11 mmol) and HATU (0.35 g, 0.92 mmol) at 0 °C. The mixture was stirred at rt for 2 h, then poured into ice-cold water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 50% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-chlorophen yl)- oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.15 g, 0.32 mmol, 84% yield). LCMS: Method C1, 1.27 min, MS: ES+ 473.4. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3-chlorophenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3- chlorophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.15 g, 0.32 mmol) in DCM (3 mL) was added TFA (2.25 mL, 15 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)pyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carbo xamide TFA salt (0.10 g, 0.20 mmol, 64% yield). LCMS: Method C1, 1.04 min, MS: ES+ 373.3. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-chlorophenyl)oxazole-2- carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3- chlorophenyl)oxazole-2-carboxamide TFA salt (0.10 g, 0.20 mmol) in MeCN (3 mL) was added K2CO3 (0.08 g, 0.62 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.03 g, 0.24 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole -2-carboxamide (0.04 g, 0.10 mmol, 49% yield) which was further purified by reverse phase preparative HPLC (Method X1) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-chlorophenyl)oxazole-2- carboxamide (0.02 g, 0.05 mmol, 23% yield). LCMS: Method H1, 2.64 min, MS: ES+ 398.0; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 9.37 (d, J = 6.8 Hz, 1H), 8.20 (s, 1H), 8.06 (s, 1H), 7.93 (s, 1H), 7.79 - 7.81 (m, 2H), 7.51 - 7.59 (m, 2H), 4.62 - 4.64 (m, 2H), 4.34 - 4.38 (m, 2H), 3.66 - 3.70 (m, 1H), 3.40 - 3.44 (m, 1H), 2.18 - 2.24 (m, 1H), 1.96 - 2.03 (m, 1H); Chiral SFC: Method Y20, 5.44 min. Example 6 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-methoxyphenyl)oxazole-2- carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-methoxyphe nyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of 5-(2-methoxyphenyl)oxazole-2-carboxylic acid (0.2 g, 0.91 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.21 g, 1.01 mmol) in THF (5 mL) were added DIPEA (0.35.g, 0.49 mL, 1.11 mmol) and HATU (0.52 g, 1.36 mmol) at 0 °C. The mixture was stirred at rt for 12 h, then poured into ice-cold water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 50% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol- 1-yl)methyl)-4-(5-(2-methoxyphenyl)oxazole-2-carboxamido)pyr rolidine-1-carboxylate (0.18 g, 0.38 mmol, 42% yield). LCMS: Method C1, 1.22 min, MS: ES+ 469.8. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-methoxyphenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl) methyl)-4-(5-(2-methoxyphenyl) oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.18 g, 0.38 mmol) in DCM (3 mL) was added TFA (1.08 mL, 6 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin- 3-yl)-5-(2-methoxyphenyl)oxazole-2-carboxamide TFA salt (0.15 g, quantitative yield). LCMS: Method C1, 1.00 min, MS: ES+ 369.4. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-methoxyphenyl)oxazole-2- carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2- methoxyphenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.31 mmol) in THF (5 mL) was added K 2 CO 3 (0.12 g, 0.93 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.03 g, 0.34 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazol e-2-carboxamide (0.09 g, 0.22 mmol, 59% yield over two steps). LCMS: Method H1, 2.47 min, MS: ES+ 394.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.33 (d, J = 6.4 Hz, 1H), 8.19 (s, 1H), 7.82 (dd, J = 1.2, 7.6 Hz, 1H), 7.78 (s, 1H), 7.71 (s, 1H), 7.42 - 7.47 (m, 1H), 7.21 (d, J = 8.4, Hz 1H), 7.13 (t, J = 7.6 Hz, 1H), 4.61 - 4.62 (m, 2H), 4.34 - 4.39 (m, 2H), 3.97 (s, 3H), 3.64 - 3.68 (m, 1H), 3.38 - 3.43 (m, 1H), 2.17 - 2.24 (m, 1H), 1.95 - 2.01 (m, 1H); Chiral SFC: Method Y4, 5.36 min. Example 7 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropy lphenyl)-1,3,4-oxadiazole-2- carboxamido)pyrrolidine-1-carboxylate A stirred solution of ethyl 5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (0.7 g, 2.71 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.76 g, 2.84 mmol) in THF (7 mL) was purged with N2 for 10 min. TBD (0.41 g, 2.98 mmol) was added in portions at 0 °C The mixture was allowed to warm to rt and stirred for 16 h at rt The mixture was poured into water (50 mL), precipitated solid was collected by filtration under reduced pressure, washed with water (2 x 10 mL), n-hexanes (2 x 20 mL) and dried under reduced pressure to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropy lphenyl)-1,3,4-oxadiazole-2- carboxamido)pyrrolidine-1-carboxylate (0.46 g, 0.97 mmol, 36% yield). LCMS: Method C1, 1.29 min, MS: ES+ 480.41. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidin e-1-carboxylate (0.46 g, 0.95 mmol) in DCM (5 mL) was added TFA (2.3 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-o xadiazole-2-carboxamide TFA salt (0.48 g, quantitative yield). LCMS: Method C1, 1.03 min, MS: ES+ 380.2. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.48 g, 0.97 mmol) in THF (5 mL) was added K2CO3 (0.40 g, 2.92 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.10 g, 0.97 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1- cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazo le-2-carboxamide (0.1 g, 0.24 mmol, 26% yield over two steps). LCMS: Method H1, 2.72 min, MS: ES+ 405.2; 1 H NMR (400 MHz, DMSO-d6) δ 9.77 (d, J = 6.4 Hz, 1H), 8.21 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.80 (s, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 4.64 - 4.65 (m, 2H), 4.36 - 4.39 (m, 2H), 3.67 - 3.71 (m, 1H), 3.43 - 3.46 (m, 1H), 2.69 - 2.71 (m, 1H), 2.19 - 2.25 (m, 1H), 1.99 - 2.04 (m, 1H), 1.03 - 1.04 (m, 2H), 0.77 - 0.78 (m, 2H); Chiral HPLC: Method Y21, 10.58 min. Example 8 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2- cyclopropylphenyl)oxazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropy lphenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(2-cyclopropylphenyl)oxazole-2-carboxylate (0.5 g, 2.12 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.45 g, 1.70 mmol) in THF (10 mL) was added DIPEA (0.82 g, 1.09 mL, 6.38 mmol) at 0 °C. After 10 min, T 3 P (50% in EtOAc) (1.01 g, 2.02 mL, 3.19 mmol) was added dropwise at 0 °C. The mixture was stirred at rt for 5 h, then poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 90% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropy lphenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate (0.15 g, 0.31 mmol, 16% yield over two steps). LCMS: Method H1, 3.32 min, MS: ES- 477.2. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropylphenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2- cyclopropylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carbox ylate (0.15 g, 0.31 mmol) in DCM (5 mL) was added TFA (1.5 mL, 10 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2- carboxamide TFA salt (0.17 g, quantitative yield). LCMS: Method H1, 3.00 min, MS: ES+ 379.0. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2- cyclopropylphenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2- cyclopropylphenyl)oxazole-2-carboxamide TFA salt (0.17 g, 0.34 mmol) in THF (5 mL) was added K 2 CO 3 (0.14 g, 1.03 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.04 g, 0.34 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)ox azole-2-carboxamide (0.08 g, 0.19 mmol, 63% yield over two steps) which was further purified by reverse phase preparative HPLC (Method X4) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2- cyclopropylphenyl)oxazole-2-carboxamide (0.04 g, 0.11 mmol, 35% yield over two steps). LCMS: Method H1, 2.68 min, MS: ES+ 404.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.38 (d, J = 6.8 Hz, 1H), 8.21 (s, 1H), 7.75 - 7.82 (m, 3H), 7.38 - 7.39 (m, 2H), 7.24 - 7.26 (m, 1H), 4.62 - 4.64 (m, 2H), 4.34 - 4.39 (m, 2H), 3.65 - 3.69 (m, 1H), 3.41 - 3.45 (m, 1H), 2.19 - 2.23 (m, 1H), 2.11 - 2.15 (m, 1H), 1.98 - 2.02 (m, 1H), 1.02 - 1.07 (m, 2H), 0.69 - 0.73 (m, 2H); Chiral SFC: Method Y12A, 4.52 min. Example 9 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)oxazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-Triazol-1-yl)methyl)-4-(5-(5-cyano-2-cy clopropylphenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate (0.5 g, 1.92 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1- carboxylate (0.36 g, 1.34 mmol) in pyridine (5 mL) was added POCl 3 (0.88 g, 0.54 mL, 5.76 mmol) dropwise at 0 °C and the mixture was stirred for 2 h at rt. The mixture was then poured into ice-cold water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 90% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol- 1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)oxazole-2-car boxamido)pyrrolidine-1-carboxylate (0.07 g, 0.14 mmol, 8% yield over two steps). LCMS: Method H1, 3.09 min, MS: ES- 502.2. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2- cyclopropylphenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2- cyclopropylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carbox ylate (0.07 g, 0.14 mmol) in DCM (5 mL) was added TFA (0.7 mL, 10 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)ox azole-2-carboxamide TFA salt (0.09 g, quantitative yield). LCMS: Method H1, 2.50 min, MS: ES+ 404.2. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2- cyclopropylphenyl)oxazole-2-carboxamide TFA salt (0.09 g, 0.17 mmol) in THF (5 mL) was added K2CO3 (0.07 g, 0.52 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.02 g, 0.17 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (50 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylp henyl)oxazole-2-carboxamide (0.05 g, 0.10 mmol, 75% yield over two steps) which was further purified by reverse phase preparative HPLC (Method X3) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5- cyano-2-cyclopropylphenyl)oxazole-2-carboxamide (0.02 g, 0.06 mmol, 42% yield over two steps). LCMS: Method H1, 2.92 min, MS: ES+ 429.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.42 (d, J = 5.6 Hz, 1H), 8.21 (s, 1H), 8.18 (d, J = 1.2 Hz, 1H), 7.93 (s, 1H), 7.85 (dd, J = 8.0, 1.2 Hz, 1H), 7.79 (s, 1H), 7.40 (d, J = 8.0 Hz, 1H), 4.63 - 4.64 (m, 2H), 4.36 - 4.39 (m, 2H), 3.67 - 3.71 (m, 1H), 3.41 - 3.45 (m, 1H), 2.21 - 2.26 (m, 2H), 1.98 - 2.04 (m, 1H), 1.12 - 1.17 (m, 2H), 0.82 - 0.86 (m, 2H); Chiral SFC: Method Y9, 5.54 min. Example 10 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2- (trifluoromethoxy)phenyl)oxazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-(trifluoro methoxy)phenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, 1.09 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1- carboxylate (0.33 g, 1.20 mmol) in THF (5 mL) were added DIPEA (0.42 g, 0.56 mL, 3.29 mmol) and T 3 P (50% in EtOAc) (0.69g, 2.19 mmol) at 0 °C. The mixture was stirred at rt for 3 h, then poured into ice-cold water (30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-(trifluoro methoxy)phenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate (0.18 g, 0.34 mmol, 34% yield). LCMS: Method C1, 1.38 min, MS: ES+ 523.3. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-(trifluoromethoxy)phenyl)oxazole- 2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2- (trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1 -carboxylate (0.18 g, 0.34 mmol) in DCM (5 mL) was added TFA (0.9 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)pyrrolidin-3-yl)-5-(2-(trifluoromethoxy)phenyl)o xazole-2-carboxamide TFA salt (0.2 g, quantitative yield). LCMS: Method C1, 1.13 min, MS: ES+ 423.3. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2- (trifluoromethoxy)phenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2- (trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.2 g, 0.37 mmol) in MeCN : THF (6 mL, 1:1) was added K 2 CO 3 (0.15 g, 1.11 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.04 g, 0.41 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexanes) to yield N-((3R,5S)-5- ((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2 -(trifluoromethoxy)phenyl)oxazole-2- carboxamide (0.12 g, 0.26 mmol, 77% yield over two steps). LCMS: Method H1, 2.79 min, MS: ES+ 448.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.42 (d, J = 6.4 Hz, 1H), 8.20 (s, 1H), 8.00 (d, J = 7.2 Hz, 1H), 7.79 (s, 1H), 7.71 (s, 1H), 7.61 (d, J = 6.0 Hz, 3H), 4.62 - 4.64 (m, 2H), 4.36 - 4.39 (m, 2H), 3.66 - 3.70 (m, 1H), 3.41 - 3.44 (m, 1H), 2.18- 2.25 (m, 1H), 1.97 - 2.03 (m, 1H); Chiral SFC: Method Y9, 4.77 min. Example 11 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-ethylphenyl)oxazole-2- carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-bromopheny l)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-bromophenyl)oxazole-2-carboxylate (1.05 g, 3.92 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.7 g, 2.62 mmol) in THF (10 mL) were added DIPEA (1.01 g, 1.38 mL, 7.86 mmol) and T 3 P (50% in EtOAc) (1.66 g, 5.24 mmol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h, then poured into water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic phases were dried over Na2SO4 filtered and concentrated under reduced pressure The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3- triazol-1-yl)methyl)-4-(5-(3-bromophenyl)oxazole-2-carboxami do)pyrrolidine-1-carboxylate (0.6 g, 1.16 mmol, 29% yield over two steps). LCMS: Method C1, 1.26 min, MS: ES+ 517.1, 519.1. Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-vinylpheny l)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3- bromophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.30 g, 0.58 mmol) and potassium vinyltrifluoroborate (CAS 13682-77-4, from Combi-Blocks, 0.10 g, 0.75 mmol) in EtOH (9 mL) was added TEA (0.076 g, 0.1 mL, 0.75 mmol). The mixture was purged with N2 gas for 20 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.04 g, 0.06 mmol) and heated at 80 °C for 3 h. The mixture was poured into water (50 mL) and extracted with EtOAc (2 x 40 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3- vinylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.25 g, 0.53 mmol, 93% yield). LCMS: Method C1, 1.25 min, MS: ES+ 465.3. Step (iii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-ethylpheny l)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-vinylpheny l)- oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.25 g, 0.53 mmol) in MeOH (10 mL) was added 10% Pd/C (50% moisture) (0.12 g, 0.5 w/w). The mixture was purged with H2 gas for 1 h, then filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-ethylpheny l)oxazole-2-carboxamido)pyrrolidine-1- carboxylate (0.22 g, 0.47 mmol, 88%). LCMS: Method C1, 1.44 min, MS: ES+ 467.4. Step (iv) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3-ethylphenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3- ethylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.22 g, 0.47 mmol) in DCM (10 mL) was added TFA (2.2 mL, 10 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)pyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2-carbox amide TFA salt (0.20 g, 0.41 mmol, 88% yield). LCMS: Method C1, 1.07 min, MS: ES+ 367.2. Step (v) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-ethylphenyl)oxazole-2- carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3- ethylphenyl)oxazole-2-carboxamide TFA salt (0.20 g, 0.41 mmol) in THF (5 mL) was added K 2 CO 3 (0.17 g, 1.24 mmol) at rt and the mixture was stirred for 10 min. Cyanogen bromide (0.05 g, 0.45 mmol) was added at 0 °C and the mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5- (3-ethylphenyl)oxazole-2-carboxamide (0.08 g, 0.20 mmol, 43% yield over two steps). LCMS: Method H, 2.81 min, MS: ES+ 392.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.35 (d, J = 6.4 Hz, 1H), 8.20 (s, 1H), 7.94 (s, 1H), 7.79 (s, 1H), 7.68 (s, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 7.6 Hz, 1H), 4.62 - 4.64 (m, 2H), 4.35 - 4.37 (m, 2H), 3.63 - 3.72 (m, 1H), 3.42 - 3.44 (m, 1H), 2.67 - 2.70 (m, 2H), 2.18 - 2.25 (m, 1H), 1.97 - 2.02 (m, 1H), 1.24 (t, J = 7.6 Hz, 3H); Chiral SFC: Method Y9, 5.71 min. Example 12 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3- cyclopropylphenyl)oxazole2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-cyclopropy lphenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-bromopheny l)- oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.18 g, 0.34 mmol) and cyclopropylboronic acid (CAS 411235-57-9, from Combi-Blocks, 0.044 g, 0.52 mmol) in toluene : water (8 mL, 9:1) was added K 3 PO 4 (0.22 g, 1.04 mmol). The mixture was purged with N 2 gas for 20 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.025 g, 0.034 mmol) and heated at 100 °C for 3 h. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-cyclopropy lphenyl)- oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.1 g, 0.20 mmol, 60% yield). LCMS: Method C1, 1.30 min, MS: ES+ 479.3. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3-cyclopropylphenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3- cyclopropylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carbox ylate (0.1 g, 0.20 mmol) in DCM (2.5 mL) was added TFA (0.5 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)pyrrolidin-3-yl)-5-(3-cyclopropylphenyl)oxazole-2- carboxamide TFA salt (0.08 g, 0.16 mmol, 78% yield). LCMS: Method C1, 1.06 min, MS: ES+ 379.2. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3- cyclopropylphenyl)oxazole-2-carboxamide TFA salt (0.08 g, 0.16 mmol) in THF (5 mL) was added K2CO3 (0.07 g, 0.48 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.02 g, 0.17 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 97% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1 ,3,4-oxadiazole-2-carboxamide (0.02 g, 0.06 mmol, 38% yield). LCMS: Method H1, 2.81 min, MS: ES+ 404.2; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.34 (d, J = 6.4 Hz, 1H), 8.19 (s, 1H), 7.94 (s, 1H), 7.78 (s, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.51 (s, 1H), 7.39 (t, J = 7.6 Hz, 1H), 7.15 (d, J = 8.0 Hz, 1H), 4.61 - 4.62 (m, 2H), 4.32 - 4.41 (m, 2H), 3.62 - 3.7 (m, 1H), 3.40 - 3.41 (m, 1H), 2.67 - 2.69 (m, 1H), 2.18 - 2.20 (m, 1H), 1.98 - 1.99 (m, 1H), 0.99 - 1.01 (m, 2H), 0.75 - 0.76 (m, 2H); Chiral HPLC: Method Y10, 10.27 min. Example 13 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropy l-5-(trifluoromethoxy)phenyl)- 1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate A stirred solution of ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol e-2- carboxylate (0.40 g, 1.16 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4- aminopyrrolidine-1-carboxylate (0.31 g, 1.16 mmol) in THF (4 mL) was purged with N 2 for 10 min. DBU (1.2 mL, 3 vol) was added dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 4 h at rt. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 78% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropy l-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.08 g, 0.14 mmol, 12% yield). LCMS: Method C1, 1.32 min, MS: ES+ 564.3. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropy l-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.08 g, 0.14 mmol) in DCM (0.8 mL) was added TFA (0.4 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h, then concentrated under reduced pressure to yield N-((3R,5S)- 5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclo propyl-5-(trifluoromethoxy)phenyl)- 1,3,4-oxadiazole-2-carboxamide TFA salt (0.09 g, quantitative yield). LCMS: Method C1, 1.13 min, MS: ES+ 464.3. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl- 5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.095 g, 0.16 mmol) in THF (1 mL) was added K 2 CO 3 (0.068 g, 0.49 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.017 g, 0.16 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 2 h, then poured into water (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC (Method X8) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1- cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)p henyl)-1,3,4-oxadiazole-2-carboxamide (0.03 g, 0.06 mmol, 41 % yield over two steps). LCMS: Method H1, 3.01 min, MS: ES+ 489.2; 1 H NMR (400 MHz, DMSO-d6) δ 9.77 (d, J = 6.0 Hz, 1H), 8.19 (s, 1H), 7.78 - 7.83 (m, 2H), 7.57 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 4.62 - 4.64 (m, 2H), 4.35 - 4.38 (m, 2H), 3.66 - 3.70 (m, 1H), 3.41 - 3.45 (m, 1H), 2.67 - 2.69 (m, 1H), 2.17 - 2.24 (m, 1H), 1.97 - 2.04 (m, 1H), 1.05 - 1.07 (m, 2H), 0.80 - 0.81 (m, 2H); Chiral HPLC: Method Y9, 4.98 min. Example 14 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cy clopropylphenyl)-1,3,4- oxadiazole-2-carboxamido) pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxyla te (0.25 g, 0.98 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl) methyl)-4-aminopyrrolidine-1- carboxylate (0.34 g, 1.27 mmol) in THF (5 mL) were added DIPEA (2.5 mL, 2.94 mmol) and HATU (0.74 g, 1.96 mmol) at 0 °C. The mixture was stirred at rt for 3 h, then poured into ice-cold water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 83.6% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H- 1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl )-1,3,4-oxadiazole-2-carboxamido)- pyrrolidine-1-carboxylate (0.47 g, quantitative yield). LCMS: Method C1, 1.21 min, MS: ES+ 505.3. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidin e-1-carboxylate (0.47 g, 0.93 mmol) in DCM (3 mL) was added TFA (2.3 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl) -1,3,4-oxadiazole-2-carboxamide TFA salt (0.32 g, 0.62 mmol, 87% yield over three steps). LCMS: Method H1, 2.38 min, MS: ES+ 405.2. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.31 g, 0.60 mmol) in THF (5 mL) was added K2CO3 (0.41 g, 3.04 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.07 g, 0.68 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 30 min, then poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 82% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropy lphenyl)-1,3,4-oxadiazole-2- carboxamide (0.05 g, 0.12 mmol, 17% yield over three steps), which was further purified by reverse phase preparative HPLC (Method X10) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1- cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide (0.01 g, 0.03 mmol, 5% yield over three steps). LCMS: Method H1, 2.55 min, MS: ES+ 430.2; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 9.77 (s, 1H), 8.30 (s, 1H), 8.20 (s, 1H), 7.9 (d, J = 8.0 Hz, 1H), 7.78 (s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 4.62 - 4.64 (m, 2H), 4.33 - 4.44 (m, 2H), 3.65 - 3.72 (s, 1H), 3.42 - 3.45 (m, 1H), 2.77 - 2.9 (m, 1H), 2.16 - 2.25 (m, 1H), 1.98 - 2.05 (s, 1H), 1.16 - 1.17 (m, 2H), 0.93 (s, 2H); Chiral SFC: Method Y4, 5.15 min. Example 15 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropoxy-5- (trifluoromethoxy) phenyl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl) methyl)-4-(5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamido) pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(2-fluoro-5-(trifluoromethoxy) phenyl)-1,3,4-oxadiazole-2-carboxylate (1.2 g, 4.49 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl) methyl)-4-aminopyrrolidine-1- carboxylate (1.43 g, 4.49 mmol) in THF (12 mL) was added TBD (0.75 g, 5.38 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 6 h, then poured into water (50 mL) and extracted with EtOAc (2 x 60 mL). The combined organic phases were dried over anhydrous Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol- 1-yl)methyl)-4-(5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3, 4-oxadiazole-2- carboxamido)pyrrolidine-1-carboxylate (0.13 g, 0.24 mmol, 6% yield). LCMS: Method J1, 3.90 min, MS: ES- 540.1. Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropo xy-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate To a stirred solution of cyclopropanol (CAS 16545-68-9, from Synthonix, 0.03 g, 0.48 mmol) in THF (1.3 mL) was added NaH (60% in oil) (0.02 g, 0.48 mmol) in portions at 0 °C and stirred at 0 °C for 45 min. A solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-fluoro-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.13 g, 0.24 mmol) in THF (1.3 mL) was added dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 6 h, then poured into ice-cold water (20 mL) and extracted with EtOAc (3 x 40 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 40% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropo xy-5-(trifluoromethoxy)- phenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxy late (0.08 g, 0.14 mmol, 57% yield). LCMS: Method J1, 3.66 min, MS: ES+ 580.4. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2- cyclopropoxy(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-car boxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropo xy-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.08 g, 0.13 mmol) in DCM (0.8 mL) was added TFA (0.4 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)- 5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclo propoxy-5-(trifluoromethoxy)phenyl)- 1,3,4-oxadiazole-2-carboxamide TFA salt (0.1 g, quantitative yield). LCMS: Method J1, 2.91 min, MS: ES+ 480.2. Step (iv) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropoxy-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2- cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2- carboxamide TFA salt (0.1 g, 0.16 mmol) in THF (1 mL) was added K2CO3 (0.11 g, 0.84 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.02 g, 0.24 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 96% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3- triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropo xy-5-(trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamide (0.02 g, 0.03 mmol, 24% yield over two steps). LCMS: Method H1, 2.88 min, MS: ES+ 505.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.78 (d, J = 4.0 Hz, 1H), 8.20 (s, 1H), 7.87 (s, 1H), 7.78 (s, 1H), 7.73 - 7.76 (m, 1H), 7.67 - 7.69 (m, 1H), 4.62 - 4.63 (m, 2H), 4.33 - 4.45 (m, 2H), 4.07 - 4.13 (m, 1H), 3.65 - 3.69 (m, 1H), 3.41 - 3.44 (m, 1H), 2.18 - 2.21 (m, 1H), 1.97 - 2.04 (m, 1H), 0.86 - 0.88 (m, 2H), 0.72 - 0.77 (m, 2H); Chiral SFC: Method Y21, 9.32 min. Example 16 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2-(oxetan-3- yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-fl uorophenyl)-N- cyclopropyloxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate (0.25 g, 0.81 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.28 g, 1.22 mmol) in pyridine (2.5 mL) was added POCl 3 (0.37 g, 0.22 mL, 2.44 mmol) dropwise at 0 °C. The mixture was stirred at rt for 30 min, then poured into water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 90% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2- fluorophenyl)-N-cyclopropyloxazole-2-carboxamido)pyrrolidine -1-carboxylate (0.15 g, 0.28 mmol, 26% yield over two steps). LCMS: Method C1, 1.25 min, MS: ES+ 522.3. Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-(o xetan-3-yloxy)phenyl)-N- cyclopropyloxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of oxetan-3-ol (0.02 g, 0.38 mmol) in THF (2 mL) was added NaH (60% in oil) (0.01 g, 0.38 mmol) in portions under N 2 atmosphere at 0 °C. After 15 min, a solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-fl uorophenyl)-N-cyclopropyloxazole-2- carboxamido)pyrrolidine-1-carboxylate (0.18 g, 0.34 mmol) in THF (1 mL) was added dropwise at 0 °C. The mixture was stirred at rt for 2 h, then poured into water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic phases were dried over anhydrous Na 2 SO 4, filtered and concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2- (oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamido)p yrrolidine-1-carboxylate (0.13 g, 0.22 mmol, 75% yield). LCMS: Method C1, 1.17 min, MS: ES+ 476.3 (M-100). Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2-(oxetan-3-yloxy)phenyl)- N-cyclopropyloxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-(o xetan- 3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamido)pyrrolidi ne-1-carboxylate (0.13 g, 0.22 mmol) in DCM (2 mL) was added TFA (0.65 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3- triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3- yloxy)phenyl)-N-cyclopropyloxazole-2- carboxamide TFA salt (0.14 g, quantitative yield). LCMS: Method C1, 0.99 min, MS: ES+ 476.2. Step (iv) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2-(oxetan-3- yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2- (oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide TFA salt (0.14 g, 0.23 mmol) in THF (2 mL) was added K2CO3 (0.09 g, 0.71 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.02 g, 0.23 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (30 mL) and extracted with EtOAc (2 x 40 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC (Method X9) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3-yl oxy)phenyl)-N-cyclopropyloxazole-2- carboxamide (0.01 g, 0.02 mmol, 13% yield over two steps). LCMS: Method H1, 2.43 min, MS: ES+ 501.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 8.20 - 8.23 (m, 2H), 7.93 (s, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.79 (s, 1H), 7.01 (d, J = 8.8 Hz, 1H), 5.57 - 5.60 (m, 1H), 4.99 - 5.03 (m, 2H), 4.75 - 4.78 (m, 2H), 4.60 - 4.61(m, 2H), 4.40 (br s, 1H), 4.32 (br s, 1H), 3.76 - 3.80 (m, 1H), 3.61 - 3.65 (m, 1H), 3.13 (br s, 1H), 2.50 - 2.54 (m, 1H), 2.18 - 2.20 (m, 1H), 0.65 - 0.72 (m, 2H), 0.54 - 0.57 (m, 2H); Chiral HPLC: Method Y21, 11.44 min.
Example 17 N-((3R,5S)-5-((2H-1,2,3-Triazol-2-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide Step (i) tert-Butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-(5-(3-cyanopheny l)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-cyanophenyl)oxazole-2-carboxylate (0.54 g, 2.24 mmol) and tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.30 g, 1.12 mmol) in THF (6 mL) was added TBD (0.31 g, 2.24 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 24 h and heated at 70 °C for 24 h. The mixture was poured into water (100 mL) and extracted with EtOAc (4 x 100 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 3% MeOH in DCM) to yield tert-butyl (2S,4R)-2-((2H-1,2,3- triazol-2-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxami do)pyrrolidine-1-carboxylate (0.15 g, 0.32 mmol, 29% yield). LCMS: Method C, 1.62 min, MS: ES+ 464.5. Step (ii) N-((3R,5S)-5-((2H-1,2,3-Triazol-2-yl)methyl)pyrrolidin-3-yl) -5-(3-cyanophenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-(5-(3-cyanopheny l)- oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.15 g, 0.32 mmol) in DCM (3 mL) was added TFA (0.75 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)pyrrolidin- 3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.31 mmol, 97% yield). LCMS: Method C, 1.33 min, MS: ES+ 364.5. Step (iii) N-((3R,5S)-5-((2H-1,2,3-Triazol-2-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide To a stirred solution of N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)pyrrolidin-3-yl) -5-(3- cyanophenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.31 mmol) in THF (3 mL) was added K 2 CO 3 (0.13 g, 0.94 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.03 g, 0.31 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into ice-cold water (100 mL) and solid filtered through a Buchner funnel, washed with n-hexanes (2 x 100 mL) to yield N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide (0.07 g, 0.17 mmol, 56% yield). LCMS: Method H, 2.47 min, MS: ES+ 389.1; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.40 (d, J = 6.4 Hz, 1H), 8.34 (s, 1H), 8.14 (d, J = 8.0 Hz, 1H), 8.10 (s, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.86 (s, 2H), 7.75 (t, J = 8.0 Hz, 1H), 4.63 - 4.65 (m, 2H), 4.37 - 4.46 (m, 1H), 4.26 - 4.35 (m, 1H), 3.61 - 3.65 (m, 1H), 3.38 - 3.41 (m, 1H), 2.17 - 2.25 (m, 1H), 2.01 - 2.08 (m, 1H); Chiral SFC: Method Y12A, 3.99 min. Example 18 N-((3R,5S)-5-((1H-1,2,4-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-(5-(3-cyanopheny l)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-cyanophenyl)oxazole-2-carboxylate (0.31 g, 1.40 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.25 g, 0.93 mmol) in pyridine (2.5 mL) was added POCl3 (0.43 g, 0.27 mL, 2.81 mmol) dropwise at 0 °C and the mixture was stirred for 2 h at 0 °C. The mixture was then poured into ice-cold water (100 mL) and extracted with DCM (4 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 2% MeOH in DCM) to yield tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-(5-(3- cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.06 g, 0.13 mmol, 14% yield). LCMS: Method C, 1.531 min, MS: ES+ 464.4. Step (ii) N-((3R,5S)-5-((1H-1,2,4-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3-cyanophenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-(5-(3- cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.06 g, 0.13 mmol) in DCM (1.2 mL) was added TFA (0.3 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,4-triazol-1- yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carbox amide TFA salt (0.07 g, quantitative yield). LCMS: Method C, 1.316 min, MS: ES+ 364.3. Step (iii) N-((3R,5S)-5-((1H-1,2,4-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3- cyanophenyl)oxazole-2-carboxamide TFA salt (0.07 g, 0.15 mmol) in THF (1.4 mL) was added K2CO3 (0.06 g, 0.44 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.01 g, 0.15 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into ice-cold water (100 mL) and extracted with DCM (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 5.6% MeOH in DCM) to yield N-((3R,5S)-5-((1H-1,2,4-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole- 2-carboxamide (0.01 g, 0.02 mmol, 30% yield over two steps). LCMS: Method N, 13.05 min, MS: ES+ 389.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.40 (d, J = 6.4 Hz, 1H), 8.58 (s, 1H), 8.34 (s, 1H), 8.10 - 8.15 (m, 2H), 8.04 (s, 1H), 7.91 - 7.93 (m, 1H), 7.74 - 7.77 (m, 1H), 4.30 - 4.42 (m, 4H), 3.67 - 3.70 (m, 1H), 3.40 - 3.43 (m, 1H), 2.16 - 2.23 (m, 1H), 1.99 - 2.07 (m, 1H); Chiral SFC: Method Y12A, 4.12 min. Example 19 N-((3R,5S)-5-((4H-1,2,4-Triazol-4-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide Step (i) tert-Butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-(5-(3-cyanopheny l)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-aminopyrrolidine -1- carboxylate (0.26 g, 0.97 mmol) and lithium 5-(3-cyanophenyl)oxazole-2-carboxylate (0.25 g, 1.16 mmol) in DMF (2.6 mL) were added DIPEA (0.25 g, 0.33 mL, 1.94 mmol) and T 3 P (50% in EtOAc) (0.46 g, 0.92 mL, 1.45 mmol) at 0 °C. The mixture was stirred at rt for 15 h. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by trituration using diethyl ether (2 x 10 mL) to yield tert-butyl (2S,4R)-2-((4H-1,2,4-triazol- 4-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)pyrro lidine-1-carboxylate (0.13 g, 0.28 mmol, 29% yield). LCMS: Method J, 3.79 min, MS: ES+ 464.2. Step (ii) N-((3R,5S)-5-((4H-1,2,4-Triazol-4-yl)methyl)pyrrolidin-3-yl) -5-(3-cyanophenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-(5-(3- cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.13 g, 0.28 mmol) in DCM (2.6 mL) was added TFA (0.65 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((4H-1,2,4-triazol-4- yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carbox amide TFA salt (0.13 g, 0.27 mmol, 97% yield). LCMS: Method J, 2.81 min, MS: ES+ 364.0. Step (iii) N-((3R,5S)-5-((4H-1,2,4-Triazol-4-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide To a stirred solution of N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)pyrrolidin-3-yl) -5-(3- cyanophenyl)oxazole-2-carboxamide TFA salt (0.13 g, 0.27 mmol) in THF (5 mL) was added K2CO3 (0.11 g, 0.81 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.028 g, 0.27 mmol) was added into the reaction mixture at 0 °C. The mixture was allowed to warm to rt, stirred for 1 h, then poured into water (50 mL) and extracted with DCM (4 x 100 mL). The combined organic phases were dried over anhydrous Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 8% MeOH in DCM) to yield N-((3R,5S)-5-((4H-1,2,4-triazol- 4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazol e-2-carboxamide (0.04 g, 0.10 mmol, 38 % yield). LCMS: Method H, 2.14 min, MS: ES- 387.1; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 9.38 (d, J = 6.8 Hz, 1H), 8.57 (s, 2H), 8.34 (s, 1H), 8.14 (d, J = 8.0 Hz, 1H), 8.11 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.75 (t, J = 8.0 Hz, 1H), 4.38 - 4.48 (m, 1H), 4.23 - 4.31 (m, 3H), 3.69 - 3.73 (m, 1H), 3.40 - 3.43 (m, 1H), 2.15 - 2.20 (m, 1H), 1.90 - 1.93 (m, 1H); Chiral SFC: Method Y12A, 4.3 min. Example 24 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-4-(3- (trifluoromethyl)phenyl)picolinamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-bromopicolina mido)pyrrolidine-1- carboxylate To a stirred solution of 4-bromopicolinic acid (0.22 g, 1.12 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3- triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.20 g, 0.74 mmol) in DCM (6.8 mL) were added DIPEA (0.28 g, 0.37 mL, 2.24 mmol) and HATU (0.42 g, 1.12 mmol) at 0 °C. The mixture was stirred at rt for 2 h, then poured into water (30 mL) and extracted with DCM (2 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 11% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-bromopicolina mido)pyrrolidine-1- carboxylate (0.2 g, 0.44 mmol, 59% yield). LCMS: Method C1, 1.18 min, MS: ES+ 451.1, 453.1. Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoro methyl)phenyl)picolinamido) pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-bromopicolina mido)- pyrrolidine-1-carboxylate (0.27 g, 0.59 mmol) and (3-(trifluoromethyl)phenyl)boronic acid (CAS 1423- 26-3, from Combi-Blocks, 0.14 g, 0.72 mmol) in toluene : water (10 mL, 1:1) was added K3PO4 (0.38 g, 1.79 mmol). The mixture was purged with N2 gas for 15 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.04 g, 0.06 mmol) and heated at 90 °C for 1 h. The mixture was poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 56% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoro methyl)phenyl)picolinamido)- pyrrolidine-1-carboxylate (0.27 g, 0.52 mmol, 87% yield). LCMS: Method H1, 1.33 min, MS: ES+ 517.4. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -4-(3-(trifluoromethyl)phenyl) picolinamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoro methyl)- phenyl)picolinamido)pyrrolidine-1-carboxylate (0.27 g, 0.52 mmol) in DCM (2.7 mL) was added TFA (1.35 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin- 3-yl)-4-(3-(trifluoromethyl)phenyl)picolinamide TFA salt (0.35 g, quantitative yield). Step (iv) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-4-(3-(trifluoromethyl)phenyl) picolinamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -4-(3- (trifluoromethyl)phenyl)picolinamide TFA salt (0.35 g, 0.66 mmol) in THF (4 mL) was added K2CO3 (0.36 g, 2.64 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.08 g, 0.79 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1.5 h, then poured into water (20 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole -2-carboxamide (0.03 g, 0.06 mmol, 13% yield over 2 steps). LCMS: Method H1, 2.89 min, MS: ES+ 442.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.21 (d, J = 6.8 Hz, 1H), 8.76 (d, J = 4.8 Hz, 1H), 8.33 (s, 1H), 8.18 - 8.21 (m, 3H), 8.06 (d, J = 3.2 Hz, 1H), 7.88 - 7.90 (m, 1H), 7.78 - 7.82 (m, 2H), 4.61 - 4.63 (m, 2H), 4.35 - 4.40 (m, 2H), 3.65 - 3.69 (m, 1H), 3.43 - 3.46 (m, 1H), 2.23 - 2.33 (m, 1H), 1.96 - 2.02 (m, 1H); Chiral SFC: Method Y9, 5.07 min. Example 25 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-4-(3- (trifluoromethoxy)phenyl)picolinamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoro methoxy)phenyl)picolinamido)- pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-bromopicolina mido)- pyrrolidine-1-carboxylate (0.20 g, 0.44 mmol) and (3-(trifluoromethoxy)phenyl)boronic acid (CAS# 179113-90-7, from Combi-Blocks, 0.11 g, 0.53 mmol) in toluene : water (3 mL, 1:1) was added K 3 PO 4 (0.28 g, 1.32 mmol). The mixture was purged with N 2 gas for 20 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.02 g, 0.02 mmol) and heated at 80 °C for 2 h. The mixture was poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 60% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoro methoxy)phenyl)picolinamido)- pyrrolidine-1-carboxylate (0.15 g, 0.28 mmol, 63% yield). LCMS: Method C1, 1.33 min, MS: ES+ 533.3. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -4-(3-(trifluoromethoxy)phenyl)- picolinamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3- (trifluoromethoxy)phenyl)picolinamido)pyrrolidine-1-carboxyl ate (0.14 g, 0.27 mmol) in DCM (1.5 mL) was added TFA (0.72 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)pyrrolidin-3-yl)-4-(3-(trifluoromethoxy)phenyl)p icolinamide TFA salt (0.17 g, quantitative yield). LCMS: Method C1, 1.11 min, MS: ES+ 433.3. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-4-(3-(trifluoromethoxy)- phenyl)picolinamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -4-(3- (trifluoromethoxy)phenyl)picolinamide TFA salt (0.17 g, 0.31 mmol) in THF (6 mL) was added K 2 CO 3 (0.17 g, 1.24 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.04 g, 0.37 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 82% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethoxy)ph enyl)picolinamide (0.025 g, 0.05 mmol, 20% yield over 2 steps). LCMS: Method H1, 2.95 min, MS: ES+ 458.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.19 (d, J = 6.8 Hz, 1H), 8.75 (d, J = 4.8 Hz, 1H), 8.29 (s, 1H), 8.20 (s, 1H), 8.01 (d, J = 4.8 Hz, 1H), 7.88 - 7.93 (m, 2H), 7.78 (s, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 4.61 - 4.63 (m, 2H), 4.36 - 4.38 (m, 2H), 3.65 - 3.69 (m, 1H), 3.42 - 3.46 (m, 1H), 2.24 - 2.28 (m, 1H), 1.98 - 2.01 (m, 1H); Chiral SFC: Method Y10, 8.67 min. Example 26 N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(3-cyanophenyl)oxazole-2- carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxaz ole-2-carboxamido)- pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-cyanophenyl)oxazole-2-carboxylate (0.25 g, 1.13 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-car boxylate (0.30 g, 1.13 mmol) in DMF (5 mL) were added DIPEA (0.44 g, 0.58 mL, 3.41 mmol) and HATU (0.65 g, 1.70 mmol) at 0 °C. The mixture was stirred at rt for 3 h, then poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure The residue was purified by flash column chromatography (silica gel 85% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxaz ole-2- carboxamido) pyrrolidine-1-carboxylate (0.08 g, 0.18 mmol, 16% yield). LCMS: Method C1, 1.59 min, MS: ES+ 463.4. Step (ii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3- cyanophenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxaz ole- 2-carboxamido)pyrrolidine-1-carboxylate (0.08 g, 0.17 mmol) in DCM (3 mL) was added TFA (0.24 mL, 3 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)- 5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.09 g, quantitative yield). LCMS: Method C1, 1.33 min, MS: ES+ 363.2. Step (iii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(3-cyanophenyl)oxazole-2- carboxamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3- cyanophenyl)oxazole-2-carboxamide TFA salt (0.08 g, 0.17 mmol) in THF (3 mL) was added K2CO3 (0.07 g, 0.50 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.03 g, 0.25 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 89% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-pyrazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole- 2-carboxamide (0.01 g, 0.02 mmol, 15% yield over two steps). LCMS: Method H, 2.46 min, MS: ES+ 388.1; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.36 (d, J = 6.4 Hz, 1H), 8.35 (s, 1H), 8.16 (d, J = 7.6 Hz, 1H), 8.10 (s, 1H), 7.93 (d, J = 7.2 Hz, 1H), 7.74 -7.79 (m, 2H), 7.51 (s, 1H), 6.29 (s, 1H), 4.25 - 4.37 (m, 4H), 3.62 - 3.66 (m, 1H), 3.40 - 3.42 (m, 1H), 2.10 - 2.18 (m, 1H), 2.00 - 2.04 (m, 1H); Chiral SFC: Method Y12A, 3.99 min. Example 27 N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide Step (i) Lithium 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, 0.99 mmol) in THF : water (3 : 2, 5 mL) was added lithium hydroxide monohydrate (0.08 g, 1.99 mmol) in portions at 0 °C. The mixture was stirred at rt for 2 h, then concentrated under reduced pressure to yield lithium 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, quantitative yield). LCMS: Method C1, 1.15 min, MS: m/z not supportive. Step (ii) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethox y)phenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.30 g, 1.07 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-car boxylate (0.29 g, 1.07 mmol) in pyridine (3 mL) was added POCl 3 (0.49 g, 0.29 mL, 3.22 mmol) dropwise at 0 °C. The mixture was stirred at rt for 30 min, then poured into water (50 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 55% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1 -carboxylate (0.14 g, 5.83 mmol, 26% yield). LCMS: Method C1, 1.36 min, MS: ES+: 522.3. Step (iii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1 -carboxylate (0.14 g, 0.26 mmol) in DCM (5 mL) was added TFA (1.2 mL, 8.5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-pyrazol- 1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)o xazole-2-carboxamide TFA salt (0.15 g, quantitative yield). LCMS: Method C1, 1.11 min, MS: ES+ 422.3. Step (iv) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.35 mmol) in THF (3.0 mL) was added K 2 CO 3 (0.14 g, 1.06 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.03 g, 0.35 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 20% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-pyrazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)ph enyl)oxazole-2-carboxamide (0.03 g, 0.33 mmol, 21% yield over two steps). LCMS: Method H1, 2.95 min, MS: ES+ 447.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.30 (s, 1H), 8.07 (s, 1H), 7.77 - 7.87 (m, 3H), 7.65 - 7.69 (m, 1H), 7.46 - 7.49 (m, 2H), 6.28 (s, 1H), 4.22 - 4.29 (m, 4H), 3.61 - 3.65 (m, 1H), 3.38 - 3.40 (m, 1H), 2.1 - 2.21 (m, 1H), 1.97 - 2.08 (m, 1H); Chiral SFC: Method Y10, 7.24 min. Example 28 and 29 N-((3R,5S)-1-Cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide & N-((3R,5S)-1-Cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((3-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(triflu oromethoxy)phenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate & tert-Butyl (2S,4R)-2-((5-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(triflu oromethoxy)phenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.29 g, 1.03 mmol) and tert-butyl (2S,4R)-4-amino-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1- carboxylate & tert-butyl (2S,4R)-4-amino-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolid ine-1- carboxylate (0.29 g, 1.03 mmol) in pyridine (0.28 mL) was added POCl3 (0.29 mL, 3.11 mmol) dropwise at 0 °C and stirred for 15 min at 0 °C. The mixture was poured into saturated NaHCO3 solution (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30-35% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((3- methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phe nyl)oxazole-2-carboxamido)- pyrrolidine-1-carboxylate & tert-butyl (2S,4R)-2-((5-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1 -carboxylate as a mixture (0.09 g, 0.17 mmol, 17% yield). LCMS: Method H1, 3.48 min, MS: ES+ 536.1 & 3.59 min, MS: ES+ 536.0. Step (ii) N-((3R,5S)-5-((3-Methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3- yl)-5-(3-(trifluoromethoxy)phenyl)- oxazole-2-carboxamide TFA salt & N-((3R,5S)-5-((5-Methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3- yl)-5-(3-(trifluoromethoxy)phenyl)- oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((3-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1 -carboxylate & tert-butyl (2S,4R)-2- ((5-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy )phenyl)oxazole-2-carboxamido)- pyrrolidine-1-carboxylate (0.09 g, 0.17 mmol) in DCM (2 mL) was added TFA (0.48 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 30 min, then concentrated under reduced pressure to yield N-((3R,5S)-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3- yl)-5- (3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide & N-((3R,5S)-5-((5-methyl-1H-pyrazol-1- yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxa zole-2-carboxamide TFA salt as a mixture (0.11 g, quantitative yield). LCMS: Method C1, 1.18 min, MS: ES+ 436.2. Step (iii) N-((3R,5S)-1-Cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide & N-((3R,5S)-1-Cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3- yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide & N-((3R,5S)-5-((5-methyl-1H-pyrazol-1- yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxa zole-2-carboxamide TFA salt (0.11 g, 0.20 mmol) in THF (3 mL) was added K 2 CO 3 (0.13 g, 1.00 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.03 g, 0.20 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at 0 °C for 30 min, then poured into ice-cold water (100 mL) extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to yield N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide & N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1- yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxa zole-2-carboxamide as a mixture (0.04 g, 0.10 mmol, 55% yield). The two compounds were separated by chiral preparative HPLC (Method Z1, UV spectra recorded at 287 nm lambda max) to yield N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3- yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide (0.02 g, 0.04 mmol, 22% yield) & N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide (0.01 g, 0.03 mmol, 16% yield). Regioisomer assignments were made on the basis of nOe NMR experiments in which the part of the 1 H NMR spectrum corresponding to the methylene attached to the pyrazole was irradiated and the effect on the part of the 1 H NMR spectrum corresponding to the methyl group was measured.a N-((3R,5S)-1-Cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide (Example 28) LCMS: Method H1, 2.97 min, MS: ES+ 461.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.34 (d, J = 6.8 Hz, 1H), 8.09 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.82 (s, 1H), 7.68 (t, J = 8.0 Hz, 1H), 7.62 (s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 6.04 (s, 1H), 4.28 - 4.31 (m, 1H), 4.21 - 4.23 (m, 3H), 3.62 - 3.66 (m, 1H), 3.2 - 3.3 (m, 1H), 2.16 (s, 3H), 2.08 - 2.13 (m, 1H), 1.91 - 2.03 (m, 1H); Chiral HPLC: Method Y30, 7.05 min. N-((3R,5S)-1-Cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrro lidin-3-yl)-5-(3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide (Example 29) LCMS: Method H1, 2.95 min MS: ES- 459.0; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 9.36 (d, J = 6.8 Hz, 1H), 8.09 (s, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.82 (s, 1H), 7.68 (t, J = 8.0 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.36 (s, 1H), 6.04 (s, 1H), 4.36 - 4.37 (m, 1H), 4.26 - 4.31(m, 1H), 4.19 - 4.20 (m, 2H), 3.66 - 3.70 (m, 1H), 3.2 - 3.3 (m, 1H), 2.28 (s, 3H), 2.12 - 2.16 (m, 1H), 2.02 - 2.08 (m, 1H); Chiral HPLC: Method Y30, 7.65 min. Example 30 N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)(3(trifluoromethyl)phenyl)oxazole-2- carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethyl )phenyl)oxazole-2- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxylate (0.5 g, 1.75 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-car boxylate (0.46 g, 1.75 mmol) in THF (5 mL) was added DBU (1.5 mL, 3 vol) dropwise at 0 ℃. The mixture was allowed to warm to rt and heated at 65 °C for 2 h. The mixture was poured into water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3- (trifluoromethyl)phenyl)oxazole-2-carboxamido)pyrrolidine-1- carboxylate (0.21 g, 0.41 mmol, 13% yield). LCMS: Method J1, 3.72 min, MS: ES+ 506.3. Step (ii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3- (trifluoromethyl)phenyl)oxazole-2- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3- (trifluoromethyl)phenyl)oxazole-2-carboxamido)pyrrolidine-1- carboxylate (0.21 g, 0.41 mmol) in DCM (2.1 mL) was added TFA (2.1 mL, 10 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-pyrazol- 1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)ox azole-2-carboxamide TFA salt (0.34 g, quantitative yield). LCMS: Method C1, 1.08 min, MS: ES+ 406.3. Step (iii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(-3- (trifluoromethyl)phenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3- (trifluoromethyl)phenyl)oxazole-2-carboxamide TFA salt (0.34 g, 0.65 mmol) in THF (3.4 mL) was added K 2 CO 3 (0.27 g, 1.96 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.08 g, 0.72 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1.5 h, then poured into ice-cold water (100 mL) to form a precipitate. Solid was collected by filtration through a Buchner funnel, washed with n-hexanes (3 x 20 mL) to yield N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1- cyanopyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2 -carboxamide (0.15 g, 0.35 mmol, 82% yield over two steps). LCMS: Method H1, 2.87 min, MS: ES+ 431.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.39 (d, J = 6.4 Hz, 1H), 8.13 - 8.17 (m, 3H), 7.79 - 7.82 (m, 3H), 7.52 (s, 1H), 6.30 (s, 1H), 4.29 - 4.32 (m, 4H), 3.63 - 3.66 (m, 1H), 3.41 - 3.42 (m, 1H), 2.14 - 2.19 (m, 1H), 2.01 - 2.05 (m, 1H); Chiral SFC: Method Y8, 6.27 min. Example 34 N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-2-fluoro-4-(1-methyl-1H-indazol-5- yl)benzamide Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(2-fluoro-4-(1-methyl- 1h-indazol-5- yl)benzamido)pyrrolidine-1-carboxylate To a stirred solution of 2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzoic acid (0.3 g, 1.11 mmol) in THF (3 mL) were added DIPEA (0.43 g, 0.58 mL, 3.33 mmol) and HATU (0.84 g, 2.22 mmol) in portions at 0 °C. After 30 min, tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1- carboxylate (0.32 g, 1.22 mmol) was added at 0 °C. The mixture was slowly warmed to rt and stirred for 3 h, then poured into ice-cold water (15 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(2-fluoro-4-(1-methyl- 1H-indazol-5- yl)benzamido)pyrrolidine-1-carboxylate (0.50 g, 0.96 mmol, 86% yield). LCMS: Method J1, 3.90 min, MS: ES+: 519.1. Step (ii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)pyrrolidin-3-yl)-2-flu oro-4-(1-methyl-1H-indazol-5- yl)benzamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(2-fluoro-4-(1-methyl- 1H- indazol-5-yl)benzamido)pyrrolidine-1-carboxylate (0.50 g, 0.96 mmol) in DCM (5 mL) was added TFA (2.5 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)- 2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide TFA salt (0.35 g, 0.83 mmol, 86% yield). LCMS: Method J1, 2.97 min, MS: ES+ 419.0. Step (iii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-2-fluoro-4-(1-methyl-1H-indazol-5- yl)benzamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-2-flu oro-4-(1-methyl- 1H-indazol-5-yl)benzamide TFA salt (0.35 g, 0.83 mmol) in THF (3.5 mL) was added K2CO3 (0.46 g, 3.34 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.09 g, 0.92 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 5% MeOH in DCM) to yield N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1- cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)b enzamide (0.07 g, 0.17 mmol, 29% yield). LCMS: Method H1, 2.58 min, MS: ES+ 444.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 8.71 (d, J = 6.0 Hz, 1H), 8.14 (d, J = 10.4 Hz, 2H), 7.75 - 7.82 (m, 3H), 7.66 - 7.70 (m, 3H), 7.51 (s, 1H), 6.29 (s, 1H), 4.23 - 4.33 (m, 4H), 4.09 (s, 3H), 3.61 - 3.65 (m, 1H), 3.31 - 3.34 (m, 1H), 1.97 - 2.09 (m, 2H); Chiral SFC: Method Y9, 5.60 min. Example 35 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-2-fluoro-4-(1-methyl-1H- indazol-5-yl)benzamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(2-fluoro-4-(1-m ethyl-1H-indazol-5- yl)benzamido)pyrrolidine-1-carboxylate To a stirred solution of 2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzoic acid (0.3 g, 1.11 mmol) in THF (3 mL) were added DIPEA (0.43 g, 0.58 mL, 3.33 mmol) and HATU (0.84 g, 2.22 mmol) in portions at 0 °C. After 30 min, tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1- carboxylate (0.32 g, 1.22 mmol) was added at 0 °C. The mixture was slowly warmed to rt and stirred for 3 h, then poured into ice-cold water (15 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 90% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(2-fluoro-4-(1-m ethyl-1H-indazol-5- yl)benzamido)pyrrolidine-1-carboxylate (0.50 g, 0.96 mmol, 86% yield). LCMS: Method C1, 1.20 min, MS: ES+: 520.3. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -2-fluoro-4-(1-methyl-1H-indazol-5- yl)benzamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(2-fluoro-4-(1-m ethyl- 1H-indazol-5-yl)benzamido)pyrrolidine-1-carboxylate (0.50 g, 0.96 mmol) in DCM (5 mL) was added TFA (2.5 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin- 3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide TFA salt (0.35 g, 0.65 mmol, 86% yield). LCMS: Method C1, 0.99 min, MS: ES+ 420.5. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-2-fluoro-4-(1-methyl-1H- indazol-5-yl)benzamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -2-fluoro-4-(1- methyl-1H-indazol-5-yl)benzamide TFA salt (0.35 g, 0.65 mmol) in THF (3.5 mL) was added K 2 CO 3 (0.45 g, 3.28 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.07 g, 0.72 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 10% MeOH in DCM) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-i ndazol-5-yl)benzamide (0.08 g, 0.18 mmol, 21% yield). LCMS: Method H1, 2.45 min, MS: ES+ 445.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 8.79 (d, J = 5.2 Hz, 1H), 8.15 - 8.21 (m, 3H), 7.77 - 7.84 (m, 3H), 7.68 - 7.72 (m, 3H), 4.64 - 4.66 (m, 2H), 4.31 - 4.42 (m, 2H), 4.10 (s, 3H), 3.66 - 3.70 (m, 1H), 3.35 (s, 1H), 2.09 - 2.19 (m, 1H), 1.97 - 2.01 (m, 1H); Chiral SFC: Method Y9, 6.07 min. Example 36 N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-3-(3-(trifluoromethoxy)phenyl) pyrrolidine-1-carboxamide Step tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(3-(3-(trifluoromethox y)phenyl)pyrrolidine-1- carboxamido)pyrrolidine-1-carboxylate To a stirred solution of 3-(3-(trifluoromethoxy) phenyl) pyrrolidine TFA salt (0.5 g, 2.16 mmol) in THF (4 mL) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl) methyl)-4-aminopyrrolidine-1-carboxylate (0.57 g, 3.16 mmol) was added TEA (0.89 mL, 6.49 mmol) at 0 °C and stirred for 10 min. Triphosgene (0.32 g, 1.08 mmol) was added in portions into the reaction mixture at 0 °C. The mixture was stirred at rt for 5 h, then poured into water (20 mL) and extracted with DCM (3 x 20 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 3% MeOH in DCM) to yield tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(3-(3-(trifluoromethox y)phenyl)pyrrolidine-1- carboxamido)pyrrolidine-1-carboxylate (0.14 g, 0.34 mmol, 13% yield). LCMS: Method C1 141 min MS: ES+ 5244 Step (ii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)pyrrolidin-3-yl)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1- carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(3-(3-(trifluoromethox y)- phenyl)pyrrolidine-1-carboxamido)pyrrolidine-1-carboxylate (0.14 g, 0.34 mmol) in DCM (3 mL) was added TFA (0.73 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-pyrazol-1- yl)methyl)pyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyr rolidine-1-carboxamide TFA salt (0.1 g, 0.22 mmol, 70% yield). LCMS: Method C1, 1.17 min, MS: ES+ 424.2. Step (iii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-3-(3-(trifluoromethoxy)phenyl) pyrrolidine-1-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide TFA salt (0.1 g, 0.22 mmol) in THF (2 mL) was added K2CO3 (0.09 g, 068 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.04 g, 0.34 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 95% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-pyrazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)ph enyl)pyrrolidine-1-carboxamide (0.04 g, 0.08 mmol, 14% yield). LCMS: Method H1, 2.90 min, MS: ES+ 449.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 7.77 (s, 1H), 7.46 - 7.50 (m, 2H), 7.36 (d, J = 7.2 Hz, 1H), 7.31 (s, 1H), 7.25 (d, J = 7.6 Hz, 1H), 6.28 (s, 2H), 4.19 - 4.29 (m, 3H), 3.97 - 4.05 (m, 1H), 3.69 - 3.77 (m, 1H), 3.40 - 3.56 (m, 4H), 3.15 - 3.23 (m, 2H), 2.20 - 2.30 (s, 1H), 1.86 - 2.00 (m, 3H); Chiral SFC: Method Y31, 15.52 min and 17.04 min. Example 37 & Example 38 (S)-N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin -3-yl)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; (R)-N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin -3-yl)-3-(3- (trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; The diastereomers were separated by chiral preparative HPLC (Method Z2, UV spectra recorded at 220 nm lambda max) to yield Diastereomer 1 of the title compounds as the first eluting isomer (0.008 g, 0.02 mmol, 18% yield) & Diastereomer 2 of the title compounds as the second eluting isomer (0.009 g, 0.02 mmol, 20% yield). The absolute configuration of Diastereomer 1 and Diasteromer 2 is not determined. Example 37 is designated as Diastereomer 1. Example 38 is designated as Diastereomer 2. Example 37 Diastereomer 1: LCMS: Method H1, 2.88 min, MS: ES+ 449.2; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 7.77 (s, 1H), 7.46 - 7.50 (m, 2H), 7.36 (d, J = 8.0 Hz, 1H), 7.30 (s, 1H), 7.25 (d, J = 8.0 Hz, 1H), 6.28 (s, 2H), 4.19 - 4.29 (m, 3H), 3.97 - 4.05 (m, 1H), 3.69 - 3.77 (m, 1H), 3.42 - 3.56 (m, 4H), 3.15 - 3.23 (m, 2H), 2.20 - 2.30 (s, 1H), 1.86 - 2.00 (m, 3H); Chiral SFC: Method Y31, 15.99 min. Example 38 Diastereomer 2: LCMS: Method H1, 2.88 min, MS: ES+ 449.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 7.76 (d, J = 4.0 Hz, 1H), 7.46 - 7.50 (m, 2H), 7.36 (d, J = 8.0 Hz, 1H), 7.30 (s, 1H), 7.25 (d, J = 8.0 Hz, 1H), 6.28 (s, 2H), 4.19 - 4.29 (m, 3H), 3.97 - 4.05 (m, 1H), 3.71 - 3.77 (m, 1H), 3.42 - 3.56 (m, 4H), 3.14 - 3.23 (m, 2H), 2.20 - 2.28 (s, 1H), 1.86 - 2.00 (m, 3H); Chiral SFC: Method Y31, 16.99 min. Example 39 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(4-fluoro-3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(4-fluoro-3- (trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1 -carboxylate To a stirred solution of ethyl 5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.50 g, 1.56 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.49 g, 1.87 mmol) in THF (5 mL) was added TBD (0.26 g, 1.87 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 6 h. The mixture was poured into water (100 mL) and extracted with EtOAc (2 x 150 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol- 1-yl)methyl)-4-(5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazo le-2-carboxamido)pyrrolidine-1- carboxylate (0.23 g, 0.42 mmol, 27% yield). LCMS: Method J1, 3.99 min, MS: ES+ 541.0. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(4-fluoro-3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(4-fluoro-3- (trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1 -carboxylate (0.23 g, 0.42 mmol) in DCM (5 mL) was added TFA (1.15 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 0.5 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3- triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(4-fluoro-3-(trifluor omethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.40 g, quantitative yield). LCMS: Method J1, 2.83 min, MS: ES+ 441.2. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(4-fluoro-3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(4-fluoro-3- (trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.40 g, 0.72 mmol) in THF (4 mL) was added K2CO3 (0.49 g, 3.6 mmol) at rt and stirred for 5 min. The mixture was cooled to 0 °C, then cyanogen bromide (0.08 g, 0.79 mmol) was added. The mixture was allowed to warm to rt, stirred for 0.5 h, then poured into water (50 mL) and extracted with EtOAc (2 x 75 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 96% EtOAc in n-hexanes) to yield N-((3R,5S)-5- ((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(4 -fluoro-3-(trifluoromethoxy)phenyl) oxazole-2-carboxamide (0.04 g, 0.09 mmol, 21% yield over two steps). LCMS: Method H1, 2.85 min, MS: ES+ 466.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.37 (d, J = 4.0 Hz, 1H), 8.20 (s, 1H), 8.04 - 8.07 (m, 2H), 7.93 (br s, 1H), 7.71 - 7.79 (m, 2H), 4.63 - 4.64 (m, 2H), 4.30 - 4.40 (m, 2H), 3.66 - 3.70 (m, 1H), 3.40 - 3.43 (m, 1H), 2.20 - 2.23 (m, 1H), 1.99 - 2.02 (m, 1H); Chiral SFC: Method Y32, 4.35 min. Example 40 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-(azetidin-1-yl)-5- cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-(azetidin- 1-yl)-5-cyanopyridin-3-yl)- 1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate A stirred solution of ethyl 5-(2-(azetidin-1-yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2 -carboxylate (0.25 g, 0.83 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1- carboxylate (0.26 g, 0.99 mmol) in THF (4 mL) was added TBD (0.17 g, 1.24 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h at rt. The mixture was poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 24% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3- triazol-1-yl)methyl)-4-(5-(2-(azetidin-1-yl)-5-cyanopyridin- 3-yl)-1,3,4-oxadiazole-2- carboxamido)pyrrolidine-1-carboxylate (0.07 g, 0.13 mmol, 15% yield). LCMS: Method C1, 1.18 min, MS: ES+ 521.4. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-(azetidin-1-yl)-5-cyanopyridin-3- yl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-(azetidin- 1-yl)-5- cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidin e-1-carboxylate (0.07 g, 0.13 mmol) in DCM (1 mL) was added TFA (0.35 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)pyrrolidin-3-yl)-5-(2-(azetidin-1-yl)-5-cyanopyr idin-3-yl)-1,3,4-oxadiazole-2- carboxamide TFA salt (0.10 g, quantitative yield). LCMS: Method C1, 0.95 min, MS: ES+ 421.1. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-(azetidin-1-yl)-5- cyanopyridin-3-yl)-134-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-(azetidin-1- yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.10 g, 0.19 mmol) in THF (1 mL) was added K 2 CO 3 (0.08 g, 0.57 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.03 g, 0.28 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC (Method X11) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)- 1-cyanopyrrolidin-3-yl)-5-(2-(azetidin-1-yl)-5-cyanopyridin- 3-yl)-1,3,4-oxadiazole-2-carboxamide (0.04 g, 0.09 mmol, 66% yield over two steps). LCMS: Method H1, 2.23 min, MS: ES+ 446.2; 1 H NMR (400 MHz, DMSO-d6) δ 9.77 (d, J = 6.4 Hz, 1H), 8.72 (d, J = 2.0 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.19 (s, 1H), 7.78 (s, 1H), 4.62 - 4.64 (m, 2H), 4.35 - 4.38 (m, 2H), 4.02 - 4.11 (m, 4H), 3.66 - 3.70 (m, 1H), 3.41 - 3.44 (m, 1H), 2.26 - 2.33 (m, 2H), 2.18 - 2.23 (m, 1H), 1.98 - 2.03 (m, 1H); Chiral HPLC: Method Y4, 5.32 min. Example 41 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2-(pyrrolidin-1- yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-(p yrrolidin-1-yl)pyridin-3-yl)- 1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate A stirred solution of ethyl 5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole -2-carboxylate (0.23 g, 0.73 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1- carboxylate (0.19 g, 0.73 mmol) in THF (2.3 mL) was added TBD (0.10 g, 0.73 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 0.5 h at rt. The mixture was poured into water (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 95% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3- triazol-1-yl)methyl)-4-(5-(5-cyano-2-(pyrrolidin-1-yl)pyridi n-3-yl)-1,3,4-oxadiazole-2- carboxamido)pyrrolidine-1-carboxylate (0.10 g, 0.19 mmol, 25% yield). LCMS: Method C1 118 min MS: ES+ 5344 Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3- yl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2- (pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxamid o)pyrrolidine-1-carboxylate (0.10 g, 0.19 mmol) in DCM (1 mL) was added TFA (0.3 mL, 3 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H- 1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-(pyr rolidin-1-yl)pyridin-3-yl)-1,3,4- oxadiazole-2-carboxamide TFA salt (0.12 g, quantitative yield). LCMS: Method C1, 0.98 min, MS: ES- 433.3. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(5-cyano-2-(pyrrolidin-1- yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(5-cyano-2- (pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxamid e TFA salt (0.12 g, 0.22 mmol) in THF (1.2 mL) was added K2CO3 (0.09 g, 0.66 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.02 g, 0.22 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 4% MeOH in DCM) to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(pyrrolidi n-1-yl)pyridin-3-yl)-1,3,4-oxadiazole-2- carboxamide (0.02 g, 0.05 mmol, 26% yield over two steps). LCMS: Method H1, 2.40 min, MS: ES+ 460.2; 1 H NMR (400 MHz, DMSO-d6) δ 9.77 (d, J = 6.4 Hz, 1H), 8.72 (d, J = 2.0 Hz, 1H), 8.30 (d, J = 2.0 Hz, 1H), 8.19 (s, 1H), 7.78 (s, 1H), 4.58 - 4.63 (m, 2H), 4.34 - 4.37 (m, 2H), 3.65 - 3.69 (m, 1H), 3.40 - 3.44 (m, 1H), 3.29 - 3.34 (m, 4H), 2.16 - 2.22 (m, 1H), 1.96 - 2.03 (m, 1H), 1.85 (br s, 4H); Chiral HPLC: Method Y4, 5.45 min. Example 42 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-chloro-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide
Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-chloro-5-( trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-c arboxylate (0.50 g, 1.48 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1- carboxylate (0.39 g, 1.48 mmol) in THF (5 mL) was added TBD (0.20 g, 1.48 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred at rt for 0.5 h, then poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol- 1-yl)methyl)-4-(5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3, 4-oxadiazole-2- carboxamido)pyrrolidine-1-carboxylate (0.30 g, 0.53 mmol, 36% yield). LCMS: Method C1, 1.28 min, MS: ES+ 558.1. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-chloro-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-chloro-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.30 g, 0.53 mmol) in DCM (3 mL) was added TFA (1.5 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H- 1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-chloro-5-(tr ifluoromethoxy)phenyl)-1,3,4-oxadiazole- 2-carboxamide TFA salt (0.32 g, quantitative yield). LCMS: Method C, 1.36 min, MS: ES+ 458.1. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-chloro-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-chloro-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.32 g, 0.56 mmol) in THF (32 mL) was added K2CO3 (023 g 168 mmol) at rt and stirred for 5 min Cyanogen bromide (006 g 0.56 mmol) was added at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 85% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-chloro-5-(trifluorom ethoxy)phenyl)-1,3,4-oxadiazole-2- carboxamide (0.06 g, 0.12 mmol, 25% yield over two steps). LCMS: Method H1, 2.81 min, MS: ES+ 483.0; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 9.88 (d, J = 6.0 Hz, 1H), 8.22 (s, 1H), 8.05 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.81 (s, 1H), 7.78 (s, 1H), 4.65 - 4.66 (m, 2H), 4.39 - 4.41 (m, 2H), 3.69 - 3.73 (m, 1H), 3.45 - 3.47 (m, 1H), 2.21 - 2.24 (m, 1H), 2.01 - 2.05 (m, 1H); Chiral SFC: Method Y21, 10.11 min. Example 43 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-(trifluoro methoxy)phenyl)-1,3,4- oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylat e (0.47 g, 1.56 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1-carboxylate (0.42 g, 1.56 mmol) in THF (6 mL) was added TBD (0.32 g, 2.33 mmol) in portions at 0 °C and stirred at 0 °C for 15 min. The mixture was poured into water (100 mL) and extracted with EtOAc (2 x 120 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 60% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.19 g, 0.36 mmol, 23% yield). LCMS: Method C1, 1.25 min, MS: ES+ 524.2. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3-(trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.18 g, 0.34 mmol) in DCM (1.8 mL) was added TFA (1.8 mL, 10 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)- 5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trif luoromethoxy)phenyl)-1,3,4-oxadiazole-2- carboxamide TFA salt (0.18 g, quantitative yield). LCMS: Method C1, 1.05 min, MS: ES+ 424.2. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(3- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(3- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.17 g, 0.32 mmol) in THF (1.7 mL) was added K2CO3 (0.13 g, 0.95 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.04 g, 0.35 mmol) was added to the mixture at 0 °C. The mixture was stirred at 0 °C for 1 h, then poured into water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,3-triazol- 1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy) phenyl)-1,3,4-oxadiazole-2- carboxamide (0.05 g, 0.11 mmol, 32% yield over two steps). LCMS: Method H1, 3.50 min, MS: ES+ 449.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.80 (d, J = 4.0 Hz, 1H), 8.22 (s, 1H), 8.15 (d, J = 8.0 Hz, 1H), 8.01 (s, 1H), 7.81 - 7.85 (m, 2H), 7.75 - 7.76 (m, 1H), 4.65 - 4.66 (m, 2H), 4.40 - 4.41 (m, 2H), 3.70 - 3.74 (m, 1H), 3.47 - 3.48 (m, 1H), 2.20 - 2.27 (m, 1H), 2.00 - 2.07 (m, 1H); Chiral SFC: Method Y4, 4.14 min. Example 44 N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(2-cyclopropyl-5-(t rifluoromethoxy)phenyl)- 1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol e-2- carboxylate (0.36 g, 1.05 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4- aminopyrrolidine-1-carboxylate (0.28 g, 1.05 mmol) in THF (3.6 mL) was added TBD (0.17 g, 1.26 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 0.5 h at rt, then poured into water (20 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 60% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(2-cyclopropyl-5-(t rifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate (0.17 g, 0.31 mmol, 30% yield). LCMS: Method C1, 1.40 min, MS: ES+ 563.1. Step (ii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2- cyclopropyl-5(trifluoromethoxy)phenyl)- 1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.17 g, 3.10 mmol) in DCM (2 mL) was added TFA (0.57 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)- 5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropyl -5-(trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamide TFA salt (0.23 g, quantitative yield). LCMS: Method C1, 1.13 min, MS: ES+ 463.2. Step (iii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2- cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.23 g, 0.41 mmol) in THF (3 mL) was added K2CO3 (0.28 g, 2.06 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.13 g, 1.20 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (10 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 50% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H- pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropy l-5-(trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamide (0.065 g, 0.13 mmol, 43% yield over two steps). LCMS: Method H1, 3.14 min, MS: ES+ 488.2; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.76 (s, 1H), 7.83 (s, 1H) 778 (s 1H) 758 (d J = 80 Hz 1H) 751 (s 1H) 731 (d J = 80 Hz 1H) 629 (s 1H) 429 4.32 (m, 4H), 3.63 - 3.67 (m, 1H), 3.39 - 3.42 (m, 1H), 2.68 - 2.70 (m, 1H), 2.13 - 2.15 (m, 1H), 2.02 - 2.05 (m, 1H), 1.05 - 1.07 (m, 2H), 0.78 - 0.82 (m, 2H); Chiral HPLC: Method Y14, 3.75 min. Example 45 N-((3R,5S)-5-((2H-1,2,3-Triazol-2-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-(5-(2-cyclopropy l-5-(trifluoromethoxy)phenyl)- 1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol e-2- carboxylate (0.33 g, 0.96 mmol) and tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4- aminopyrrolidine-1-carboxylate (0.30 g, 1.15 mmol) in THF (5 mL) was added TBD (0.20 g, 1.44 mmol) in portions at 0 °C and stirred at 0 °C for 0.5 h. The mixture was poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 37% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((2H-1,2,3-triazol- 2-yl)methyl)-4-(5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl) -1,3,4-oxadiazole-2- carboxamido)pyrrolidine-1-carboxylate (0.23 g, 0.40 mmol, 42% yield). LCMS: Method H1, 3.61 min, MS: ES- 562.2. Step (ii) N-((3R,5S)-5-((2H-1,2,3-Triazol-2-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-(5-(2-cyclopropy l-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.23 g, 0.39 mmol) in DCM (3 mL) was added TFA (1.1 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((2H- 1,2,3-triazol-2-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropyl- 5-(trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamide TFA salt (0.30 g, quantitative yield). LCMS: Method H1, 2.97 min, MS: ES+ 464.2. Step (iii) N-((3R,5S)-5-((2H-1,2,3-Triazol-2-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl- 5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.28 g, 0.49 mmol) in THF (5 mL) was added K 2 CO 3 (0.34 g, 2.46 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.05 g, 0.49 mmol) was added into the reaction mixture at 0 °C. The mixture was allowed to warm to rt, and stirred at rt for 15 min, then poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 37% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2- cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-c arboxamide (0.07 g, 0.15 mmol, 38% yield over two steps). LCMS: Method H1, 3.15 min, MS: ES+ 489.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.78 (d, J = 6.8 Hz, 1H), 7.81 - 7.84 (m, 3H), 7.56 (d, J = 7.6 Hz, 1H), 7.29 (d, J = 8.8 Hz, 1H), 4.62 - 4.64 (m, 2H), 4.40 - 4.43 (m, 1H), 4.30 - 4.32 (m, 1H), 3.61 - 3.65 (m, 1H), 3.38 - 3.42 (m, 1H), 2.66 - 2.70 (m, 1H), 2.18 - 2.24 (m, 1H), 2.03 - 2.08 (m, 1H), 1.03 - 1.05 (m, 2H), 0.79 - 0.80 (m, 2H), Chiral SFC: Method Y10, 7.61 min. Example 46 N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(5-cyano-2-cyclopropylphenyl)- 1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopro pylphenyl)-1,3,4-oxadiazole- 2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxyla te (0.44 g, 1.55 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-car boxylate (0.49 g, 1.86 mmol) in THF (6 mL) was added TBD (0.32 g, 2.32 mmol) in portions at 0 °C and the mixture was stirred at 0 °C for 15 min, then poured into water (80 mL) and extracted with EtOAc (2 x 100 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 40% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(5-cyano-2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidin e-1-carboxylate (0.17 g, 0.33 mmol, 21% yield). LCMS: Method C, 1.72 min, MS: ES+ 504.4. Step (ii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5- cyano-2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(5-cyano-2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidin e-1-carboxylate (0.16 g, 0.32 mmol) in DCM (1.6 mL) was added TFA (1.6 mL, 10 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-pyrazol- 1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl) -1,3,4-oxadiazole-2-carboxamide TFA salt (0.23 g, quantitative yield). LCMS: Method C1, 1.04 min, MS: ES+ 404.3. Step (iii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-5-(5-cyano-2-cyclopropylphenyl)- 1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5- cyano-2- cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.23 g, 0.45 mmol) in THF (2.3 mL) was added K2CO3 (0.18 g, 1.33 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.05 g, 0.49 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at 0 °C for 1 h, then poured into water (50 mL) and extracted with EtOAc (2 x 80 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 50% EtOAc in n-hexanes) to yield N-((3R,5S)-5- ((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano -2-cyclopropylphenyl)-1,3,4- oxadiazole-2-carboxamide (0.06 g, 0.14 mmol, 44% yield over two steps). LCMS: Method H1, 2.68 min, MS: ES+ 429.2; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 9.71 (d, J = 6.4 Hz, 1H), 8.29 (d, J = 1.6 Hz, 1H), 7.98 (dd, J = 1.2, 8.4 Hz, 1H), 7.77 (d, J = 2.0 Hz, 1H), 7.49 (d, J = 1.2 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 6.27 (s, 1H), 4.25 - 4.32 (m, 4H), 3.62 - 3.66 (m, 1H), 3.38 - 3.41 (m, 1H), 2.77 - 2.85 (m, 1H), 2.10 - 2.16 (m, 1H), 1.99 - 2.05 (m, 1H), 1.13 - 1.17 (m, 2H), 0.90 - 0.91 (m, 2H); Chiral SFC: Method Y10, 9.37 min. Example 47 N-((3R,5S)-5-((1H-1,2,4-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-(5-(2-cyclopropy l-5-(trifluoromethoxy)phenyl)- 1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol e-2- carboxylate (0.40 g, 1.17 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4- aminopyrrolidine-1-carboxylate (0.46 g, 1.75 mmol) in THF (6 mL) was added TBD (0.24 g, 1.75 mmol) in portions at 0 °C and stirred at 0 °C for 15 min. The mixture was poured into water (80 mL) and extracted with EtOAc (2 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 85% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,4- triazol-1-yl)methyl)-4-(5-(2-cyclopropyl-5-(trifluoromethoxy )phenyl)-1,3,4-oxadiazole-2- carboxamido)pyrrolidine-1-carboxylate (0.22 g, 0.39 mmol, 33% yield). LCMS: Method C, 1.78 min, MS: ES+ 564.4. Step (ii) N-((3R,5S)-5-((1H-1,2,4-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-(5-(2-cyclopropy l-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.22 g, 0.39 mmol) in DCM (2.2 mL) was added TFA (2.2 mL, 10 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)- 5-((1H-1,2,4-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclo propyl-5-(trifluoromethoxy)phenyl)- 1,3,4-oxadiazole-2-carboxamide TFA salt (0.32 g, quantitative yield). LCMS: Method C1, 1.08 min, MS: ES+ 464.2. Step (iii) N-((3R,5S)-5-((1H-1,2,4-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl- 5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.32 g, 0.55 mmol) in THF (3.2 mL) was added K 2 CO 3 (0.23 g, 1.66 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.06 g, 0.61 mmol) was added into the mixture at 0 °C. The mixture was stirred at 0 °C for 1 h, then poured into water (50 mL) and extracted with EtOAc (2 x 80 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 85% EtOAc in n-hexanes) to yield N-((3R,5S)-5-((1H-1,2,4- triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropy l-5-(trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamide (0.05 g, 0.10 mmol, 26% yield over two steps), which was further purified by reverse phase preparative HPLC purification (Method X15) to yield N-((3R,5S)-5-((1H-1,2,4- triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropy l-5-(trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamide (0.01 g, 0.03 mmol, 8% yield over two steps). LCMS: Method H1, 2.95 min, MS: ES+ 489.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.74 (br s, 1H), 8.53 - 8.56 (m, 1H), 7.98 -8.01 (m, 1H), 7.78 - 7.81 (m, 1H), 7.54 - 7.56 (m, 1H), 7.27 - 7.29 (m, 1H), 4.30 - 4.40 (m, 4H), 3.51 - 3.63 (m, 1H), 3.35 - 3.42 (m, 1H), 2.61 - 2.72 (m, 1H), 2.13 - 2.23 (m, 1H), 1.98 - 2.07 (s, 1H), 0.98 - 1.09 (m, 2H), 0.72 - 0.83 (m, 2H); Chiral SFC: Method Y14, 3.7 min. Example 48 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-propyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-bromo-5-(t rifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(2-bromo-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-ca rboxylate (1.5 g, 3.94 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine -1- carboxylate (1.05 g, 3.94 mmol) in THF (15 mL) was added DBU (4.5 mL, 3 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then poured into water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-bromo- 5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)p yrrolidine-1-carboxylate (0.45 g, 0.70 mmol, 18% yield). LCMS: Method C1, 1.28 min, MS: ES+ 602.2, 604.1. Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-allyl-5-(t rifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-bromo-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.40 g, 0.66 mmol) and 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (CAS 72824-04-5, from Combi- Blocks, 0.13 g, 0.79 mmol) in 1,4-Dioxane : water (4 mL, 4:1) was added K3PO4 (0.42 g, 1.99 mmol). The mixture was purged with N2 gas for 10 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.04 g, 0.05 mmol) and heated at 110 °C for 2 h. The mixture was poured into water (25 mL) and extracted with EtOAc (3 x 25 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-allyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.15 g, 0.26 mmol, 40% yield). LCMS: Method C, 1.84 min, MS: ES+ 564.4. Step (iii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-propyl-5-( trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-allyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.14 g, 0.24 mmol) in MeOH (1.4 mL) was added 10% Pd/C (50% moisture) (0.03 g, 0.2 w/w). The mixture was purged with H 2 gas for 3 h, then filtered through Celite Hyflow® and the filtrate was concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-propyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.06 g, 0.11 mmol, 46%). LCMS: Method C1, 1.38 min, MS: ES+ 566.4. Step (iv) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-propyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-propyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.06 g, 0.11 mmol) in DCM (1 mL) was added TFA (0.2 mL, 3 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H- 1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-propyl-5-(tr ifluoromethoxy)phenyl)-1,3,4-oxadiazole- 2-carboxamide TFA salt (0.08 g, quantitative yield). LCMS: Method C, 1.43 min, MS: ES+ 466.3. Step (v) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-propyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-propyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.08 g, 0.14 mmol) in THF (1 mL) was added K2CO3 (0.06 g, 0.41 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.01 g, 0.14 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC (Method X16) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-propyl-5-(trifluorom ethoxy)phenyl)-1,3,4-oxadiazole-2- carboxamide (0.01 g, 0.02 mmol, 6% yield over two steps). LCMS: Method H1, 3.15 min, MS: ES+ 491.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.75 (d, J = 5.6 Hz, 1H), 8.18 (s, 1H), 7.86 (s, 1H), 7.77 (s, 1H), 7.62 (s, 2H), 4.62 - 4.63 (m, 2H), 4.36 - 4.37 (m, 2H), 3.66 - 3.70 (m, 1H), 3.41 - 3.44 (m, 1H), 3.00 (t, J = 8.0 Hz, 2H), 2.18 - 2.21 (m, 1H), 1.98 - 2.03 (m, 1H), 1.57 (q, J = 6.8 Hz, 2H), 0.91 (t, J = 6.8 Hz, 3H); Chiral SFC: Method Y14, 3.61 min.
Example 49 N-((3R,5S)-5-((4H-1,2,4-Triazol-4-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide Step (i) tert-Butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-(5-(2-cyclopropy l-5-(trifluoromethoxy)phenyl)- 1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol e-2- carboxylate (0.40 g, 1.16 mmol) and tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4- aminopyrrolidine-1-carboxylate (0.31 g, 1.68 mmol) in MeOH (7 mL) was added DMAP (0.17 g, 1.40 mmol) in portions at 0 °C. The mixture was heated at 75 °C for 16 h. The mixture was concentrated under reduced pressure to yield tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-(5- (2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole- 2-carboxamido)pyrrolidine-1- carboxylate (0.29 g, 0.52 mmol, 44% yield). LCMS: Method C, 1.68 min, MS: ES+ 564.2. Step (ii) N-((3R,5S)-5-((4H-1,2,4-Triazol-4-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-(5-(2-cyclopropy l-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyr rolidine-1-carboxylate (0.29 g, 0.52 mmol) in DCM (3 mL) was added TFA (1.5 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((4H- 1,2,4-triazol-4-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropyl- 5-(trifluoromethoxy)phenyl)-1,3,4- oxadiazole-2-carboxamide TFA salt (0.40 g, quantitative yield). LCMS: Method C, 1.42 min, MS: ES+ 464.2. Step (iii) N-((3R,5S)-5-((4H-1,2,4-Triazol-4-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl- 5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.40 g, 0.69 mmol) in THF (4 mL) was added K 2 CO 3 (0.28 g, 2.07 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.11 g, 1.03 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC (Method X14) to yield N-((3R,5S)-5-((4H-1,2,4-triazol-4- yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifl uoromethoxy)phenyl)-1,3,4-oxadiazole- 2-carboxamide (0.07 g, 0.12 mmol, 27% yield over two steps). LCMS: Method H1, 2.79 min, MS: ES+ 489.2; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 9.77 (br s, 1H), 8.57 (s, 2H), 7.83 (s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 4.41 - 4.49 (m, 1H), 4.24 - 4.32 (m, 3H), 3.71 - 3.75 (m, 1H), 3.42 - 3.46 (m, 1H), 2.67 - 2.69 (m, 1H), 2.15 - 2.20 (m, 1H), 1.91 - 1.96 (m, 1H), 1.05 - 1.07 (m, 2H), 0.80 - 0.81 (m, 2H); Chiral SFC: Method Y4, 5.48 min. Example 50 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-3-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamide Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(3-(2-cyclopropy l-5-(trifluoromethoxy)phenyl)- 1,2,4-oxadiazole-5-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 3-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol e-5- carboxylate (0.70 g, 2.04 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4- aminopyrrolidine-1-carboxylate (0.54 g, 2.04 mmol) in THF (5 mL) was added TBD (0.42 g, 3.06 mmol) in portions at 0 °C and stirred at 0 °C for 30 min. The mixture was poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 40% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H-1,2,3- triazol-1-yl)methyl)-4-(3-(2-cyclopropyl-5-(trifluoromethoxy )phenyl)-1,2,4-oxadiazole-5- carboxamido)pyrrolidine-1-carboxylate (0.14 g, 0.30 mmol, 27% yield). LCMS: Method C, 1.85 min, MS: ES+ 564.4. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -3-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(3-(2-cyclopropy l-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamido)pyr rolidine-1-carboxylate (0.40 g, 0.73 mmol) in DCM (5 mL) was added TFA (2 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H- 1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-3-(2-cyclopropyl- 5-(trifluoromethoxy)phenyl)-1,2,4- oxadiazole-5-carboxamide TFA salt (0.50 g, quantitative yield). LCMS: Method F, 5.28 min, MS: ES+ 464.0. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-3-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -3-(2-cyclopropyl- 5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamide TFA salt (0.50 g, 0.86 mmol) in THF (5 mL) was added K2CO3 (0.59 g, 4.33 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.09 g, 0.86 mmol) was added into the reaction mixture at 0 °C. The mixture was stirred at rt for 15 min, then poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 87% EtOAc in n-hexanes) to yield N-((3R,5S)-5- ((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(2 -cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamide (0.12 g, 0.25 mmol, 35% yield over two steps). LCMS: Method H1, 3.19 min, MS: ES+ 489.2; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.85 (d, J = 6.8 Hz, 1H), 8.21 (s, 1H), 7.80 - 7.81 (m, 2H), 7.55 (d, J = 7.6 Hz, 1H), 7.30 (d, J = 8.8 Hz, 1H), 4.64 - 4.66 (m, 2H), 4.36 - 4.41 (m, 2H), 3.68 - 3.72 (m, 1H), 3.45 - 3.48 (m, 1H), 3.35 (m, 1H), 2.19 - 2.24 (m, 1H), 2.01 - 2.06 (m, 1H), 1.02 - 1.06 (m, 2H), 0.77 - 0.80 (m, 2H); Chiral SFC: Method Y21, 7.47 min.
Example 51 N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxamide Step (iv) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropy l-5-(trifluoromethoxy)phenyl)- 1,2,4-oxadiazole-3-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol e-3- carboxylate (0.15 g, 0.43 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4- aminopyrrolidine-1-carboxylate (0.13 g, 0.48 mmol) in THF (1.5 mL) was added TBD (0.09 g, 0.65 mmol) in portions at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h, then poured into water (10 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H- 1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropyl-5-(trifluorom ethoxy)phenyl)-1,2,4-oxadiazole-3- carboxamido)pyrrolidine-1-carboxylate (0.08 g, 0.14 mmol, 33% yield). LCMS: Method C1, 1.35 min, MS: ES+ 564.2. Step (ii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropy l-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxamido)pyr rolidine-1-carboxylate (0.08 g, 0.14 mmol) in DCM (0.8 mL) was added TFA (0.4 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)- 5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclo propyl-5-(trifluoromethoxy)phenyl)- 1,2,4-oxadiazole-3-carboxamide TFA salt (0.10 g, quantitative yield). LCMS: Method C1, 1.16 min, MS: ES+ 464.2. Step (iii) N-((3R,5S)-5-((1H-1,2,3-Triazol-1-yl)methyl)-1-cyanopyrrolid in-3-yl)-5-(2-cyclopropyl-5- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl) -5-(2-cyclopropyl- 5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxamide TFA salt (0.10 g, 0.21 mmol) in THF (1.0 mL) was added K 2 CO 3 (0.12 g, 0.83 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.02 g, 0.21 mmol) was added at 0 °C. The mixture was stirred at rt for 1 h, then poured into water (10 mL) and extracted with EtOAc (2 x 15 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC (Method X17) to yield N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1- cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)p henyl)-1,2,4-oxadiazole-3-carboxamide (0.02 g, 0.045 mmol, 32% yield over two steps). LCMS: Method F, 5.93 min, MS: ES+ 489.0; 1 H NMR (400 MHz, DMSO-d6) δ ppm: 9.50 (d, J = 4.0 Hz, 1H), 8.20 (s, 1H), 7.94 (s, 1H), 7.78 (s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 4.58 - 4.69 (m, 2H), 4.35 - 4.38 (m, 2H), 3.67 - 3.70 (m, 1H), 3.40 - 3.43 (m, 1H), 2.57 - 2.65 (m, 1H), 2.19 - 2.25 (m, 1H), 1.99 - 2.02 (m, 1H), 1.06 - 1.08 (m, 2H), 0.77 - 0.85 (m, 2H); Chiral SFC: Method Y14, 4.11 min. Example 52 N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-6-(1H-indazol-4-yl)nicotinamide Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(6-bromonicotinamido)p yrrolidine-1-carboxylate To a stirred solution of 6-bromonicotinic acid (CAS 6311-35-9, from Combi-Blocks, 0.60 g, 2.97 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-car boxylate (0.79 g, 2.97 mmol) in THF (6 mL) were added DIPEA (1.14 g, 1.58 mL, 0.07 mmol) and HATU (1.69 g, 2.97 mmol) at 0 °C. The mixture was allowed to warm to rt and stirred at rt for 16 h, then poured into water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 60% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-2-((1H- pyrazol-1-yl)methyl)-4-(6-bromonicotinamido)pyrrolidine-1-ca rboxylate (0.63 g, 1.40 mmol, 49% yield). LCMS: Method C, 1.58 min, MS: ES+ 450.2, 452.2. Step (ii) tert-Butyl (2S,4R)-4-(6-(1H-indazol-4-yl) nicotinamido)-2-((1H-pyrazol-1-yl)methyl)pyrrolidine-1- carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(6-bromonicotinamido) pyrrolidine-1-carboxylate (0.30 g, 0.66 mmol) and (1H-indazol-4-yl)boronic acid (CAS 1023595-17-6, from Combi-Blocks, 0.10 g, 0.66 mmol) in 1,4-dioxane : water (3 mL, 2:1) was added K3PO4 (0.28 g, 1.33 mmol). The mixture was purged with N2 gas for 15 min, followed by addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (0.05 g, 0.06 mmol) and heated at 100 °C for 2 h. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexanes) to yield tert-butyl (2S,4R)-4-(6-(1H-indazol-4-yl)nicotinamido)-2-((1H-pyrazol-1 -yl)methyl)pyrrolidine- 1-carboxylate (0.20 g, 0.41 mmol, 77% yield). LCMS: Method C, 1.43 min, MS: ES+ 488.3. Step (iii) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)pyrrolidin-3-yl)-6-(1H -indazol-4-yl)nicotinamide TFA salt To a stirred solution of tert-butyl (2S,4R)-4-(6-(1H-indazol-4-yl)nicotinamido)-2-((1H-pyrazol-1 - yl)methyl)pyrrolidine-1-carboxylate (0.20 g, 0.41 mmol) in DCM (2 mL) was added TFA (1.0 mL, 5 vol) dropwise at 0 °C. The mixture was allowed to warm to rt and stirred for 1 h, then concentrated under reduced pressure to yield N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-6-(1H - indazol-4-yl)nicotinamide TFA salt (0.20 g, quantitative yield). LCMS: Method C, 1.23 min, MS: ES+ 388.3. Step (iv) N-((3R,5S)-5-((1H-Pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-6-(1H-indazol-4-yl)nicotinamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-6-(1H -indazol-4- yl)nicotinamide TFA salt (0.20 g, 0.36 mmol) in THF (2 mL) was added K2CO3 (0.16 g, 1.19 mmol) at rt and stirred for 5 min. Cyanogen bromide (0.05 g, 0.47 mmol) was added into the reaction mixture at 0 °C. The reaction mixture was stirred at rt for 1 h, then poured into water (20 mL) and extracted with EtOAc (2 x 15 mL). The combined organic phases were dried over anhydrous Na 2 SO 4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 8% MeOH in DCM) to yield N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-y l)-6- (1H-indazol-4-yl)nicotinamide (0.10 g, 0.24 mmol, 39% yield over two steps). LCMS: Method H1, 2.14 min, MS: ES- 411.2; 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm: 13.29 (s, 1H), 9.21 (d, J = 1.6 Hz, 1H), 8.90 (d, J = 6.4 Hz, 1H), 8.66 (s, 1H), 8.33 (dd, J = 8.4, 2.0 Hz, 1H), 8.21 (d, J = 8.4 Hz, 1H), 7.81 - 7.83 (m, 2H), 7.70 (d, J = 8.4 Hz, 1H), 7.49 - 7.53 (m, 2H), 6.31 (s, 1H), 4.33 - 4.35 (m, 3H), 3.67 - 3.71 (m, 1H), 3.39 - 3.44 (m, 2H), 2.07 - 2.14 (m, 1H), 2.01 - 2.06 (m, 1H). Chiral SFC: Method Y32, 6.08 min. Biological Activity of Compounds of the Invention Abbreviations: TAMRA carboxytetramethylrhodamine Tris 2-amino-2-(hydroxymethyl)-1,3-propanediol BSA bovine serum albumin USP30 biochemical IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 µM for a final concentration of 100µM) in 50% DMSO in a 96-well polypropylene V-bottom plate (Greiner #651201). A typical 8-point dilution series would be 100, 30, 10, 3, 1, 0.3, 0.1, 0.03 µM final. Reactions were performed in duplicate in black 384 well plates (small volume, Greiner 784076) in a final reaction volume of 21 µl. Either 1µl of 50% DMSO or diluted compound was added to the plate. USP30 (Boston Biochem #E582) was diluted in reaction buffer (40 mM Tris, pH 7.5, 0.005% Tween 20, 0.5 mg/ml BSA, 5 mM beta-mercaptoethanol) to achieve a final assay concentration of 4 nM, and 10 µl of diluted USP30 was added to the compound. Enzyme and compound were incubated for 30 min at room temp. Reactions were initiated by the addition of 50 nM of TAMRA labelled peptide linked to ubiquitin via an isopeptide bond as fluorescence polarisation substrate. Reactions were read immediately after addition of substrate and following a 2-hour incubation at room temperature. Readings were performed on a Pherastar Plus (BMG Labtech). λ Excitation 540 nm; λ Emission 590 nm. Activity of exemplary compounds in USP30 biochemical assay (IC50 geomean): TOM20-ubiquitylation assay Human cell lines can be challenged with mitochondrial depolarizing agents (ionophores (eg. CCCP, valinomycin), mitochondrial complex inhibitors (oligomycin, antimycin A)) to induce ubiquitylation of TOM20, which is then further promoted in the presence of USP30 inhibitors. TOM20 ubiquitylation is subsequently assessed through western blotting of the cell lysates, with TOM20 ubiquitylation adduct detection possible due to an 8 kDa molecule weight increase for each molecule of ubiquitin added, resulting in laddering of a TOM20 immunoreactive band. TOM20-ubiquitylation levels can be quantified using chemiluminescence densitometry of laddered immunoreactive bands. Activity of exemplary compounds in TOM20-ubiquitylation assay (TOM20-Ub 1.5-fold gain, antimycin A/oligomycin mitophagy trigger EC1.5x): Preclinical in vivo models Compounds of the invention may be tested for efficacy in representative in vivo disease models, using standard study procedures from the published literature, including, for example: (a) Bleomycin-induced lung fibrosis model, which is a leading preclinical in vivo model of Idiopathic Pulmonary Fibrosis. [Kobayashi et al, 2016, J Immunol, 197(2):504-516] (b) Diet-induced model of NAFLD and glucose homeostasis. [Nishida et al, 2013, Lab Invest; Feb;93(2):230-41] (c) MPTP Model of Parkinson’s Disease, which is a commonly used paradigm for looking at neurodegeneration in the dopaminergic system of the brain which is triggered by chemically-induced mitochondrial dysfunction. [Karuppagouner et al, 2014, Sci Rep.2014 May 2;4:4874] (d) Ndufs4KO Leigh syndrome model. [Kruse et al, 2008, Cell Metab. Apr;7(4):312-20] (e) Aged mice model: effects on cognitive and motor function. [Kobilo et al, 2014, Learn Mem. Jan 17;21(2):119-26; Creed et al, 2019, Neuroscience. Jun 15;409:169-179] (f) The unilateral ureteral obstructive kidney disease model (UUO). [Chevalier et al, 2009, Kidney Int 75(11): 1145-1152] (g) The ischemia-induced acute kidney injury model (AKI).